
<html lang="en"     class="pb-page"  data-request-id="8b570c0b-7f49-4f1c-a0aa-46f9b8199027"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2016.59.issue-8;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.6b00087"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors" /></meta><meta name="dc.Creator" content="Bénédicte  Daydé-Cazals" /></meta><meta name="dc.Creator" content="Bénédicte  Fauvel" /></meta><meta name="dc.Creator" content="Mathilde  Singer" /></meta><meta name="dc.Creator" content="Clémence  Feneyrolles" /></meta><meta name="dc.Creator" content="Benoit  Bestgen" /></meta><meta name="dc.Creator" content="Fanny  Gassiot" /></meta><meta name="dc.Creator" content="Aurélia  Spenlinhauer" /></meta><meta name="dc.Creator" content="Pierre  Warnault" /></meta><meta name="dc.Creator" content="Nathalie  Van Hijfte" /></meta><meta name="dc.Creator" content="Nozha  Borjini" /></meta><meta name="dc.Creator" content="Gwénaël  Chevé" /></meta><meta name="dc.Creator" content="Abdelaziz  Yasri" /></meta><meta name="dc.Description" content="Efforts were made to improve a series of potent dual ABL/SRC inhibitors based on a 7-azaindole core with the aim of developing compounds that demonstrate a wider activity on selected oncogenic kina..." /></meta><meta name="Description" content="Efforts were made to improve a series of potent dual ABL/SRC inhibitors based on a 7-azaindole core with the aim of developing compounds that demonstrate a wider activity on selected oncogenic kina..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 15, 2016" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b00087" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2016 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00087" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b00087" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00087" /></link>
        
    
    

<title>Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b00087" /></meta><meta property="og:title" content="Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/large/jm-2016-00087m_0013.jpeg" /></meta><meta property="og:description" content="Efforts were made to improve a series of potent dual ABL/SRC inhibitors based on a 7-azaindole core with the aim of developing compounds that demonstrate a wider activity on selected oncogenic kinases. Multi-targeted kinase inhibitors (MTKIs) were then derived, focusing on kinases involved in both angiogenesis and tumorigenesis processes. Antiproliferative activity studies using different cellular models led to the discovery of a lead candidate (6z) that combined both antiangiogenic and antitumoral effects. The activity of 6z was assessed against a panel of kinases and cell lines including solid cancers and leukemia cell models to explore its potential therapeutic applications. With its potency and selectivity for oncogenic kinases, 6z was revealed to be a focused MTKI that should have a bright future in fighting a wide range of cancers." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b00087"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b00087">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b00087&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b00087&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b00087&amp;href=/doi/10.1021/acs.jmedchem.6b00087" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 8</span><span class="cit-fg-pageRange">, 3886-3905</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/8" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b00084" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.6b00106" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=B%C3%A9n%C3%A9dicte++Dayd%C3%A9-Cazals">Bénédicte Daydé-Cazals</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=B%C3%A9n%C3%A9dicte++Fauvel">Bénédicte Fauvel</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mathilde++Singer">Mathilde Singer</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Cl%C3%A9mence++Feneyrolles">Clémence Feneyrolles</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Benoit++Bestgen">Benoit Bestgen</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Fanny++Gassiot">Fanny Gassiot</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Aur%C3%A9lia++Spenlinhauer">Aurélia Spenlinhauer</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Pierre++Warnault">Pierre Warnault</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nathalie++Van+Hijfte">Nathalie Van Hijfte</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nozha++Borjini">Nozha Borjini</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gw%C3%A9na%C3%ABl++Chev%C3%A9">Gwénaël Chevé</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Abdelaziz++Yasri">Abdelaziz Yasri</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">OriBase Pharma, Cap Gamma, Parc Euromédecine, 1682 rue de la Valsière, CS 17383, Montpellier 34189 CEDEX 4, France</span></div><div class="corresp-info"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#dbbaa2baa8a9b29bb4a9b2b9baa8bef6abb3baa9b6baf5b8b4b6"><span class="__cf_email__" data-cfemail="3e5f475f4d4c577e514c575c5f4d5b134e565f4c535f105d5153">[email protected]</span></a>. Phone: (+33) 467 727 670.</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00087&amp;href=/doi/10.1021%2Facs.jmedchem.6b00087" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 8</span><span class="cit-pageRange">, 3886–3905</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 24, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>19 January 2016</li><li><span class="item_label"><b>Published</b> online</span>15 April 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 28 April 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b00087" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00087</a></div><div class="article_header-article-copyright"><strong>Copyright © 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D3886%26pageCount%3D20%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DB%25C3%25A9n%25C3%25A9dicte%2BDayd%25C3%25A9-Cazals%252C%2BB%25C3%25A9n%25C3%25A9dicte%2BFauvel%252C%2BMathilde%2BSinger%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D8%26contentID%3Dacs.jmedchem.6b00087%26title%3DRational%2BDesign%252C%2BSynthesis%252C%2Band%2BBiological%2BEvaluation%2Bof%2B7-Azaindole%2BDerivatives%2Bas%2BPotent%2BFocused%2BMulti-Targeted%2BKinase%2BInhibitors%26numPages%3D20%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D3905%26publicationDate%3DApril%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b00087"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2138</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">26</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b00087" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Bénédicte&quot;,&quot;last_name&quot;:&quot;Daydé-Cazals&quot;},{&quot;first_name&quot;:&quot;Bénédicte&quot;,&quot;last_name&quot;:&quot;Fauvel&quot;},{&quot;first_name&quot;:&quot;Mathilde&quot;,&quot;last_name&quot;:&quot;Singer&quot;},{&quot;first_name&quot;:&quot;Clémence&quot;,&quot;last_name&quot;:&quot;Feneyrolles&quot;},{&quot;first_name&quot;:&quot;Benoit&quot;,&quot;last_name&quot;:&quot;Bestgen&quot;},{&quot;first_name&quot;:&quot;Fanny&quot;,&quot;last_name&quot;:&quot;Gassiot&quot;},{&quot;first_name&quot;:&quot;Aurélia&quot;,&quot;last_name&quot;:&quot;Spenlinhauer&quot;},{&quot;first_name&quot;:&quot;Pierre&quot;,&quot;last_name&quot;:&quot;Warnault&quot;},{&quot;first_name&quot;:&quot;Nathalie&quot;,&quot;last_name&quot;:&quot;Van Hijfte&quot;},{&quot;first_name&quot;:&quot;Nozha&quot;,&quot;last_name&quot;:&quot;Borjini&quot;},{&quot;first_name&quot;:&quot;Gwénaël&quot;,&quot;last_name&quot;:&quot;Chevé&quot;},{&quot;first_name&quot;:&quot;Abdelaziz&quot;,&quot;last_name&quot;:&quot;Yasri&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;15&quot;,&quot;issue&quot;:&quot;8&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;3886-3905&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b00087&quot;},&quot;abstract&quot;:&quot;Efforts were made to improve a series of potent dual ABL/SRC inhibitors based on a 7-azaindole core with the aim of developing compounds that demonstrate a wider activity on selected oncogenic kinases. Multi-targeted kinase inhibitors (MTKIs) were then derived, focusing on kinases involved in both angiogenesis and tumorigenesis processes. Antiproliferative activity studies using different cellular models led to the discovery of a lead candidate (6z) that combined both antiangiogenic and antitumoral effects. The activity of 6z was assessed against a panel of kinases and cell lines including solid cancers and leukemia cell models to explore its potential therapeutic applications. With its potency and selectivity for oncogenic kinases, 6z was revealed to be a focused MTKI that should have a bright future in fighting a wide range of cancers.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00087&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00087" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00087&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00087" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00087&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00087" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00087&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00087&amp;href=/doi/10.1021/acs.jmedchem.6b00087" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b00087" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b00087" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b00087%26sid%3Dliteratum%253Aachs%26pmid%3D27010810%26genre%3Darticle%26aulast%3DDayd%25C3%25A9-Cazals%26date%3D2016%26atitle%3DRational%2BDesign%252C%2BSynthesis%252C%2Band%2BBiological%2BEvaluation%2Bof%2B7-Azaindole%2BDerivatives%2Bas%2BPotent%2BFocused%2BMulti-Targeted%2BKinase%2BInhibitors%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D8%26spage%3D3886%26epage%3D3905%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/8" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/jmcmar.2016.59.issue-8/20160428/jmcmar.2016.59.issue-8.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/medium/jm-2016-00087m_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/large/jm-2016-00087m_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00087&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Efforts were made to improve a series of potent dual ABL/SRC inhibitors based on a 7-azaindole core with the aim of developing compounds that demonstrate a wider activity on selected oncogenic kinases. Multi-targeted kinase inhibitors (MTKIs) were then derived, focusing on kinases involved in both angiogenesis and tumorigenesis processes. Antiproliferative activity studies using different cellular models led to the discovery of a lead candidate (<b>6z</b>) that combined both antiangiogenic and antitumoral effects. The activity of <b>6z</b> was assessed against a panel of kinases and cell lines including solid cancers and leukemia cell models to explore its potential therapeutic applications. With its potency and selectivity for oncogenic kinases, <b>6z</b> was revealed to be a focused MTKI that should have a bright future in fighting a wide range of cancers.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06350" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06350" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The modulation of kinase function is an important goal in drug discovery and, more particularly, in cancer-targeted therapies where an increased number of kinase inhibitors have entered the market in recent years.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> Two opposing concepts govern the design and development of new kinase inhibitors in oncology. Although the first strategy proposes the design of selective molecules to increase efficacy and limit toxicity, the second strategy highlights benefits in developing multi-targeted kinase inhibitors (MTKIs). Although almost all major human cancers seem to harbor not a single but several concomitant dysregulations of kinase pathways, the latest approach offers the opportunity not only to catch tumor progression more effectively but also to avoid mechanisms of resistance commonly activated by the tumor to escape targeted therapies.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3, 4)</a> Moreover, given that different types of tumors may originate from different cell types and are frequently driven by different combinations of genetic alterations, MTKIs will have the ability not only to be used in a wide range of cancers but also to prove as effective as combinatorial therapy without the disadvantages of using multiple selective agents together (drug–drug interactions, difficulty in obtaining sufficient potencies against the tumor cells, potentiation of adverse effects, etc.).<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Thus, kinase inhibitor development efforts in cancer therapy have shifted from the dogma of one molecule against one target for one disease to a more controlled multitargeting approach with the aim of addressing the genetic diversity and multiple driving forces of disease.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6, 7)</a> The three major groups of targets in the current kinase inhibitor drug discovery are receptor tyrosine kinases, kinases of the mitogen-activated protein kinase (MAPK) pathway and kinases of the phosphoinositide 3-kinase (PI3K) pathway. Because these three groups of targets are mechanistically linked, there is a compelling biological rationale for simultaneously targeting several members of each of these groups to create therapeutic benefits.</div><div class="NLM_p last">Using fragment-based drug design combined with medicinal chemistry approaches, we have developed a new generation of type-II ATP-competitive MTKIs. The series was rationally designed according to a structure-based drug design and kinase-focused approach to identify single agents with an optimized multipharmacological inhibition profile. Recently, a series of DFG-in inhibitors was first designed and evaluated against kinases of the ABL and SRC families.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8, 9)</a> Using these DFG-in inhibitors composed of a 7-azaindole core as the initial fragment followed by iterative structural and kinase activity improvements, we have identified new type-II MTKIs that are highly potent against not only the ABL and SRC families but also other oncogenic kinase members of the receptor tyrosine kinase group and the MAPK pathway. Thus, the compounds target multiple kinase pathways involved in tumor progression, angiogenesis, immune system modulation, and metastasis. This new series presents high antiproliferative activity, demonstrating the inhibition of the tumor cells, the angiogenesis process, and more broadly, an effect on the tumor microenvironment against a wide range of cancer types. Moreover, with this multitargeted profile, the compounds are expected not only to avoid development of tumor resistance but also to be used as a therapeutic aid for patients developing resistance while being treated with currently marketed kinase inhibitors.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42420" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42420" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Fragment-Based Drug Design of 7-Azaindole Series</h3><div class="NLM_p">Two main strategies are used to design kinase inhibitors. The strategy adopted depends on the targeted conformation of the kinase.</div><div class="NLM_p">As depicted in <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>, type-I inhibitors are designed to interact with the kinase in its active, or DFG-in, conformation. In this strategy, a cyclic core (aromatic or not) is used to interact with the segment linking the N-terminal lobe to the C-terminal lobe of the kinase, therefore called the hinge. A second fragment, usually an aromatic ring, is used to interact with a first specificity pocket of the kinase that is separated from the hinge by a single amino acid called the gatekeeper. Because the gatekeeper presents an obstacle to the interaction with the specificity pocket through steric hindrance, a linker is used between the aromatic ring and the cyclic ring system interacting with the hinge to bypass this binding obstacle.</div><div class="NLM_p">As depicted in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>, type-II inhibitors are designed to interact and block the kinase in its inactive, or DFG-out, conformation. As in the DFG-in strategy, the interactions with the hinge and the specificity pocket are found in type-II inhibitors. The difference lies in the exploration of the rest of the kinase pocket. The aromatic fragment interacting with the first hydrophobic pocket is extended via a linker (amide or urea) by another aromatic ring holding or not holding some substituents. This last fragment is supposed to interact with a new hydrophobic pocket formed after the structural rearrangement of the activation loop of the kinase. This second selective pocket is the less conserved among the kinases and allows the establishment of more interactions between the inhibitor and the active site, therefore increasing the potency and the selectivity of the inhibitor. The design of the type-II inhibitor strategy was then selected for the present work. Our series of compounds is composed of a 7-azaindole core that is considered an adenine mimetic heterocycle and is predicted to dock into the purine binding site by interacting with the hinge. As shown in a previous study,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> the addition of a first aromatic ring (best with methyl-substituted phenyl) to the 7-azaindole moiety with an aminomethyl linker allows interaction with the first hydrophobic pocket juxtaposed to the gatekeeper existing both in the active or inactive conformation. Accordingly, to design selective type-II inhibitors, a second aromatic moiety was added to the inhibitor structure to create new hydrophobic interactions with the second specificity pocket. A docking study predicted that such compounds should adopt the classical binding mode of type II-inhibitors such as Imatinib (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). An example of the superposition of our compound <b>6x</b> docked into the active site of Imatinib cocrystallized ABL kinase is depicted in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>, showing a similar type-II binding mode with at least 5 hydrogen bonds established within the kinase active site.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/medium/jm-2016-00087m_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/large/jm-2016-00087m_0002.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Classical structural scheme of type-I kinase inhibitor docked into the DFG-in conformation. Example of Dasatinib cocrystallized within the SRC kinase (Protein Data Bank: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3G5D">3G5D</a>).<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> (A) Representation of the principal amino acids surrounding the ligand. (B) View of the active site surface. PBP: purine binding pocket, SP I: selectivity pocket I.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/large/jm-2016-00087m_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00087&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/medium/jm-2016-00087m_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/large/jm-2016-00087m_0003.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Classical structural scheme of a type-II kinase inhibitor docked into DFG-out conformation. Example of Imatinib cocrystallized within the SRC kinase (Protein Data Bank: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2OIQ">2OIQ</a>).<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> (A) Representation of the principal amino acids surrounding the ligand. (B) View of the active site surface. PBP: purine binding pocket, SP I: selectivity pocket I, SP II: selectivity pocket II, and SP III: selectivity pocket III.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/large/jm-2016-00087m_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00087&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/medium/jm-2016-00087m_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/large/jm-2016-00087m_0004.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Superposition of the predicted binding mode of <b>6x</b> (in cyan) and Imatinib (in green) within the active site of ABL (in gray). Potential hydrogen bonds are depicted in black dashed lines. Docking studies were carried out with ABL X-ray structure cocrystallized with Imatinib (Protein Data Bank: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1IEP">1IEP</a>).<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/large/jm-2016-00087m_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00087&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Medicinal Chemistry and Kinase Assays</h3><div class="NLM_p">Starting from the DFG-in series previously described,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> the aim was to design compounds able to inhibit kinases belonging to the receptor tyrosine kinase family, the SRC family, and the MAPK pathway. We selected four representative kinases from the growth receptor tyrosine kinase family (EGFR, epidermal growth factor receptor; VEGFR2, vascular endothelial growth factor receptor 2; FGFR2, fibroblast growth factor receptor 2; PDGFRA, platelet-derived growth factor receptor alpha), SRC kinase as a representative member of the SRC family, and B-RAF kinase as one of the first kinases involved in the MAPK signaling pathway activation. Given the role of the specificity pocket in determining type-II inhibitor selectivity, chemical modulations were carried out to explore different chemical fragments and their impact on the activity against the six targeted kinases.</div><div class="NLM_p">The general route of synthesis is described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Compounds <b>6a</b>–<b>z</b> were obtained after a three-step synthesis from commercially available 5-amino-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic acid methyl ester (<b>1a</b>). After a reductive amination with 2-methyl-5-nitrobenzaldehyde (<b>2</b>) and sodium cyanoborohydride, the nitro-intermediate (<b>3a</b>) was reduced under hydrogen pressure and yielded the aniline intermediate (<b>4a</b>). To obtain final compounds <b>6a</b>–<b>z</b>, the aniline (<b>4a</b>) was coupled with several carboxylic acids or acyl chlorides, commercially available <b>5a</b>–<b>w</b> or in-house-synthesized <b>5x</b>–<b>z</b>, according to procedures described in the literature.<a onclick="showRef(event, 'ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15">(13-15)</a> Carboxylic acids and acyl chlorides <b>5a</b>–<b>w</b> are aromatic or heteroaromatic derivatives bearing hydrophobic or hydrophilic substituents in order to create potential interactions such as π-stacking or hydrogen bound with the second hydrophobic pocket of the kinase. Last carboxylic acids <b>5x</b>–<b>z</b> are fragments that were derived from marketed drugs (Imatinib, Bafetinib, and Nilotinib, respectively) well-known to interact with the specificity pocket of kinases such as ABL and/or SRC in its inactive conformation.</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/medium/jm-2016-00087m_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/large/jm-2016-00087m_0006.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Route of Synthesis to Explore the Specificity Pocket in the Design of DFG-Out Type-II Inhibitors<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/large/jm-2016-00087m_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00087&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) AcOH/MeOH (1/10), rt, 2 h, then NaBH<sub>3</sub>CN, rt, 16 h-48 h, 82–86%; (b) H<sub>2</sub> (30 bar), Pd/C 10%, DMF or MeOH/HCl aq, rt, 16 h-48 h, 96–97%; (c) carboxylic acid, HATU, DIEA, rt, 12 h or acyl chloride, NEt<sub>3</sub>, DMF, rt, 16 h, 4–55%.</p></p></figure><div class="NLM_p">In this first series, a set of 26 compounds was synthesized and evaluated for their inhibition potency for targeted kinases at a concentration of 100 nM. As summarized in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>, this pharmacological assay resulted in a majority of compounds presenting at least 50% inhibition of SRC and PDGFRA kinase activities. These two kinases were slightly impacted by the nature of the substituent R<sub>2</sub>. Inversely, with only two compounds (<b>6y</b> and <b>6z</b>) able to inhibit the FGFR2 kinase at more than 40% inhibition, this kinase likely adopts a more restrained type-II conformation. For the three other targets, B-RAF, EGFR, and VEGFR2, no relevant correlation between the structure of the R<sub>2</sub> of the hydrophobic groups and the inhibition percentage of these kinases was observed.</div><div class="NLM_p">Otherwise, when R<sub>2</sub> is a pyridine group, the nature and the position of the substituent as well as the position of the aromatic nitrogen atom with regard to the substitution (compounds <b>6m</b>–<b>q</b>) impact the inhibition profiles of the six kinases. Whatever the nature of the substituent (Me or CF<sub>3</sub>), the 3-pyridine group allows an increase in the number of inhibited kinases by comparison with compounds bearing a phenyl group or a 4-pyridine group. For exemple, the nitrogen atom adjacent to the CF<sub>3</sub> group on the 4-pyridine ring leads to a less active compound (<b>6p</b>), whereas with a 3-pyridine group, compounds <b>6m</b> and <b>6o</b> inhibit five kinases. Globally, these results illustrated the difficulty of rationalizing the difference in the specificity profile observed among the 26 compounds on the targeted kinase panel. The 3-pyridine group would seem to be the best aromatic ring in R<sub>2</sub> position to have a MTKI profile, and its combination with Imatinib and Bafetinib moiety would be interesting to test if the chemistry allows that. On the basis of these first findings, very interesting inhibition activities were observed for some of these compounds. On the basis of a value of 40% as an inhibition threshold, one compound (<b>6y</b>) showed a high inhibition of the six kinases, and one compound (<b>6z</b>) exhibited a moderate inhibition for the six kinases. Six compounds (<b>6m</b>–<b>o</b>, <b>6s</b>, <b>6u</b>, and <b>6x</b>) inhibited five kinases except for FGFR2. Moreover, four compounds (<b>6a</b>, <b>6b</b>, <b>6j</b>, and <b>6k</b>) inhibited four kinases and do not inhibit EGFR and FGRF2. The rest of the compounds inhibited three or fewer kinases and showed a heterogeneous inhibition profile.</div><div class="NLM_p">These results highlight the MTKI potential of eight compounds (<b>6m</b>–<b>o</b>, <b>6s</b>, <b>6u</b>, and <b>6x</b>–<b>z</b>) inhibiting at least five kinases of the selected primary kinase panel.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Percent Inhibition at 100 nM for the First Series of Compounds</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/medium/jm-2016-00087m_0009.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/medium/jm-2016-00087m_0010.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Mean of duplicate experiments. Blue cells are percent inhibition greater than 40% at 100 nM.</p></div></div><div></div></div><div class="NLM_p">In a set of pharmacomodulation experiments, the influence of the nature of the substituent on the 7-azaindole core was investigated. The modifications focused on (1) replacing the methyl ester group on position 2 of the 7-azaindole core by acetyl, <i>N</i>-methylamide, or carboxylic functions or (2) changing the nature of the linker in position 5.</div><div class="NLM_p">The first modifications in position 2 were introduced either by hydrolysis of the most active compounds of the first series to afford the carboxylic derivatives <b>8x</b>–<b>z</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>A) or by using the 1-(5-amino-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-2-yl) ethanone (<b>1b</b>) bearing the acetyl group in position 2 to synthesize the acetyl derivatives <b>7x</b>–<b>z</b> according to the reaction pathway described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> (R<sub>1</sub> = Me). Otherwise, the methyl ester function in position 2 of the 7-azaindole was replaced by its corresponding <i>N</i>-methylamide from 5-nitro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic acid methyl ester (<b>9</b>) in two steps to afford the new precursor <b>10.</b> This nitro intermediate was reduced, and the corresponding aniline was used according to the same three-step synthesis strategy as for the first series (reductive amination, reduction by hydrogenation, and coupling reaction), as depicted in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>B to prepare the methylamide derivatives <b>12x</b>–<b>y</b>. This second series of compounds with modifications in position 2 of the 7-azaindole core was screened on the six main targeted kinases for their inhibition potency at 100 nM concentration and compared to their analogs in the methylester series (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>).</div><div class="NLM_p">Some differences in the inhibition profile were observed regardless of the small variations generated at position 2 of the 7-azaindole. Whatever the nature of the R<sub>2</sub> group, replacing the methyl ester group by its corresponding carboxylic acid induces an important decrease of B-RAF inhibition. Inversely, compounds with an acetyl substituent exhibit similar or better profiles than those of the ester series. These results revealed the interest in working with the methyl ester and acetyl series in position 2 of the 7-azaindole core to optimize the series.</div><div class="NLM_p">In parallel, several variations were carried out in the position 5 of the 7-azaindole core to modify the linker bound to the central aromatic ring and to study the impact of five new linkers on the inhibition profile of the compounds. The chemistry investigated is depicted in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>.</div><figure id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/medium/jm-2016-00087m_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/large/jm-2016-00087m_0007.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis Pathway to Modify the Substituents on Position 2 of the 7-Azaindole Core<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/large/jm-2016-00087m_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00087&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) KOH or LiOH, MeOH/H<sub>2</sub>O (1/1), reflux, 42–76%; (b) MeNH<sub>2</sub>, HATU, DIEA, DMF, 59%; (c) H<sub>2</sub> (30 bar), Pd/C 10%, MeOH, overnight; (d) 2-methyl-5-nitrobenzaldehyde <b>2</b>, AcOH/MeOH (1/10), rt, 2 h; then, NaBH<sub>3</sub>CN, rt, 16 h. Overall yield for the three steps (c,d,c): 53%. (e) Carboxylic acid, HATU, DIEA, DMF, rt, 16 h, 3–7%.</p></p></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Percent Inhibition at 100 nM for Compounds with Modifications in Position 2 of the 7-Azaindole Core</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/medium/jm-2016-00087m_0011.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/medium/jm-2016-00087m_0016.gif" alt="" id="GRAPHIC-d7e620-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">Mean of duplicate experiments. Blue cells are percent inhibition greater than 40% at 100 nM.</p></div></div><div></div></div><div class="NLM_p">The key intermediates used to introduce different linkers were 5-formyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic acid methyl ester (<b>14a</b>) and 2-acetyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-5-carbaldehyde (<b>14b</b>) obtained, respectively, from 5-cyano-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic acid methyl ester (<b>13a</b>) and 2-acetyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-5-carbonitrile (<b>13b</b>). Although one reduction step with Raney nickel catalyst and hydrogen pressure was sufficient in the ester series to obtain the aldehyde derivative <b>14a</b>, a supplementary step of oxidation with manganese oxide was necessary in the acetyl series to obtain <b>14b</b> because of the reduction of the acetyl group that occurred during the first reduction step. These two aldehyde derivatives (<b>14a</b> and <b>14b</b>) allowed access to the final compounds <b>26</b>–<b>29</b> with 3 different X–Y linkers, either CH<sub>2</sub>O, CH═CH, or CH<sub>2</sub>CH<sub>2</sub>. To access compounds with the first cited ether linker CH<sub>2</sub>O, aldehyde derivative <b>14a</b> was reduced with DIBAL-H reagent to its corresponding alcohol (<b>15a</b>). This intermediate was used in a Mitsunobu reaction with 2-methyl-5-nitrophenol. Then, a reduction of the nitro group followed by a peptide coupling reaction with two carboxylic acids <b>5x</b> and <b>5y</b> led to final compounds <b>26x</b> and <b>26y.</b> A Wittig reaction was carried out using aldehydes <b>14a</b> and <b>14b</b> with 2-methyl-5-nitrobenzyltriphenylphosphonium to generate intermediates <b>17a</b>–<b>b</b> with the alkene linker. These derivatives were partially or completely reduced (step f or g, respectively) to derivatives <b>18a</b> or <b>19a</b>−<b>b</b> that were finally coupled with the two carboxylic acids <b>5x</b> and <b>5y</b> to obtain the final compounds with an alkene CH═CH (<b>27x</b>–<b>y</b>) or an alkyl linker CH<sub>2</sub>CH<sub>2</sub> (<b>28x</b>–<b>y</b> and <b>29x</b>–<b>y</b>). Compounds <b>24x</b>–<b>y</b> with the amide linker NHC(O) were obtained from 5-amino-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic acid methyl ester <b>1a</b> and 5-amino-2-methyl-benzoic acid methyl ester <b>20</b> in three steps (coupling reaction, followed by nitro-reduction, then final coupling reaction). Finally, from 4-methyl-3-nitroaniline <b>22</b>, a peptide coupling reaction followed by a reduction of the nitro group and a reductive amination with <b>14a</b> led to final derivative <b>25x</b> with the reverse amine linker CH<sub>2</sub>NH.</div><figure id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/medium/jm-2016-00087m_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/large/jm-2016-00087m_0008.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis Pathway to Modify the Linker in Position 5 of the 7-Azaindole Core<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/large/jm-2016-00087m_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00087&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <b>14a</b>: H<sub>2</sub> (10 bar), Raney Ni, Pyridine/H<sub>2</sub>O/AcOH (2/1/1), overnight, 67%.<b>14b</b>: (1) DIBAL-H, toluene, 0 °C, 1.5 h, 31%; (2) MnO<sub>2</sub>, THF, rt, overnight, 65%. (b) DIBAL-H, THF, 0 °C, 3 h, 45%; (c) 2-methyl-5-nitrophenol, PPh<sub>3</sub>, DEAD, CH<sub>2</sub>Cl<sub>2</sub>, rt, overnight, 40%; (d) Zn, AcOEt/AcOH (2/1), 50 °C, rt, 1 h 30; (e) 2-methyl-5-nitrobenzyl-triphenylphosphonium, LiOH, MeOH, rt or reflux, overnight, 69–71%; (f) Zn, AcOH/AcOEt (1/2), sonic bath, rt, 30 min, 56%; (g) H<sub>2</sub> (10 bar), Pd/C 10%, DMF, rt, 24 h, 26%–38%; (h) HATU, DIEA, DMF, rt, w-end, 93%; (i) H<sub>2</sub> (35 bar), Pd/C 10%, MeOH, rt, overnight, 81%; (j) <b>5x</b> or <b>5y</b>, DIEA, HATU, DMF, rt, overnight, 5–55%; (k) <b>5x</b>, DIEA, EDCI, rt, overnight, 45%; (l) Zn, AcOEt/AcOH (2/1), rt, 1 h 20, quant. yield; (m) (1) <b>14a</b>, AcOH/MeOH (10/1), rt, 2 h; (2) NaBH<sub>3</sub>CN, rt, overnight, 17%.</p></p></figure><div class="NLM_p">A total of 11 new compounds (<b>24</b>–<b>29</b>) were synthesized bearing five new linkers, and their inhibition profile was evaluated on the six targeted kinases and compared to their analogs with the initial linker NHCH<sub>2</sub> as depicted in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Percent Inhibition at 100 nM for Compounds with Modifications on Position 5 of the 7-Azaindole Core</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/medium/jm-2016-00087m_0012.gif" alt="" id="fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/medium/jm-2016-00087m_0015.gif" alt="" id="GRAPHIC-d7e886-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">Mean of duplicate experiments. Blue cells are percent inhibition greater than 40% at 100 nM.</p></div></div><div></div></div><div class="NLM_p last">The pharmacomodulations with the reverse amine linker (CH<sub>2</sub>NH) or the alkene (CH═CH) linker induce an important decrease of the activity on the targeted kinases, excluding PDGFRA for which the modifications that were used slightly affect the inhibition of this kinase. For the other new tested linkers (NHC(O), CH<sub>2</sub>O or CH<sub>2</sub>CH<sub>2</sub>), similar MTKI profiles were obtained on the targeted kinases when compared with compounds bearing the initial linker NHCH<sub>2</sub> except for B-RAF. Indeed, B-RAF kinase inhibition was the most negatively affected by the nature of the linker (decrease of the activity for 8 compounds over the 11 new ones). The best inhibition profiles were obtained for compounds bearing linkers NHCH<sub>2</sub> and CH<sub>2</sub>CH<sub>2.</sub> This new series of variations on position 5 of the 7-azaindole allowed us to highlight the MTKI potency of six new compounds: <b>24x</b>, <b>24y</b>, <b>26y</b>, <b>28y</b>, <b>29x</b>, and <b>29y.</b> These derivatives inhibited at least 5 of 6 targeted kinases with at least a 40% inhibition at 100 nM similar to the compounds <b>6x</b>, <b>6y</b>, and <b>7y</b>.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Cellular Antiproliferative Effects of Compounds</h3><div class="NLM_p">The six targeted kinases are members of different signaling pathways involved in tumor growth and progression, including angiogenesis and metastasis processes. To validate the dual mechanism of action of the 19 best compounds inhibiting at least 5 of 6 targeted kinases developed to date, their antiproliferative potency was evaluated in a first screening experiment on human primary endothelial cells (HUVEC, human umbilical vein endothelial cells) to prove the antiangiogenic effect and on a hepatocellular carcinoma cell line (HepG2) to prove the antitumoral activity of the compounds. In parallel, Sorafenib, a marketed MTKI approved by the FDA in the treatment of liver cancer, was incubated with cells and used as a reference compound. Although presenting a good profile of kinase inhibition, <b>8y</b> and <b>8z</b> were not evaluated in cellular assays. We previously observed a lack of antiproliferative activity for other DFG-out inhibitors bearing, as compounds <b>8y</b> and <b>8z</b> do, a carboxylic acid in position 2 of the 7-azaindole. The EC<sub>50</sub> on cells for different carboxylic compounds of this series could not have been calculated because no inhibition of proliferation was observed even at the highest evaluated concentration of 3 μM, indicating an EC<sub>50</sub> at least 10-fold the EC<sub>50</sub> of corresponding methylester compounds. Consequently, for this series, the presence of the carboxylic acid would prevent cell membrane penetration and thus would not allow such compounds to demonstrate antiproliferative activity.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Antiproliferative Effects of Compounds Represented by Their EC<sub>50</sub> Values on the HUVEC Primary Cells and the HepG2 Cancer Cell Line</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">compounds</th><th class="colsep0 rowsep0" align="center">HUVEC</th><th class="colsep0 rowsep0" align="center">HepG2</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="18" align="left" valign="middle">EC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">ref<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">718</td><td class="colsep0 rowsep0" align="left">302</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6m</b></td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">510</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6n</b></td><td class="colsep0 rowsep0" align="left">986</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6o</b></td><td class="colsep0 rowsep0" align="left">390</td><td class="colsep0 rowsep0" align="left">963</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6s</b></td><td class="colsep0 rowsep0" align="left">298</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6u</b></td><td class="colsep0 rowsep0" align="left">199</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6x</b></td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6y</b></td><td class="colsep0 rowsep0" align="left">689</td><td class="colsep0 rowsep0" align="left">673</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6z</b></td><td class="colsep0 rowsep0" align="left">34</td><td class="colsep0 rowsep0" align="left">38</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7y</b></td><td class="colsep0 rowsep0" align="left">97</td><td class="colsep0 rowsep0" align="left">275</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12x</b></td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12y</b></td><td class="colsep0 rowsep0" align="left">83</td><td class="colsep0 rowsep0" align="left">179</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24x</b></td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24y</b></td><td class="colsep0 rowsep0" align="left">631</td><td class="colsep0 rowsep0" align="left">977</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26y</b></td><td class="colsep0 rowsep0" align="left">426</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28y</b></td><td class="colsep0 rowsep0" align="left">171</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29x</b></td><td class="colsep0 rowsep0" align="left">118</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29y</b></td><td class="colsep0 rowsep0" align="left">163</td><td class="colsep0 rowsep0" align="left">248</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">Reference: Sorafenib.</p></div></div></div><div class="NLM_p">Although three compounds (<b>6x</b>, <b>12x</b>, and <b>24x</b>) have failed to demonstrate any activity on HUVEC and HepG2 (requiring a concentration of compound greater than 1 μM to obtain a 50% inhibition of the cell proliferation), the other compounds exhibit good to excellent activity on at least one cell type as described in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>. With seven compounds showing both antiproliferative and antiangiogenic activities, four of the compounds outperformed Sorafenib (<b>6z</b>, <b>7y</b>, <b>12y</b>, and <b>29y</b>). These four new leads were subjected to a second cellular screening approach aiming to confirm and compare them in terms of antiproliferative activities on another type of endothelial cells (HRMEC, human retinal microvascular endothelial cells) and two other human cancer cell lines (A549, a non-small-cell lung cancer cell line, and HT29, a colorectal cancer cell line) as described in <a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>. Erlotinib and Regorafenib were selected as reference compounds for lung and colorectal cancer cell lines, respectively, and demonstrated weak antiproliferative activities. These new assays confirmed previous findings revealing new antiproliferative effects on lung and colorectal cell lines. The compound <b>6z</b> showed the best antiproliferative and antiangiogenic effects with EC<sub>50</sub> lower than 70 nM on each cell type (<a class="ref internalNav" href="#tbl4" aria-label="Tables 4">Tables 4</a> and <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>). Demonstrating high in cellulo antiangiogenic and antitumoral potency, <b>6z</b> was thus selected as our most promising lead compound for further in vitro development.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Antiproliferative Effects of Compounds Represented by Their EC<sub>50</sub> Values on the HRMEC Primary Cells and the A549 and HT29 Cancer Cell Lines</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="7" align="center" char=".">EC<sub>50</sub> (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."><b>6z</b></th><th class="colsep0 rowsep0" align="center" char="."><b>7y</b></th><th class="colsep0 rowsep0" align="center" char="."><b>12y</b></th><th class="colsep0 rowsep0" align="center" char="."><b>29y</b></th><th class="colsep0 rowsep0" align="center">Sorafenib</th><th class="colsep0 rowsep0" align="center">Erlotinib</th><th class="colsep0 rowsep0" align="center">Regorafenib</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">A549</td><td class="colsep0 rowsep0" align="char" char=".">64</td><td class="colsep0 rowsep0" align="char" char=".">204</td><td class="colsep0 rowsep0" align="char" char=".">495</td><td class="colsep0 rowsep0" align="char" char=".">293</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HT29</td><td class="colsep0 rowsep0" align="char" char=".">37</td><td class="colsep0 rowsep0" align="char" char=".">150</td><td class="colsep0 rowsep0" align="char" char=".">227</td><td class="colsep0 rowsep0" align="char" char=".">303</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HRMEC</td><td class="colsep0 rowsep0" align="char" char=".">62</td><td class="colsep0 rowsep0" align="char" char=".">179</td><td class="colsep0 rowsep0" align="char" char=".">81</td><td class="colsep0 rowsep0" align="char" char=".">304</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">nd<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">nd: not determined.</p></div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Selectivity Profile of <b>6z</b></h3><div class="NLM_p">To assess the kinase selectivity profile of <b>6z</b>, a broad panel kinase screening was conducted using a biochemical enzymatic assay by evaluating the ability of the compound to inhibit kinases at a 100 nM concentration (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>). In these studies, <b>6z</b> was found to be a multitargeted inhibitor with inhibition greater than 40% against 34 of 104 kinases tested. The main kinases targeted by <b>6z</b> are important clinical targets in a variety of malignancies and support the therapeutic potential of <b>6z</b> as a broad antitumor agent. Kinases such as the Aurora kinase family or the Polo-like kinase 1 (PLK1) whose inhibition may have negative and particularly adverse effects (i.e., bone marrow suppression and neutropenia) were not inhibited by the compound. Moreover, <b>6z</b> is active on mutated kinases such as different ABL mutants involved in leukemia resistance, the well-known B-RAF mutant involved in melanoma, and the mutation T790M of EGFR that is involved in the resistance of cells to anti-EGFR therapies in lung cancer. An IC<sub>50</sub> less than or close to 50 nM was observed on ABL WT, ABL<sup>G250E</sup>, ABL<sup>Y253F</sup>, ABL<sup>E255K</sup>, and SRC, historically the first kinases targeted by this compound. As an MTKI, <b>6z</b> presents IC<sub>50</sub> values less than 50 nM against at least EGFR WT, LYN A, HCK, PDGFRA, YES, and B-RAF<sup>V600E</sup> (<a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>). These results confirm that our approach allows the selective design of MTKI compounds targeting only oncogenic kinases.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Kinase Inhibition Profile of <b>6z</b> for a Broad Panel of Kinases</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col /></col><col /></col><col /></col><col /></col><col /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" colspan="3" align="center">% < 40</th><th class="rowsep1 colsep0" align="center">40 ≤ % < 80</th><th class="rowsep1 colsep0" align="center">% ≥ 80</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">ABL<sup>T315I</sup></td><td class="colsep0 rowsep0">FGFR1</td><td class="colsep0 rowsep0">PI3Kα</td><td class="colsep0 rowsep0">c-SRC</td><td class="colsep0 rowsep0">ABL WT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">AKT2</td><td class="colsep0 rowsep0">GSK3b</td><td class="colsep0 rowsep0">PIM1</td><td class="colsep0 rowsep0">ARG</td><td class="colsep0 rowsep0">ABL<sup>E255 K</sup></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">AMPK</td><td class="colsep0 rowsep0">IGF-1R</td><td class="colsep0 rowsep0">PKA</td><td class="colsep0 rowsep0">B-RAF</td><td class="colsep0 rowsep0">ABL<sup>G250E</sup></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">Aurora A</td><td class="colsep0 rowsep0">IKK beta</td><td class="colsep0 rowsep0">PKCa</td><td class="colsep0 rowsep0">BTK</td><td class="colsep0 rowsep0">ABL<sup>Y253F</sup></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">Aurora B</td><td class="colsep0 rowsep0">IKK alpha</td><td class="colsep0 rowsep0">PKCd</td><td class="colsep0 rowsep0">CSK</td><td class="colsep0 rowsep0">BLK</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">Aurora C</td><td class="colsep0 rowsep0">INSRR</td><td class="colsep0 rowsep0">PKCe</td><td class="colsep0 rowsep0">EGFR<sup>T790M</sup></td><td class="colsep0 rowsep0">BMX</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">AXL</td><td class="colsep0 rowsep0">ITK</td><td class="colsep0 rowsep0">PKCg</td><td class="colsep0 rowsep0">EPHA1</td><td class="colsep0 rowsep0">EGFR WT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">CaMKII d</td><td class="colsep0 rowsep0">JAK2</td><td class="colsep0 rowsep0">PKCθ</td><td class="colsep0 rowsep0">EPHA2</td><td class="colsep0 rowsep0">EPHB2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">CDK1/cyclin B</td><td class="colsep0 rowsep0">JAK3</td><td class="colsep0 rowsep0">PKD2</td><td class="colsep0 rowsep0">EPHA4</td><td class="colsep0 rowsep0">FGR</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">CDK2/cyclin A</td><td class="colsep0 rowsep0">MEK1</td><td class="colsep0 rowsep0">PLK1</td><td class="colsep0 rowsep0">EPHB4</td><td class="colsep0 rowsep0">HCK</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">CDK5/p25</td><td class="colsep0 rowsep0">ERK2</td><td class="colsep0 rowsep0">ROCKII</td><td class="colsep0 rowsep0">ERBB4</td><td class="colsep0 rowsep0">LCK</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">CDK7/cyclin H/MNAT1</td><td class="colsep0 rowsep0">MAPKAPK2</td><td class="colsep0 rowsep0">ROS1</td><td class="colsep0 rowsep0">FGFR2</td><td class="colsep0 rowsep0">LYN A</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">Cdk9/cyclin T1</td><td class="colsep0 rowsep0">MAPKAPK5</td><td class="colsep0 rowsep0">SYK</td><td class="colsep0 rowsep0">FLT3</td><td class="colsep0 rowsep0">YES</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">CHK2</td><td class="colsep0 rowsep0">MATK</td><td class="colsep0 rowsep0">TEC</td><td class="colsep0 rowsep0">CSF1R</td><td class="colsep0 rowsep0">B-RAF<sup>V600E</sup></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">CK1</td><td class="colsep0 rowsep0">MST1R</td><td class="colsep0 rowsep0">TIE2</td><td class="colsep0 rowsep0">FRK</td><td class="colsep0 rowsep0"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">c-KIT</td><td class="colsep0 rowsep0">mTOR</td><td class="colsep0 rowsep0">TRKA</td><td class="colsep0 rowsep0">FYN</td><td class="colsep0 rowsep0"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">c-MER</td><td class="colsep0 rowsep0">MLCK</td><td class="colsep0 rowsep0">TSSK2</td><td class="colsep0 rowsep0">p38 alpha</td><td class="colsep0 rowsep0"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">c-MET</td><td class="colsep0 rowsep0">NEK2</td><td class="colsep0 rowsep0">TYK1</td><td class="colsep0 rowsep0">PDGFRA</td><td class="colsep0 rowsep0"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">DMPK</td><td class="colsep0 rowsep0">NUAK1</td><td class="colsep0 rowsep0">TYK2</td><td class="colsep0 rowsep0">RET</td><td class="colsep0 rowsep0"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">ERBB2</td><td class="colsep0 rowsep0">p70S6K</td><td class="colsep0 rowsep0">TYRO3</td><td class="colsep0 rowsep0">VEGFR2</td><td class="colsep0 rowsep0"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">FAK</td><td class="colsep0 rowsep0">PAK2</td><td class="colsep0 rowsep0">VEGFR1</td><td class="colsep0 rowsep0"> </td><td class="colsep0 rowsep0"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">FER</td><td class="colsep0 rowsep0">PDGFRb</td><td class="colsep0 rowsep0">VEGFR3</td><td class="colsep0 rowsep0"> </td><td class="colsep0 rowsep0"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">FES</td><td class="colsep0 rowsep0">PDK1</td><td class="colsep0 rowsep0">ZAP70</td><td class="colsep0 rowsep0"> </td><td class="colsep0 rowsep0"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"> </td><td class="colsep0 rowsep0">PHKG2</td><td class="colsep0 rowsep0"> </td><td class="colsep0 rowsep0"> </td><td class="colsep0 rowsep0"> </td></tr></tbody></table></div></div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. IC<sub>50</sub> Value of <b>6z</b> on Selected Kinases Inhibited with Percent Inhibition Greater Than 40% at 100 nM</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinases</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">kinases</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ABL WT</td><td class="colsep0 rowsep0" align="char" char=".">6</td><td class="colsep0 rowsep0" align="left">PDGFRA</td><td class="colsep0 rowsep0" align="char" char=".">50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">B-RAF<sup>V600E</sup></td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="left">ABL<sup>Y253F</sup></td><td class="colsep0 rowsep0" align="char" char=".">51</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR WT</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="left">FRK</td><td class="colsep0 rowsep0" align="char" char=".">62</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HCK</td><td class="colsep0 rowsep0" align="char" char=".">22</td><td class="colsep0 rowsep0" align="left">LCK</td><td class="colsep0 rowsep0" align="char" char=".">69</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LYN A</td><td class="colsep0 rowsep0" align="char" char=".">37</td><td class="colsep0 rowsep0" align="left">ABL<sup>E255K</sup></td><td class="colsep0 rowsep0" align="char" char=".">73</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">c-SRC</td><td class="colsep0 rowsep0" align="char" char=".">40</td><td class="colsep0 rowsep0" align="left">EGFR<sup>T790M</sup></td><td class="colsep0 rowsep0" align="char" char=".">112</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">YES</td><td class="colsep0 rowsep0" align="char" char=".">44</td><td class="colsep0 rowsep0" align="left">FYN</td><td class="colsep0 rowsep0" align="char" char=".">131</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ABL<sup>G250E</sup></td><td class="colsep0 rowsep0" align="char" char=".">46</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr></tbody></table></div></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Broad Antiproliferative Effects of <b>6z</b></h3><div class="NLM_p">Finally, we evaluated the therapeutic potential of <b>6z</b> against different types of cancers. The antiproliferative effect of <b>6z</b> was compared to different reference compounds that are currently approved agents of interest or under evaluation in clinical trial phases. With the MTKI profile of <b>6z</b> and its ability to inhibit clinically validated oncogenic kinases, we assessed its biological effect on a panel of sensitive and resistant/aggressive cancer cell lines. The cells that were considered as sensitive are the BxPC-3 and Caki-2 cell lines, which, respectively, represent human pancreatic and kidney cancer, and the murine BaF3 WT leukemia-derived cell line expressing the human BCR-ABL wild-type fusion protein that is used as a model for the Philadelphia chromosome (Ph)-positive leukemias. PC-3 (human non-hormone-dependent prostate cancer cell line), MDA-MB-231 (triple-negative breast cancer cell lines), NCI-H1975 (non-small-cell lung cancer cell line harboring the genetic modification of EGFR leading to the expression of a protein with L858R and T790M double mutations), and BaF3 T315I (the murine leukemia-derived cell line expressing the well-known mutated form of BCR-Abl fusion protein) were selected as representative of resistant and/or aggressive cancer cells.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Antiproliferative Effects of <b>6z</b> in Comparison with Reference Compounds Represented by Their EC<sub>50</sub> Values on Different Cancer Cell Lines<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="7" align="center">EC<sub>50</sub> (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">PC-3</th><th class="colsep0 rowsep0" align="center">Caki-2</th><th class="colsep0 rowsep0" align="center">MDA-MB-231</th><th class="colsep0 rowsep0" align="center">BxPC-3</th><th class="colsep0 rowsep0" align="center">NCI-H1975</th><th class="colsep0 rowsep0" align="center">BaF3 WT</th><th class="colsep0 rowsep0" align="center">BaF3 T315I</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6z</b></td><td class="colsep0 rowsep0" align="center">152</td><td class="colsep0 rowsep0" align="center">22</td><td class="colsep0 rowsep0" align="center">158</td><td class="colsep0 rowsep0" align="center">35</td><td class="colsep0 rowsep0" align="center">104</td><td class="colsep0 rowsep0" align="center">0.04</td><td class="colsep0 rowsep0" align="center">1.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Dasatinib</td><td class="colsep0 rowsep0" align="center">232</td><td class="colsep0 rowsep0" align="center">55</td><td class="colsep0 rowsep0" align="center">44</td><td class="colsep0 rowsep0" align="center">33</td><td class="colsep0 rowsep0" align="center">173</td><td class="colsep0 rowsep0" align="center"><b>0.04</b></td><td class="colsep0 rowsep0" align="center">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Erlotinib</td><td class="colsep0 rowsep0" align="center">>1000</td><td class="colsep0 rowsep0" align="center">>1000</td><td class="colsep0 rowsep0" align="center">>1000</td><td class="colsep0 rowsep0" align="center"><b>>1000</b></td><td class="colsep0 rowsep0" align="center"><b>>1000</b></td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Sunitinib</td><td class="colsep0 rowsep0" align="center">>1000</td><td class="colsep0 rowsep0" align="center"><b>>1000</b></td><td class="colsep0 rowsep0" align="center">>1000</td><td class="colsep0 rowsep0" align="center">>1000</td><td class="colsep0 rowsep0" align="center">>1000</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ponatinib</td><td class="colsep0 rowsep0" align="center">>1000</td><td class="colsep0 rowsep0" align="center">653</td><td class="colsep0 rowsep0" align="center">483</td><td class="colsep0 rowsep0" align="center">544</td><td class="colsep0 rowsep0" align="center">>1000</td><td class="colsep0 rowsep0" align="center">0.05</td><td class="colsep0 rowsep0" align="center"><b>0.3</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Imatinib</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center"><b>34</b></td><td class="colsep0 rowsep0" align="center">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Sorafenib</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center"><b>>1000</b></td><td class="colsep0 rowsep0" align="center">>1000</td><td class="colsep0 rowsep0" align="center">>1000</td><td class="colsep0 rowsep0" align="center">>1000</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Afatinib</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center">>1000</td><td class="colsep0 rowsep0" align="center">>1000</td><td class="colsep0 rowsep0" align="center"><b>116</b></td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center">nd</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup>a</sup><p class="last">nd: not determined. Bold values are for marketed references currently approved.</p></div></div></div><div class="NLM_p last">EC<sub>50</sub> values presented in <a class="ref internalNav" href="#tbl8" aria-label="Table 8">Table 8</a> demonstrate that <b>6z</b> is highly cytotoxic with similar or even better potency than reference compounds against a large panel of cancer cell types even if aggressive or resistant.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Pharmacokinetic Profile of <b>6z</b> in Mice</h3><div class="NLM_p">The pharmacokinetic (PK) parameters of <b>6z</b> were assessed in mice following intravenous (IV) and oral (PO) administrations as described in <a class="ref internalNav" href="#tbl9" aria-label="Table 9">Table 9</a>. After IV administration at a dose of 2 mg/kg, maximum concentration (<i>C</i><sub>max</sub>) reached 853 ng/mL, and area under the curve (AUC<sub>0–∞</sub>) was 558 ng/mL·h. After oral administration at 20 mg/kg, <i>C</i><sub>max</sub> reached 610 ng/mL (1.1 μM) at 0.5 h postdosing, and AUC<sub>0–∞</sub> was 3029 ng/mL·h (5.4 μM·h).</div><div class="NLM_p">These results demonstrate good pharmacokinetic properties of <b>6z</b> in mice with high oral bioavailability (close to 47%) and a sustained plasma concentration exceeding in vitro EC<sub>50</sub> during at least 8 h after oral dosing. These data indicate a favorable pharmacokinetic profile of <b>6z</b> in preparation for efficacy studies in mice.</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Pharmacokinetic Profile of <b>6z</b> in Mice after IV and PO Dosing</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">administration route</th><th class="colsep0 rowsep0" align="center" char=".">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>0–∞</sub> (ng/mL·h)</th><th class="colsep0 rowsep0" align="center"><i>F</i> (%)</th></tr></thead><tbody><tr valign="middle" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left" valign="middle"><b>6z</b></td><td class="colsep0 rowsep0" align="left" valign="middle">IV</td><td class="colsep0 rowsep0" align="char" valign="middle" char=".">2</td><td class="colsep0 rowsep0" align="char" valign="middle" char=".">853</td><td class="colsep0 rowsep0" align="char" valign="middle" char=".">0.167</td><td class="colsep0 rowsep0" align="char" valign="middle" char=".">558</td><td class="colsep0 rowsep0" align="left" valign="middle">N/A<a class="ref internalNav" href="#t9fn1" aria-label="a">a</a></td></tr><tr valign="middle" class="colsep0"><td class="colsep0 rowsep0" align="left" valign="middle">PO</td><td class="colsep0 rowsep0" align="char" valign="middle" char=".">20</td><td class="colsep0 rowsep0" align="char" valign="middle" char=".">610</td><td class="colsep0 rowsep0" align="char" valign="middle" char=".">0.500</td><td class="colsep0 rowsep0" align="char" valign="middle" char=".">3029</td><td class="colsep0 rowsep0" align="left" valign="middle">47</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup>a</sup><p class="last">N/A: not applicable.</p></div></div></div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> In Vitro hERG Patch Clamp Assay</h3><div class="NLM_p last">Blockade of the cardiac ion channel coded by human ether-a-go-go-related gene (hERG) can lead to cardiac arrhythmia, which has become a major concern in drug discovery and development mainly in the field of kinase inhibitors. The inhibitory effect of <b>6z</b> on the hERG channel was assessed using conventional patch clamp experiments. With very modest inhibition of hERG channel (26% inhibition at a 30 μM concentration), the compound <b>6z</b> bears a minor risk of potentially problematic cardiac side effects.</div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> In Vitro Cytotoxicity Effect of <b>6z</b> on Human Activated and Resting PBMC</h3><div class="NLM_p">Several in vitro methods have been suggested to predict drug-induced hematotoxicity.<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16, 17)</a> We used primary cells (PBMC) isolated from peripheral blood from two healthy donors to assess and detect drug sensitivity in a short-term assay. Cells were exposed to increasing concentrations of <b>6z</b> or Dasatinib. Dasatinib was used as reference because it is the compound most similar to <b>6z</b> in terms of antiproliferative activity as observed on cancer cell lines (<a class="ref internalNav" href="#tbl8" aria-label="Table 8">Table 8</a>) and its immunosuppressive activity was demonstrated in patients.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> When PBMC were stimulated with phytohemagglutinin (PHA) supplemented with IL-2 (PHA/IL-2), mitogen/cytokine combination used widely to induce cell division, the EC<sub>50</sub> of <b>6z</b> and Dasatinib were close to 4.8 and 2.4 μM, respectively, for donor 1 and close to 1.2 and 1.6 μM, respectively, for donor 2 (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>, left). No EC<sub>50</sub> could be determined for either compound on resting human PBMC because of the plateau shaped dose–response curves (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>, right). Human cancer cell lines showed higher sensitivity in terms of EC<sub>50</sub> to <b>6z</b> than did human PBMC indicating that even if <b>6z</b> might induce immunosuppression in clinic this should be manageable and there could be a therapeutic window for <b>6z</b> in a broad range of cancer types. Nevertheless, these results suggest that a compound optimization stage most probably achieved by redesigning <b>6z</b> to avoid inhibition of LCK could still improve its safety profile to prevent potential side effects and immunosuppressive complications.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/medium/jm-2016-00087m_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/large/jm-2016-00087m_0005.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. In vitro evaluation of cytotoxic effect of <b>6z</b> on activated (PHA/IL-2) or resting human PBMC from two healthy donors (error bars represent SD).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/large/jm-2016-00087m_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00087&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73286" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73286" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Using structure-based drug design combined with medicinal chemistry approaches, we have designed and synthesized a new and potent 7-azaindole-based chemical series showing a multitarget kinase inhibition profile. The compounds from the new series are all type-II inhibitors and are part of the follow-up series from the study of dual ABL and SRC kinase type-I inhibitors we published previously.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a></div><div class="NLM_p">A library of more than 40 type-II kinase inhibitors was synthesized in 3–6 chemical steps from commercially available 7-azaindole scaffolds. Stepwise medicinal chemistry was used to carry out pharmacomodulations around the 7-azaindole core and to increase the potency of compounds to obtain a multitarget kinase inhibition profile against six main targets. The selected targets are representative kinases from the growth receptor tyrosine kinase family, the SRC family with c-SRC, and B-RAF kinase as one of the first kinases involved in the MAPK signaling pathway activation.</div><div class="NLM_p">This study highlights the importance of the substitutions in the 7-azaindole core for modulating the activity of the compounds on the kinases of interest. Depending on the nature of the substituents, we were able to design multitarget kinase inhibitors with different inhibition profiles. The study also resulted in the design of a new lead series showing a broad antiproliferative effect on solid and liquid tumors and outperforming the reference compounds for the therapeutic indication of interest. The compounds also showed antiangiogenic activity more potent than that of Sorafenib whose antiangiogenic activity is considered to be a driver of its anticancer action.</div><div class="NLM_p last">All these studies allowed us to select the compound <b>6z</b> as our lead for further in silico and in vitro investigations. The study of the binding mode of the lead compound <b>6z</b> in docking studies revealed similar interaction modes for all the six targets (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00087/suppl_file/jm6b00087_si_001.pdf" class="ext-link">Figures S1 and S2</a>), which explains the MTKI profile. The lead compound also showed very good potency on other oncogenic kinases and no inhibition of kinases leading to moderate to severe side effects. In antiproliferation cell assays compared to several reference and marketed anticancer drugs for resistant and wild-type cancer indications (hepatocarcinoma, non-small-cell lung cancer, pancreas, kidney, leukemia, and breast), <b>6z</b> showed high cytotoxicity with potency similar to or even higher than that of reference compounds. In preliminary ADME-Tox studies, <b>6z</b> was not predicted to induce potentially cardiotoxic side effects and presented a favorable pharmacokinetic profile in mice. Nevertheless, the compound might potentially induce immunosuppression, similar to a number of other kinase inhibitors, that should be manageable in clinic. To conclude, the <b>6z</b> lead compound is a highly potent inhibitor with a broad oncogenic kinase spectrum and provides a strong rationale for its therapeutic application in multiple cancer models. However, a lead optimization phase should be started in order to improve its safety profile and prevent potential immunosuppressive complications.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13748" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13748" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Chemistry</h3><div class="NLM_p">Starting materials, reagents, and solvents employed for reactions were reagent-grade and used as purchased. Flash-column chromatography was carried out using either irregular 40–63 μm silica gel or KP-C18-HS Biotage SnapCartridge for the reverse phase. <sup>1</sup>H NMR spectra were recorded on Bruker Avance 200, 300, or 400 MHz spectrometers using DMSO-<i>d</i><sub>6</sub>. Chemical shifts are reported in parts per million (δ relative to the residual solvent peak). The multiplicity of the signals is indicated with the following abbreviations: bs (broad singlet), s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), bs (broad singlet), dd (doublet of doublets), and td (doublet of triplets). Reaction monitoring and compound purity were determined by LC/MS using Agilent technology 1260 Infinity HPLC system with a C18 column (Agilent ZORBAX SB-C18, 1.8 μm, 2.1 mm × 50 mm) operating at 30 °C and coupled with a single quadrupole spectrometer (Agilent 6100). The eluting solvents are water containing 0.1% formic acid (mobile phase A) and acetonitrile containing 0.1% formic acid (mobile phase B). Three methods were used with three different gradient elutions as described in the <a href="/doi/suppl/10.1021/acs.jmedchem.6b00087/suppl_file/jm6b00087_si_001.pdf" class="ext-link">Supporting Information</a>. Detection was carried out with (1) a diode array detector at 254 nm except if specified in the experimental part and (2) electrospray ionization (positive and/or negative mode). The HPLC purity of all final compounds was ≥95% except if specified.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 5-(2-Methyl-5-nitro-benzylamino)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methyl Ester (<b>3a</b>)</h4><div class="NLM_p last">5-Amino-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic acid methyl ester <b>1a</b> (12.16 g, 63.7 mmol) and 2-methyl-5-nitrobenzaldehyde <b>2</b> (10.5 g, 64 mmol) were stirred in a solution of AcOH 10% in MeOH (660 mL) for 2 h. Then, NaBH<sub>3</sub>CN (7.9 g, 127 mmol) was slowly added, and the mixture was stirred under argon for 48 h. Solvents were evaporated, and a saturated aqueous solution of NaHCO<sub>3</sub> was added until neutrality. Solid formed was filtered and washed with petroleum ether/EtOAc 5/5. A brownish solid was obtained (<b>3a</b>, 17.9 g, 82%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 12.09 (s, 1H), 8.12 (d, <i>J</i> = 2.5 Hz, 2H), 8.04 (dd, <i>J</i> = 2.5, 8.3 Hz, 1H), 7.50 (d, <i>J</i> = 8.3 Hz, 1H), 7.00 (d, <i>J</i> = 2.6 Hz, 1H), 6.88 (s, 1H), 6.30 (t, <i>J</i> = 5.8 Hz, 1H), 4.37 (d, <i>J</i> = 5.8 Hz, 2H), 3.82 (s, 3H), 2.49 (s, 4H). MS (ESI) <i>m</i>/<i>z</i> 341.1 [M + H]<sup>+</sup> and 339.1 [M – H]<sup>−</sup>. HPLC purity: 94%.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 1-[5-(2-Methyl-5-nitro-benzylamino)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-2-yl]-ethanone (<b>3b</b>)</h4><div class="NLM_p last">1-[5-Amino-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-2-yl]-ethanone <b>3b</b> (6.7 g, 0.038 mol) and 2-methyl-5-nitrobenzaldehyde <b>2</b> (6.3 g, 0.038 mol) were stirred in AcOH/MeOH (42 mL/420 mL) for 2 h at room temperature. Then, NaBH<sub>3</sub>CN (4.8 g, 0.076 mol) was slowly added, and the mixture was stirred under argon overnight. Solvents were evaporated, and a saturated aqueous solution of NaHCO<sub>3</sub> was added until neutrality. Solid formed was filtered and washed with water and diethyl ether to give <b>3b</b> (10.5 g, 86%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 11.88 (s, 1H), 8.18–8.09 (m, 2H), 8.04 (dd, <i>J</i> = 8.3, 2.5 Hz, 1H), 7.51 (d, <i>J</i> = 8.3 Hz, 1H), 7.05 (d, <i>J</i> = 1.9 Hz, 1H), 7.00 (d, <i>J</i> = 2.5 Hz, 1H), 6.32 (t, <i>J</i> = 5.7 Hz, 1H), 4.38 (d, <i>J</i> = 5.7 Hz, 2H), 2.49 (s, 3H), 2.47 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 325.1 [M + H]<sup>+</sup> and 323.2 [M – H]<sup>−</sup>.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 5-(5-Amino-2-methyl-benzylamino)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methyl Ester (<b>4a</b>)</h4><div class="NLM_p last">5-(2-Methyl-5-nitro-benzylamino)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic acid methyl ester <b>3a</b> (17.8 g, 54 mmol), methanol (300 mL), 7.2 mL of HCl 12 N, and palladium 10% on charcoal (1.7 g, 10% w/w) were put in an autoclave filled with 30 bar of hydrogen and stirred for 48 h at room temperature. The mixture was filtered on Celite bed and washed with methanol. Solvent was evaporated, and then a saturated aqueous solution of NaHCO<sub>3</sub> was added. The solid obtained was filtered and washed with water to obtain a brownish solid (<b>4a</b>, 14.4 g, 96%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 12.02 (s, 1H), 8.07 (d, <i>J</i> = 2.6 Hz, 1H), 6.95 (d, <i>J</i> = 2.6 Hz, 1H), 6.89 (d, <i>J</i> = 2.1 Hz, 1H), 6.83 (d, <i>J</i> = 8.0 Hz, 1H), 6.58 (d, <i>J</i> = 2.3 Hz, 1H), 6.37 (dd, <i>J</i> = 8.0, 2.3 Hz, 1H), 5.96–5.88 (m, 1H), 4.82 (s, 2H), 4.07 (d, <i>J</i> = 3.6 Hz, 2H), 3.83 (s, 3H), 2.16 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 311.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 1-[5-(5-Amino-2-methyl-benzylamino)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-2-yl]-ethanone (<b>4b</b>)</h4><div class="NLM_p last">In an autoclave, 1-[5-(2-methyl-5-nitro-benzylamino)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-2-yl]-ethanone <b>3b</b> (10.7 g, 0.033 mol) and Pd/C 10% (20% w/w, 2 g) in 400 mL DMF were stirred at room temperature under hydrogen pressure (30 bar). After full conversion, the mixture was filtered on a pad of Celite and washed several times with a solution of MeOH/10% HCl (aqueous). Then, the filtrate was neutralized with NaHCO<sub>3</sub> until pH 7–8, and the solid formed was filtered and washed with water and diethyl ether to give <b>4b</b> (9.4 g, 97%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 11.8 (s, 1H), 8.09 (s, 1H), 7.06 (d, <i>J</i> = 1.9 Hz, 1H), 6.96 (d, <i>J</i> = 2.3 Hz, 1H), 6.83 (d, <i>J</i> = 8.0 Hz, 1H), 6.58 (d, <i>J</i> = 1.9 Hz, 1H), 6.37 (dd, <i>J</i> = 8.0, 2.3 Hz, 1H), 5.93 (t, <i>J</i> = 5.2 Hz, 1H), 4.77 (s, 2H), 4.08 (d, <i>J</i> = 5.2 Hz, 2H), 2.48 (s, 3H), 2.17 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 295.2 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Preparation of 5-{2-Methyl-5-[3-amido]-benzylamino}-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Methyl Esters (Compounds <b>6</b>)</h3><div id="sec4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> General Procedure A from Carboxylic Acids</h4><div class="NLM_p last">Acid derivative was dissolved in anhydrous DMF with DIEA and HATU or PyBOP. After 15 min, compound <b>4a</b> or <b>4b</b> was slowly added, and the mixture was stirred overnight at room temperature. DMF was evaporated, and saturated NaHCO<sub>3</sub> aqueous solution was added. The crude mixture was extracted with EtOAc, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated to obtain a dark mixture. After purification by washing with MeOH or by purification on flash chromatography column, expected product was obtained as a slightly yellow or orange powder.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> General Procedure B from Acyl Chlorides</h4><div class="NLM_p last">Triethylamine and acyl chloride were added to a solution of compound <b>4a</b> or <b>4b</b> in anhydrous DMF. The reaction mixture was stirred overnight at room temperature. DMF was evaporated, and saturated NaHCO<sub>3</sub> aqueous solution was added. The crude was extracted with EtOAc, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated to obtain a dark mixture. After purification by washing with MeOH or EtOAc or by purification on silica gel column, expected product is obtained as a slightly yellow or orange powder.</div></div><div id="sec4_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 5-[2-Methyl-5-(3-methyl-benzoylamino)-benzylamino]-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methyl Ester (<b>6a</b>)</h4><div class="NLM_p last">The reaction was carried out as described in general procedure A using <b>4a</b> (50 mg, 0.16 mmol), 3-methylbenzoic acid (22 mg, 0.16 mmol), HATU (182 mg, 0.48 mmol), DIEA (140 μL, 0.8 mmol), and anhydrous DMF (3 mL). Purification by reverse-phase flash chromatography (H<sub>2</sub>O/ACN, 70/30 to 20/80) yielded <b>6a</b> (20 mg, 29%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 12.04 (s, 1H), 10.11 (s, 1H), 8.09 (d, <i>J</i> = 2.5 Hz, 1H), 7.77–7.59 (m, 4H), 7.38–7.33 (m, 2H), 7.17 (d, <i>J</i> = 8.2 Hz, 1H), 6.98 (s, <i>J</i> = 2.5 Hz, 1H), 6.90 (d, <i>J</i> = 2.1 Hz, 1H), 6.05 (t, <i>J</i> = 5.2 Hz, 1H), 4.21 (d, <i>J</i> = 5.2 Hz, 2H), 3.82 (s, 3H), 2.36 (s, 3H), 2.32 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 429.2 [M + H]<sup>+</sup> and 427.2 [M – H]<sup>−</sup>. HPLC purity: 93%.</div></div><div id="sec4_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 5-[5-(3-Bromo-benzoylamino)-2-methyl-benzylamino]-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methyl Ester (<b>6b</b>)</h4><div class="NLM_p last">The reaction was carried out as described in general procedure A using <b>4a</b> (150 mg, 0.48 mmol), 3-bromobenzoic acid (96 mg, 0.48 mmol), HATU (500 mg, 1.3 mmol), DIEA (420 μL, 2.42 mmol), and anhydrous DMF (10 mL). Purification by reverse-phase flash chromatography (H<sub>2</sub>O/ACN, 75/25 to 25/75) yielded <b>6b</b> (57 mg, 24%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 10.25 (s, 1H), 8.14–8.06 (m, 2H), 7.92–7.87 (m, 1H), 7.78–7.73 (m, 1H), 7.70–7.62 (m, 2H), 7.45 (t, <i>J</i> = 7.9 Hz, 1H), 7.18 (d, <i>J</i> = 7.9 Hz, 1H), 6.98 (d, <i>J</i> = 2.6 Hz, 1H), 6.90 (d, <i>J</i> = 2.1 Hz, 1H), 6.07 (t, <i>J</i> = 5.4 Hz, 1H), 4.22 (d, <i>J</i> = 5.4 Hz, 2H), 3.82 (s, 3H), 2.32 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 493.1–495.1 [M + H]<sup>+</sup> and 491.1–493.1 [M – H]<sup>−</sup>. HPLC purity: 83% at 295 nm.</div></div><div id="sec4_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 5-[5-(3-Isopropyl-benzoylamino)-2-methyl-benzylamino]-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methyl Ester (<b>6c</b>)</h4><div class="NLM_p last">The reaction was carried out as described in general procedure A using <b>4a</b> (50 mg, 0.16 mmol), 3-isopropylbenzoic acid (26 mg, 0.16 mmol), HATU (182 mg, 0.48 mmol), DIEA (140 μL, 0.8 mmol), and anhydrous DMF (3 mL). Purification by reverse-phase flash chromatography (H<sub>2</sub>O/ACN, 75/25 to 0/100) yielded <b>6c</b> (19 mg, 26%). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 12.00 (s, 1H), 10.08 (s, 1H), 8.10 (d, <i>J</i> = 2.4 Hz, 1H), 7.76 (s, 1H), 7.71 (d, <i>J</i> = 7.6 Hz, 1H), 7.69 (s, 1H), 7.64 (dd, <i>J</i> = 8.2, 1.8 Hz, 1H), 7.43 (t, <i>J</i> = 7.6 Hz, 1H), 7.39 (t, <i>J</i> = 7.6 Hz, 1H), 7.17 (d, <i>J</i> = 8.2 Hz, 1H), 7.00 (d, <i>J</i> = 2.4 Hz, 1H), 6.90 (d, <i>J</i> = 1.8 Hz, 1H), 6.00 (t, <i>J</i> = 5.4 Hz, 1H), 4.22 (d, <i>J</i> = 5.4 Hz, 2H), 3.83 (s, 3H), 2.99–2.93 (q, <i>J</i> = 7.0 Hz, 1H), 2.33 (s, 3H), 1.23 (d, <i>J</i> = 7.0 Hz, 6H). MS (ESI) <i>m</i>/<i>z</i> 457.3 [M + H]<sup>+</sup> and 455.2 [M – H]<sup>−</sup>. HPLC purity: 94%.</div></div><div id="sec4_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 5-[2-Methyl-5-(3-trifluoromethyl-benzoylamino)-benzylamino]-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methyl Ester (<b>6d</b>)</h4><div class="NLM_p last">The reaction was carried out as described in general procedure A using <b>4a</b> (100 mg, 0.32 mmol), 3-trifluoromethylbenzoic acid (72.2 mg, 0.38 mmol), HATU (145.9 mg, 0.38 mmol), DIEA (220 μL, 1.26 mmol), and anhydrous DMF (4 mL). Purification by reverse-phase flash chromatography (H<sub>2</sub>O/ACN with 1% TFA, 100/0 to 30/70) yielded after neutralization with NaHCO<sub>3</sub> (aqueous) and filtration <b>6d</b> (37 mg, 24%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 12.03 (s, 1H), 10.38 (s, 1H), 8.25–8.19 (m, 2H), 8.10 (d, <i>J</i> = 2.7 Hz, 1H), 7.93 (d, <i>J</i> = 8.0 Hz, 1H), 7.74 (t, <i>J</i> = 8.0 Hz, 1H), 7.69–7.64 (m, 2H), 7.20 (d, <i>J</i> = 8.0 Hz, 1H), 6.98 (d, <i>J</i> = 2.7 Hz, 1H), 6.91–6.88 (m, 1H), 6.07 (t, <i>J</i> = 5.5 Hz, 1H), 4.23 (d, <i>J</i> = 5.5 Hz, 2H), 3.82 (s, 3H), 2.33 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 483.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 5-[2-Methyl-5-(3-trifluoromethoxy-benzoylamino)-benzylamino]-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methyl Ester (<b>6e</b>)</h4><div class="NLM_p last">The reaction was carried out as described in general procedure A using <b>4a</b> (50 mg, 0.16 mmol), 3-(trifluoromethoxy)benzoic acid (33 mg, 0.16 mmol), HATU (185 mg, 0.48 mmol), DIEA (140 μL, 0.8 mmol), and anhydrous DMF (3 mL). Purification by reverse-phase flash chromatography (H<sub>2</sub>O/ACN, 80/20 to 30/70) yielded <b>6e</b> (20 mg, 25%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 12.04 (s, 1H), 10.30 (s, 1H), 8.09 (d, <i>J</i> = 2.6 Hz, 1H), 7.98–7.94 (m, 1H), 7.87–7.84 (m, 1H), 7.70–7.61 (m, 3H), 7.60–7.55 (m, 1H), 7.19 (d, <i>J</i> = 8.2 Hz, 1H), 6.97 (d, <i>J</i> = 2.5 Hz, 1H), 6.89 (d, <i>J</i> = 2.1 Hz, 1H), 6.08 (t, <i>J</i> = 5.3 Hz, 1H), 4.22 (d, <i>J</i> = 5.3 Hz, 2H), 3.82 (s, 3H), 2.33 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 499.2 [M + H]<sup>+</sup> and 497.2 [M – H]<sup>−</sup>. HPLC purity: 94%.</div></div><div id="sec4_4_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 5-[2-Methyl-5-(4-methyl-3-trifluoromethyl-benzoylamino)-benzylamino]-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methyl Ester (<b>6f</b>)</h4><div class="NLM_p last">The reaction was carried out as described in general procedure A using <b>4a</b> (100 mg, 0.32 mmol), 4-methyl-3-(trifluoromethyl)benzoic acid (73 mg, 0.36 mmol), HATU (147 mg, 0.38 mmol), DIEA (167 μL, 0.96 mmol), and anhydrous DMF (2 mL). Purification by reverse-phase flash chromatography (H<sub>2</sub>O/ACN with 1% TFA, 100/0 to 30/70) yielded after neutralization with NaHCO<sub>3</sub> (aqueous) and filtration <b>6f</b> (41 mg, 26%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 12.10 (s, 1H), 10.32 (s, 1H), 8.19 (s, 1H), 8.15–8.03 (m, 2H), 7.72–7.61 (m, 2H), 7.58 (d, <i>J</i> = 8.1 Hz, 1H), 7.19 (d, <i>J</i> = 8.1 Hz, 1H), 7.05 (s, 1H), 6.92 (s, 1H), 4.24 (s, 2H), 3.83 (s, 3H), 2,50 (s, 3H), 2.32 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 497.2 [M + H]<sup>+</sup> and 495.1 [M – H]<sup>−</sup>.</div></div><div id="sec4_4_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 5-[5-(4-Chloro-3-trifluoromethyl-benzoylamino)-2-methyl-benzylamino]-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methyl Ester (<b>6g</b>)</h4><div class="NLM_p last">The reaction was carried out as described in general procedure A using <b>4a</b> (100 mg, 0.32 mmol), 4-chloro-3-(trifluoromethyl)benzoic acid (80 mg, 0.36 mmol), HATU (147 mg, 0.35 mmol), DIEA (167 μL, 0.96 mmol), and anhydrous DMF (2 mL). Purification by reverse-phase flash chromatography (H<sub>2</sub>O/ACN with 1% TFA, 100/0 to 40/60) yielded after neutralization with NaHCO<sub>3</sub> (aqueous) and filtration <b>6g</b> (8 mg, 5%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 12.05 (s, 1H), 10.43 (s, 1H), 8.33 (s, 1H), 8.21 (d, <i>J</i> = 7.9 Hz, 1H), 8.10 (s, 1H), 7.87 (d, <i>J</i> = 8.4 Hz, 1H), 7.70–7.60 (m, 2H), 7.20 (d, <i>J</i> = 8.4 Hz, 1H), 6.98 (s, 1H), 6.90 (s, 1H), 6.10 (s, 1H), 4.23 (s, 2H), 3.82 (s, 3H), 2.33 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 517.1 [M + H]<sup>+</sup> and 515.0 [M – H]<sup>−</sup>.</div></div><div id="sec4_4_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 5-[5-(4-Hydroxy-3-trifluoromethyl-benzoylamino)-2-methyl-benzylamino]-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methyl Ester (<b>6h</b>)</h4><div class="NLM_p last">The reaction was carried out as described in general procedure A using <b>4a</b> (50 mg, 0.16 mmol), 4-hydroxy-3-(trifluoromethoxy)benzoic acid (33 mg, 0.16 mmol), HATU (182 mg, 0.48 mmol), DIEA (140 μL, 0.8 mmol), and anhydrous DMF (3 mL). Purification by reverse-phase flash chromatography (H<sub>2</sub>O/ACN, 80/20 to 30/70) yielded <b>6h</b> (12 mg, 15%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 12.03 (s, 1H), 10.07 (s, 1H), 8.12–8.08 (m, 2H), 8.01 (dd, <i>J</i> = 8.8, 1.6 Hz, 1H), 7.65 (d, <i>J</i> = 2.0 Hz, 1H), 7.63 (dd, <i>J</i> = 8.1, 2.0 Hz, 1H), 7.16 (d, <i>J</i> = 8.1 Hz, 1H), 7.02 (d, <i>J</i> = 8.8 Hz, 1H), 7.00–6.97 (m, 1H), 6.92–6.88 (m, 1H), 6.03 (t, <i>J</i> = 5.3 Hz, 1H), 4.21 (d, <i>J</i> = 5.3 Hz, 2H), 3.82 (s, 3H), 2.32 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 499.2 [M + H]<sup>+</sup> and 497.1 [M – H]<sup>−</sup>.</div></div><div id="sec4_4_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 5-[5-(3-Dimethylamino-5-trifluoromethyl-benzoylamino)-2-methyl-benzylamino]-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methyl Ester (<b>6i</b>)</h4><div class="NLM_p last">The reaction was carried out as described in general procedure A using <b>4a</b> (80 mg, 0.26 mmol), 3-dimethylamino-5-(trifluoromethyl)benzoic acid (60 mg, 0.26 mmol), HATU (288 mg, 0.78 mmol), DIEA (250 μL, 1.3 mmol), and anhydrous DMF (4 mL). Purification by reverse-phase flash chromatography (H<sub>2</sub>O/ACN, 70/30 to 30/70) yielded <b>6i</b> (32 mg, 23%). <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 12.05 (s, 1H), 10.25 (s, 1H), 8.09 (s, 1H), 7.71–7.57 (m, 2H), 7.42 (d, <i>J</i> = 6.3 Hz, 2H), 7.18 (d, <i>J</i> = 8.0 Hz, 1H), 7.03 (s, 1H), 6.98 (s, 1H), 6.89 (s, 1H), 6.06 (t, <i>J</i> = 4.0 Hz, 1H), 4.22 (d, <i>J</i> = 4.0 Hz, 2H), 3.82 (s, 3H), 3.16 (dd, <i>J</i> = 5. 1, 1.4 Hz, 2H), 3.03–2.96 (m, 6H), 2.32 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 526.2 [M + H]<sup>+</sup> and 524.2 [M – H]<sup>−</sup>.</div></div><div id="sec4_4_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 5-[5-(2-Methoxy-benzoylamino)-2-methyl-benzylamino]-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methyl Ester (<b>6j</b>)</h4><div class="NLM_p last">The reaction was carried out as described in general procedure B using <b>4a</b> (100 mg, 0.32 mmol), 2-methoxybenzoyl chloride (57 μL, 0.38 mmol), Et<sub>3</sub>N (134 μL, 0.96 mmol), and anhydrous DMF (2 mL). Purification by reverse-phase flash chromatography (H<sub>2</sub>O/ACN with 1% TFA, 100/0 to 0/100) yielded after neutralization with NaHCO<sub>3</sub> (aqueous) and filtration <b>6j</b> (34.5 mg, 24%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 12.03 (s, 1H), 10.00 (s, 1H), 8.09 (d, <i>J</i> = 2.0 Hz, 1H), 7.73–7.55 (m, 3H), 7.50–7.42 (m, 1H), 7.15 (t, <i>J</i> = 7.7 Hz, 2H), 7.09–6.97 (m, 2H), 6.90 (d, <i>J</i> = 2.0 Hz, 1H), 6.01 (t, <i>J</i> = 5.0 Hz, 1H), 4.20 (d, <i>J</i> = 5.0 Hz, 2H), 3.83 (s, 3H), 3.83 (s, 3H), 2.31 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 445.2 [M + H]<sup>+</sup> and 443.2 [M – H]<sup>−</sup>.</div></div><div id="sec4_4_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 5-{5-[2-(2-Bromo-phenyl)-acetylamino]-2-methyl-benzylamino}-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methyl Ester (<b>6k</b>)</h4><div class="NLM_p last">The reaction was carried out as described in general procedure B using <b>4a</b> (20 mg, 0.065 mmol), 2-bromophenylacetyl chloride (10 μL, 0.065 mmol), Et<sub>3</sub>N (18 μL, 0.13 mmol), and anhydrous DMF (2 mL). Purification by reverse-phase flash chromatography (H<sub>2</sub>O/ACN, 80/20 to 20/80) yielded <b>6k</b> (7 mg, 11%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 12.02 (s, 1H), 10.06 (s, 1H), 8.08 (d, <i>J</i> = 2.6 Hz, 1H), 7.65–7.49 (m, 1H), 7,42 (s, 1H), 7.39–7.29 (m, 2H), 7.22–7.15 (m, 1H), 7.11 (d, <i>J</i> = 8.1 Hz, 1H), 6.96–6.91 (m, 1H), 6.89 (s, 1H), 6.08–6.01 (m 1H), 4.23–4.14 (m, 2H), 3.83 (s, 3H), 3.76 (s, 2H), 2.28 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 505.1, 507.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_4_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 5-{2-Methyl-5-[2-(3-trifluoromethyl-phenyl)-acetylamino]-benzylamino}-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methyl Ester (<b>6l</b>)</h4><div class="NLM_p last">The reaction was carried out as described in general procedure A using <b>4a</b> (50 mg, 0.16 mmol), 3-(trifluoromethyl)phenylacetic acid (33 mg, 0.16 mmol), HATU (180 mg, 0.48 mmol), DIEA (140 μL, 0.8 mmol), and anhydrous DMF (3 mL). Purification by reverse-phase flash chromatography (H<sub>2</sub>O/ACN, 85/15 to 0/100) yielded <b>6l</b> (9 mg, 11%). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 12.00 (s, 1H), 10.07 (s, 1H), 8.08 (d, <i>J</i> = 2.5 Hz, 1H), 7.64 (s, 1H), 7.61–7.56 (m, 2H), 7.56–7 0.51 (m, 2H), 7.43 (s, 1H), 7.11 (d, <i>J</i> = 8.2 Hz, 1H), 6.95 (d, <i>J</i> = 2.4 Hz, 1H), 6.88 (d, <i>J</i> = 1.1 Hz, 1H), 6.02 (t, <i>J</i> = 5.5 Hz, 1H), 4.19 (d, <i>J</i> = 5.5 Hz, 2H), 3.83 (s, 3H), 3.70 (s, 2H), 2.28 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 497.2 [M + H]<sup>+</sup> and 495.2 [M – H]<sup>−</sup>. HPLC purity: 94%.</div></div><div id="sec4_4_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 5-{2-Methyl-5-[(5-methyl-pyridine-3-carbonyl)-amino]-benzylamino}-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methyl Ester (<b>6m</b>)</h4><div class="NLM_p last">The reaction was carried out as described in general procedure A using <b>4a</b> (100 mg, 0.32 mmol), 5-methylnicotinic acid (50.9 mg, 0.37 mmol), HATU (146 mg, 0.38 mmol), DIEA (220 μL, 1.28 mmol), and anhydrous DMF (4 mL). Purification by reverse-phase flash chromatography (H<sub>2</sub>O/ACN with 1% TFA, 100/0 to 30/70) yielded after neutralization with NaHCO<sub>3</sub> (aqueous) and filtration <b>6m</b> (28 mg, 20%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 12.04 (s, 1H), 10.29 (s, 1H), 8.85 (s, 1H), 8.55 (s, 1H), 8.20–7.95 (m, 2H), 7.85–7.55 (m, 2H), 7.21 (s, 1H), 7.04–6.82 (m, 2H), 6.08 (s, 1H), 4.22 (s, 2H), 3.82 (s, 3H), 2.42–2.22 (m, 6H). MS (ESI) <i>m</i>/<i>z</i> 430.2 [M + H]<sup>+</sup> and 428.1 [M – H]<sup>−</sup>. HPLC purity: 94%.</div></div><div id="sec4_4_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 5-{2-Methyl-5-[(2-methyl-pyridine-4-carbonyl)-amino]-benzylamino}-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methyl Ester (<b>6n</b>)</h4><div class="NLM_p last">The reaction was carried out as described in general procedure A using <b>4a</b> (100 mg, 0.32 mmol), 2-methylisonicotinic acid (52 mg, 0.38 mmol), HATU (146 mg, 0.38 mmol), DIEA (220 μL, 1.28 mmol), and anhydrous DMF (4 mL). Purification by reverse-phase flash (H<sub>2</sub>O/ACN with 1% TFA, 100/0 to 30/70) yielded after neutralization with NaHCO<sub>3</sub> (aqueous) and filtration <b>6n</b> (27 mg, 20%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 10.34 (s, 1H), 8.58 (d, <i>J</i> = 4.9 Hz, 1H), 8.14–8.03 (m, 1H), 7.72–7.50 (m, 4H), 7.19 (d, <i>J</i> = 7.9 Hz, 1H), 7.00–6.92 (m, 1H), 6.89 (s, 1H), 6.08 (t, <i>J</i> = 4.7 Hz, 1H), 4.23 (d, <i>J</i> = 4.7 Hz, 2H), 3.82 (s, 3H), 2.53 (s, 3H), 2.33 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 430.2 [M + H]<sup>+</sup> and 428.2 [M – H]<sup>−</sup>.</div></div><div id="sec4_4_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 5-{2-Methyl-5-[(5-trifluoromethyl-pyridine-3-carbonyl)-amino]-benzylamino}-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methyl Ester (<b>6o</b>)</h4><div class="NLM_p last">The reaction was carried out as described in general procedure A using <b>4a</b> (50 mg, 0.16 mmol), nicotinic acid (31 mg, 0.16 mmol), HATU (180 mg, 0.48 mmol), DIEA (150 μL, 0.8 mmol), and anhydrous DMF (3 mL). Purification by reverse-phase flash chromatography (H<sub>2</sub>O/ACN, 80/20 to 30/70) yielded <b>6o</b> (10 mg, 13%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 12.02 (s, 1H), 10.52 (s, 1H), 9.31 (s, 1H), 9.14 (s, 1H), 8.62 (s, 1H), 8.09 (d, <i>J</i> = 2.5 Hz, 1H), 7.71–7.63 (m, 2H), 7.22 (d, <i>J</i> = 8.9 Hz, 1H), 6.96 (d, <i>J</i> = 2.4 Hz, 1H), 6.89 (d, <i>J</i> = 2.0 Hz, 1H), 6.10 (t, <i>J</i> = 5.4 Hz, 1H), 4.24 (d, <i>J</i> = 5.4 Hz, 2H), 3.82 (s, 3H), 2.34 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 484.2 [M + H]<sup>+</sup> and 482.2 [M – H]<sup>−</sup>.</div></div><div id="sec4_4_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 5-{2-Methyl-5-[(2-trifluoromethyl-pyridine-4-carbonyl)-amino]-benzylamino}-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methyl Ester (<b>6p</b>)</h4><div class="NLM_p last">The reaction was carried out as described in general procedure A using <b>4a</b> (100 mg, 0.32 mmol), 2-(trifluoromethyl)pyridine-4-carboxylic acid (73.3 mg, 0.38 mmol), HATU (146 mg, 0.38 mmol), DIEA (220 μL, 1.28 mmol), and anhydrous DMF (4 mL). Purification by reverse-phase flash chromatography (H<sub>2</sub>O/ACN with 1% TFA, 100/0 to 40/60) yielded after neutralization with NaHCO<sub>3</sub> (aqueous) and filtration <b>6p</b> (9 mg, 6%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 12.06 (s, 1H), 10.59 (s, 1H), 8.94 (d, <i>J</i> = 5.6 Hz, 1H), 8.30 (s, 1H), 8.11 (d, <i>J</i> = 8.4 Hz, 2H), 7.74–7.64 (m, 2H), 7.22 (d, <i>J</i> = 8.4 Hz, 1H), 6.99 (s, 1H), 6.90 (s, 1H), 4.25 (s, 2H), 3.82 (s, 3H), 2.34 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 484.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_4_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 5-{2-Methyl-5-[(6-trifluoromethyl-pyridine-3-carbonyl)-amino]-benzylamino}-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methyl Ester (<b>6q</b>)</h4><div class="NLM_p last">The reaction was carried out as described in general procedure A using <b>4a</b> (100 mg, 0.32 mmol), 6-trifluoromethylnicotinic acid (73.3 mg, 0.38 mmol), HATU (146 mg, 0.38 mmol), DIEA (220 μL, 1.28 mmol), and anhydrous DMF (4 mL). Purification by reverse-phase flash chromatography (H<sub>2</sub>O/ACN with 1% TFA, 100/0 to 40/60) yielded after neutralization with NaHCO<sub>3</sub> (aqueous) and filtration <b>6q</b> (23 mg, 14%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 12.05 (s, 1H), 10.53 (s, 1H), 9.18 (s, 1H), 8.50 (d, <i>J</i> = 8.0 Hz, 1H), 8.15–8.00 (m, 2H), 7.72–7.62 (m, 2H), 7.21 (d, <i>J</i> = 8.0 Hz, 1H), 7.02–6.95 (m, 1H), 6.94–6.86 (m, 1H), 4.25 (s, 2H), 3.82 (s, 3H), 2.34 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 484.1 [M + H]<sup>+</sup> and 482.2 [M – H]<sup>−</sup>.</div></div><div id="sec4_4_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 5-{5-[(2,3-Dihydro-benzofuran-7-carbonyl)-amino]-2-methyl-benzylamino}-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methyl Ester (<b>6r</b>)</h4><div class="NLM_p last">The reaction was carried out as described in general procedure B using <b>4a</b> (40 mg, 0.13 mmol), 2,3-dihydro-1-benzofuran-7-carbonyl chloride (24 mg, 0.13 mmol), Et<sub>3</sub>N (36 μL, 0.26 mmol), and anhydrous DMF (3 mL). Purification by reverse-phase flash chromatography (H<sub>2</sub>O/ACN, 80/20 to 20/80) yielded <b>6r</b> (8 mg, 13%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 9.63 (s, 1H), 8.10 (d, <i>J</i> = 2.5 Hz, 1H), 7.63 (d, <i>J</i> = 1.8 Hz, 1H), 7.60–7.54 (m, 2H), 7.42 (d, <i>J</i> = 6.3 Hz, 1H), 7.18 (d, <i>J</i> = 8.2 Hz, 1H), 7.02 (d, <i>J</i> = 2.5 Hz, 1H), 6.95 (t, <i>J</i> = 7.6 Hz, 1H), 6.90 (d, <i>J</i> = 1.8 Hz, 1H), 6.00 (t, <i>J</i> = 5.5 Hz, 1H), 4.71 (t, <i>J</i> = 8.7 Hz, 2H), 4.21 (d, <i>J</i> = 5.5 Hz, 2H), 3.82 (s, 3H), 3.24 (t, <i>J</i> = 8.7 Hz, 2H), 2.33 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 457.0 [M + H]<sup>+</sup> and 455.1 [M – H]<sup>−</sup>. HPLC purity: 90%.</div></div><div id="sec4_4_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 5-{5-[(Benzo[1,3]dioxole-5-carbonyl)-amino]-2-methyl-benzylamino}-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methyl Ester (<b>6s</b>)</h4><div class="NLM_p last">The reaction was carried out as described in general procedure A using <b>4a</b> (31 mg, 0.1 mmol), 1,3-benzodioxole-5-carboxylic acid (17 mg, 0.1 mmol), HATU (115 mg, 0.3 mmol), DIEA (90 μL, 0.7 mmol), and anhydrous DMF (2 mL). Purification by reverse-phase flash chromatography (H<sub>2</sub>O/ACN, 80/20 to 0/100) yielded <b>6s</b> (5 mg, 10%). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 12.01 (s, 1H), 9.95 (s, 1H), 8.09 (d, <i>J</i> = 1.8 Hz, 1H), 7,68 (s, 1H), 7,62 (d, <i>J</i> = 8.1 Hz, 1H), 7,53 (d, <i>J</i> = 8.4 Hz, 1H), 7,47 (s, 1H), 7,16 (d, <i>J</i> = 8.1 Hz, 1H), 7,00 (d, <i>J</i> = 8.8 Hz, 2H), 6,90 (s, 1H), 6,10 (s, 2H), 6,01 (t, <i>J</i> = 4.7 Hz, 1H), 4,21 (d, <i>J</i> = 4.7 Hz, 2H), 3,83 (s, 3H), 2,32 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 459.1 [M + H]<sup>+</sup> and 457.2 [M – H]<sup>−</sup>. HPLC purity: 93%.</div></div><div id="sec4_4_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 5-{5-[(3<i>H</i>-Benzotriazole-5-carbonyl)-amino]-2-methyl-benzylamino}-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methyl Ester (<b>6t</b>)</h4><div class="NLM_p last">The reaction was carried out as described in general procedure A using <b>4a</b> (50 mg, 0.16 mmol), 1<i>H</i>-benzotriazole-5-carboxylic acid (26 mg, 0.16 mmol), HATU (182 mg, 0.48 mmol), DIEA (140 μL, 0.8 mmol), and anhydrous DMF (3 mL). Purification by reverse-phase flash chromatography (H<sub>2</sub>O/ACN, 80/20 to 30/70) yielded <b>6t</b> (10 mg, 14%). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 12.03 (s, 1H), 10.26 (s, 1H), 8.52 (s, 1H), 8.11 (d, <i>J</i> = 2.7 Hz, 1H), 7.92–7.87 (m, 2H), 7.74 (d, <i>J</i> = 2.0 Hz, 1H), 7.69 (dd, <i>J</i> = 7.8, 2.0 Hz, 1H), 7.19 (d, <i>J</i> = 8.3 Hz, 1H), 7.03–6.98 (m, 1H), 6.93–6.87 (m, 1H), 6.05 (t, <i>J</i> = 5.3 Hz, 1H), 4.23 (d, <i>J</i> = 5.3 Hz, 2H), 3.82 (s, 3H), 2.33 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 456.2 [M + H]<sup>+</sup> and 454.2 [M – H]<sup>−</sup>. HPLC purity: 94%.</div></div><div id="sec4_4_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 5-{5-[(1<i>H</i>-Indole-5-carbonyl)-amino]-2-methyl-benzylamino}-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methyl Ester (<b>6u</b>)</h4><div class="NLM_p last">The reaction was carried out as described in general procedure A using <b>4a</b> (60 mg, 0.19 mmol), 1<i>H</i>-indole-5-carboxylic acid (31 mg, 0.19 mmol), PyBOP (296 mg, 0.57 mmol), DIEA (165 μL, 0.95 mmol), and anhydrous DMF (4 mL). Purification by reverse-phase flash chromatography (H<sub>2</sub>O/ACN, 80/20 to 40/60) yielded <b>6u</b> (38 mg, 44%). <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 12.05 (s, 1H), 11.36 (s, 1H), 10.03 (s, 1H), 8.21 (d, <i>J</i> = 1.2 Hz, 1H), 8.11 (d, <i>J</i> = 2.6 Hz, 1H), 7.73 (dd, <i>J</i> = 6.5, 1.7 Hz, 2H), 7.67 (d, <i>J</i> = 1.7 Hz, 1H), 7.51–7.42 (m, 2H), 7.16 (d, <i>J</i> = 8.2 Hz, 1H), 7.00 (d, <i>J</i> = 2.6 Hz, 1H), 6.92 (d, <i>J</i> = 1.2 Hz, 1H), 6.61–6.49 (m, 1H), 6.05 (t, <i>J</i> = 5.5 Hz, 1H), 4.21 (t, <i>J</i> = 5.5 Hz, 2H), 3.82 (s, 3H), 2.32 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 454.0 [M + H]<sup>+</sup> and 452.0 [M – H]<sup>−</sup>.</div></div><div id="sec4_4_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 5-{2-Methyl-5-[4-(2-methyl-thiazol-4-yl)-benzoylamino]-benzylamino}-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methyl Ester (<b>6v</b>)</h4><div class="NLM_p last">The reaction was carried out as described in general procedure B using <b>4a</b> (40 mg, 0.13 mmol), 4-(2-methyl-thiazol-4-yl)-benzoyl chloride (30 mg, 0.13 mmol), Et<sub>3</sub>N (60 μL, 0.39 mmol), and anhydrous DMF (2 mL). Purification by reverse-phase flash chromatography (H<sub>2</sub>O/ACN, 80/20 to 20/80) yielded <b>6v</b> (24 mg, 36%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 12.03 (s, 1H), 10.18 (s, 1H), 8.09 (s, 2H), 8.04 (d, <i>J</i> = 8.4 Hz, 2H), 7.98 (d, <i>J</i> = 8.2 Hz, 2H), 7.71 (s, 1H), 7.67 (d, <i>J</i> = 8.4 Hz, 1H), 7.18 (d, <i>J</i> = 7.6 Hz, 1H), 6.99 (s, 1H), 6.90 (s, 1H), 6.05 (t, <i>J</i> = 5.5 Hz, 1H), 4.23 (d, <i>J</i> = 5.5 Hz, 2H), 3.82 (s, 3H), 2.73 (s, 3H), 2.31 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 512.2 [M + H]<sup>+</sup>. HPLC purity: 90%.</div></div><div id="sec4_4_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 5-{2-Methyl-5-[(1<i>H</i>-pyrrole-3-carbonyl)-amino]-benzylamino}-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methyl Ester (<b>6w</b>)</h4><div class="NLM_p last">The reaction was carried out as described in general procedure A using <b>4a</b> (100 mg, 0.32 mmol), 1<i>H</i>-pyrrole-3-carboxylic acid (43 mg, 0.38 mmol), HATU (147 mg, 0.38 mmol), DIEA (167 μL, 0.96 mmol), and anhydrous DMF (3 mL). Purification by reverse-phase flash chromatography (H<sub>2</sub>O/ACN with 1% TFA, 100/0 to 50/50) yielded after neutralization with NaHCO<sub>3</sub> (aqueous) and filtration <b>6w</b> (72 mg, 55%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 12.06 (s, 1H), 11.21 (s, 1H), 9.39 (s, 1H), 8.11 (s, 1H), 7.69–7.62 (m, 1H), 7.64–7.58 (m, 1H), 7.51–7.43 (m, 1H), 7.12 (d, <i>J</i> = 7.9 Hz, 1H), 7.07–6.99 (m, 1H), 6.94–6.88 (m, 1H), 6.80–6.73 (m, 1H), 6.64–6.56 (m, 1H), 6.30–5.75 (m, 1H), 4.20 (s, 2H), 3.83 (s, 3H), 2.30 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 404.2 [M + H]<sup>+</sup> and 402.1 [M – H]<sup>−</sup>.</div></div><div id="sec4_4_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 5-{2-Methyl-5-[4-(4-methyl-piperazin-1-ylmethyl)-benzoylamino]-benzylamino}-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methyl Ester (<b>6x</b>)</h4><div class="NLM_p last">The reaction was carried out as described in general procedure A using <b>4a</b> (1 g, 3.23 mmol), 4-[(4-methyl-1-piperazinyl)methyl]benzoic acid <b>5x</b> (0.9 g, 3.87 mmol), HATU (1,47 g, 3.87 mmol), DIEA (1.7 mL, 9.7 mmol), and anhydrous DMF (50 mL). Purification by washing with MeOH yielded <b>6x</b> (565 mg, 33%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 12.04 (s, 1H), 10.11 (s, 1H), 8.09 (s, 1H), 7.91–7.78 (m, 2H), 7.73–7.60 (m, 2H), 7.39 (d, <i>J</i> = 7.9 Hz, 2H), 7.17 (d, <i>J</i> = 7.9 Hz, 1H), 6.98 (s, 1H), 6.90 (s, 1H), 6.11–6.00 (m, 1H), 4.21 (d, <i>J</i> = 3.7 Hz, 2H), 3.82 (s, 3H), 3.49 (s, 2H), 2.43–2.21 (m, 11H), 2.13 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 527.3 [M + H]<sup>+</sup> and 525.2 [M – H]<sup>−</sup>.</div></div><div id="sec4_4_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 5-{5-[4-(3-Dimethylamino-pyrrolidin-1-ylmethyl)-3-trifluoromethyl-benzoylamino]-2-methyl-benzylamino}-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methyl Ester (<b>6y</b>)</h4><div class="NLM_p last">The reaction was carried out as described in general procedure A using <b>4a</b> (3.5 g, 11.3 mmol), 4-(3-dimethylamino-pyrrolidin-1-ylmethyl)-3-trifluoromethyl-benzoic acid <b>5y</b> (4.3 g, 13.5 mmol), HATU (8.58 g, 22.6 mmol), DIEA (9.8 mL, 56.4 mmol), and anhydrous DMF (50 mL). Purification by reverse-phase flash chromatography (H<sub>2</sub>O/ACN with 1% TFA, 70/30 to 50/50) yielded after neutralization with NaHCO<sub>3</sub> (aqueous) and filtration <b>6y</b> (1.9 g, 28%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 12.04 (s, 1H), 10.35 (s, 1H), 8.20–8.14 (m, 2H), 8.09 (d, <i>J</i> = 2.6 Hz, 1H), 7.85 (d, <i>J</i> = 7.8 Hz, 1H), 7.68–7.62 (m, 2H), 7.19 (d, <i>J</i> = 8.8 Hz, 1H), 6.97 (d, <i>J</i> = 2.6 Hz, 1H), 6.89 (d, <i>J</i> = 2.1 Hz, 1H), 6.08 (t, <i>J</i> = 5.3 Hz, 1H), 4.23 (d, <i>J</i> = 5.3 Hz, 2H), 3.82 (s, 3H), 3.83–3.69 (m, 2H), 2.93–2.78 (m, 1H), 2.68–2.54 (m, 3H), 2.44–2.37 (m, 1H), 2.33 (s, 3H), 2.15 (s, 6H), 1.96–1.83 (m, 1H), 1.74–1.58 (m, 1H). MS (ESI) <i>m</i>/<i>z</i> 609.3 [M + H]<sup>+</sup> and 607.3 [M – H]<sup>−</sup>.</div></div><div id="sec4_4_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 5-{2-Methyl-5-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-benzoylamino]-benzylamino}-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methyl Ester (<b>6z</b>)</h4><div class="NLM_p last">The reaction was carried out as described in general procedure A using <b>4a</b> (170 mg, 0.63 mmol), 3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-benzoic acid <b>5z</b> (200 mg, 0.63 mmol), HATU (735 mg, 1.93 mmol), DIEA (0.56 mL, 3.22 mmol), and anhydrous DMF (16 mL). Purification by flash chromatography on silica gel (EtOAc/EtOH, 100/0 to 90/10) yielded <b>6z</b> (108 mg, 30%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 12.05 (s, 1H), 10.41 (s, 1H), 8.42–8.34 (m, 2H), 8.20 (s, 1H), 8.16–8.04 (m, 2H), 7.670–7.62 (m, 3H), 7.22 (d, <i>J</i> = 8.2 Hz, 1H), 6.97 (d, <i>J</i> = 2.3 Hz, 1H), 6.90 (d, <i>J</i> = 1.9 Hz, 1H), 6.11 (t, <i>J</i> = 5.0 Hz, 1H), 4.25 (d, <i>J</i> = 5.0 Hz, 2H), 3.83 (s, 3H), 2.34 (s, 3H), 2.17 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 563.2 [M + H]<sup>+</sup> and 561.2 [M – H]<sup>−</sup>.</div></div><div id="sec4_4_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> <i>N</i>-{3-[(2-Acetyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-ylamino)-methyl]-4-methyl-phenyl}-4-(4-methyl-piperazin-1-ylmethyl)-benzamide (<b>7x</b>)</h4><div class="NLM_p last">The reaction was carried out as described in general procedure A using <b>4b</b> (100 mg, 0.34 mmol), 4-[(4-methyl-1-piperazinyl)methyl]benzoic acid <b>5x</b> (111 mg, 0.476 mmol), HATU (155 mg, 0.408 mmol), DIEA (177 μL, 1.02 mmol), and anhydrous DMF (2 mL). Purification by reverse-phase flash chromatography (H<sub>2</sub>O/ACN with 1% TFA, 100/0 to 50/50) yielded after neutralization with NaHCO<sub>3</sub> (aqueous) and filtration <b>7x</b> (54 mg, 26%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 11.82 (s, 1H), 10.10 (s, 1H), 8.11 (d, <i>J</i> = 2.0, 1H), 7.85 (d, <i>J</i> = 7.8 Hz, 2H), 7.75–7.60 (m, 2H), 7.39 (d, <i>J</i> = 7.9 Hz, 2H), 7.17 (d, <i>J</i> = 7.8 Hz, 1H), 7.06 (s, 1H), 6.98 (s, 1H), 6.07 (t, <i>J</i> = 5.2 Hz, 1H), 4.22 (d, <i>J</i> = 5.2 Hz, 2H), 3.50 (s, 2H), 2.47 (s, 3H), 2.42–2.18 (m, 11H), 2.14 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 511.3 [M + H]<sup>+</sup> and 509.1 [M – H]<sup>−</sup>.</div></div><div id="sec4_4_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> <i>N</i>-{3-[(2-Acetyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-ylamino)-methyl]-4-methyl-phenyl}-4-(3-dimethylamino-pyrrolidin-1-ylmethyl)-3-trifluoromethyl-benzamide (<b>7y</b>)</h4><div class="NLM_p last">The reaction was carried out as described in general procedure A using <b>4b</b> (100 mg, 0.34 mmol), 4-(3-dimethylamino-pyrrolidin-1-ylmethyl)-3-trifluoromethyl-benzoic acid <b>5y</b> (107 mg, 0.34 mmol), HATU (258 mg, 0.68 mmol), DIEA (442 μL, 2.54 mmol), and anhydrous DMF (3 mL). Purification by reverse-phase flash chromatography (H<sub>2</sub>O/ACN with 1% TFA, 100/0 to 50/50) yielded after neutralization with NaHCO<sub>3</sub> (aqueous) and filtration <b>7y</b> (8 mg, 4%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 11.83 (s, 1H), 10.36 (s, 1H), 8.21–8,15 (m, 2H), 8.12 (d, <i>J</i> = 2.6 Hz, 1H), 7.85 (d, <i>J</i> = 8.6 Hz, 1H), 7.70–7.62 (m, 2H), 7.19 (d, <i>J</i> = 7.9 Hz, 1H), 7.06 (s, 1H), 6.98 (d, <i>J</i> = 2.6 Hz, 1H), 6.11 (t, <i>J</i> = 5.2 Hz, 1H), 4.23 (d, <i>J</i> = 5.2 Hz, 2H), 3.85–3.65 (m, 1H), 2.81–2.52 (m, 5H), 2.47 (s, 3H), 2.33 (s, 3H), 2.07 (s, 6H), 1.93–1.79 (m, 1H), 1.70–1.55 (m, 1H). MS (ESI) <i>m</i>/<i>z</i> 593.3 [M + H]<sup>+</sup> and 591.3 [M – H]<sup>−</sup>.</div></div><div id="sec4_4_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> <i>N</i>-{3-[(2-Acetyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-ylamino)-methyl]-4-methyl-phenyl}-3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-benzamide (<b>7z</b>)</h4><div class="NLM_p last">The reaction was carried out as described in general procedure A using <b>4b</b> (100 mg, 0.34 mmol), 3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-benzoic acid <b>5z</b> (91.8 mg, 0.34 mmol), HATU (258 mg, 0.679 mmol), DIEA (442 μL, 2.54 mmol), and anhydrous DMF (3 mL). Purification by reverse-phase flash chromatography (H<sub>2</sub>O/ACN with 1% TFA, 100/0 to 50/50) yielded after neutralization with NaHCO<sub>3</sub> (aqueous) and filtration <b>7z</b> (13 mg, 7%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 11.80 (s, 1H), 10.49 (s, 1H), 8.43 (s, 1H), 8.38 (s, 1H), 8.18 (s, 1H), 8.14–8.10 (m, 2H), 7.75–7,63 (m, 3H), 7.22 (d, <i>J</i> = 8.3 Hz, 1H), 7.06 (d, <i>J</i> = 2.1 Hz, 1H), 6,99 (d, <i>J</i> = 2.6 Hz, 1H), 6.10 (t, <i>J</i> = 5.3 Hz, 1H), 4.25 (d, <i>J</i> = 5.3 Hz, 2H), 2.47 (s, 3H), 2.35 (s, 3H), 2.17 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 547.2 [M + H]<sup>+</sup> and 545.1 [M – H]<sup>−</sup>.</div></div><div id="sec4_4_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 5-{2-Methyl-5-[4-(4-methyl-piperazin-1-ylmethyl)-benzoylamino]-benzylamino}-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid (<b>8x</b>)</h4><div class="NLM_p last">Potassium hydroxide (96 mg, 1.71 mmol) was added to a solution of compound <b>6x</b> (300 mg, 0.57 mmol) in a mixture of 3 mL of methanol and 3 mL of water. The mixture was stirred at reflux until the reaction was complete. The solvents were removed, water was added and the mixture was acidified by HCl 6 N until pH 7. The precipitate formed was filtered and rinsed with water to give <b>8x</b> (222 mg, 76%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 11.77 (s, 1H), 10.10 (s, 1H), 8.05 (d, <i>J</i> = 2.4 Hz, 1H), 7.86 (d, <i>J</i> = 8.2 Hz, 2H), 7.69 (s, 1H), 7.65 (dd, <i>J</i> = 7.9, 1.6 Hz, 1H), 7.39 (d, <i>J</i> = 8.1 Hz, 2H), 7.16 (d, <i>J</i> = 8.2 Hz, 1H), 6.98 (d, <i>J</i> = 2.4 Hz, 1H), 6.80 (d, <i>J</i> = 1.7 Hz, 1H), 5.97 (s, 1H), 4.21 (s, 2H), 3.51 (s, 3H), 2.46–2.28 (m, 10H), 2.19 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 513.3 [M + H]<sup>+</sup> and 511.3 [M – H]<sup>−</sup>.</div></div><div id="sec4_4_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> 5-{5-[4-(3-Dimethylamino-pyrrolidin-1-ylmethyl)-3-trifluoromethyl-benzoylamino]-2-methyl-benzylamino}-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid (<b>8y</b>)</h4><div class="NLM_p last">Potassium hydroxide (162 mg, 2.46 mmol) was added to a solution of compound <b>6y</b> (500 mg, 0.82 mmol) in a mixture of 3 mL of methanol and 3 mL of water. The mixture was stirred at reflux until the reaction was complete. The solvents were removed, water was added, and the mixture was acidified by HCl 6 N until pH 7. The precipitate formed was filtered and rinsed with water to give <b>8y</b> (204 mg, 42%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 11.70 (s, 1H), 10.37 (s, 1H), 8.22–8.12 (m, 2H), 8.03 (s, 1H), 7.85 (d, <i>J</i> = 8.0 Hz, 1H), 7.66 (bs, 2H), 7.19 (d, <i>J</i> = 8.4 Hz, 1H), 6.96 (s, 1H), 6.75 (s, 1H), 6.01 (s, 1H), 4.22 (s, 2H), 3.80 (d, <i>J</i> = 14.5 Hz, 1H), 3.72 (d, <i>J</i> = 14.5 Hz, 1H), 2.98–2.79 (m, 1H), 2.71–2.52 (m, 3H), 2.47–2.40 (m, 1H), 2.33 (s, 3H), 2.16 (s, 6H), 1.97–1.82 (m, 1H), 1.76–1.61 (m, 1H). MS (ESI) <i>m</i>/<i>z</i> 595.3 [M + H]<sup>+</sup> and 593.3 [M – H]<sup>−</sup>.</div></div><div id="sec4_4_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> 5-{2-Methyl-5-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-benzoylamino]-benzylamino}-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid (<b>8z</b>)</h4><div class="NLM_p last">Lithium hydroxide (38 mg, 1.59 mmol) was added to a solution of compound <b>6z</b> (300 mg, 0.53 mmol) in a mixture of 4 mL of methanol and 4 mL of water. The mixture was stirred at reflux until the reaction was complete. The solvents were removed, water was added, and the mixture was acidified by HCl 6 N until pH 7. The precipitate formed was filtered and rinsed with water to give <b>8z</b> (185 mg, 64%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 11.85 (s, 1H), 10.52 (s, 1H), 9.54 (s, 1H), 8.55 (s, 1H), 8.37 (s, 2H), 8.12 (s, 1H), 8.07 (d, <i>J</i> = 2.3 Hz, 1H), 7.69 (s, 1H), 7.66 (d, <i>J</i> = 8.2 Hz, 1H), 7.23 (d, <i>J</i> = 8.2 Hz, 1H), 6.98 (s, 1H), 6.83 (d, <i>J</i> = 2.3 Hz, 1H), 6.11 (bs, 1H), 4.26 (s, 2H), 2.35 (s, 3H), 2.33 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 549.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_4_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> 5-Nitro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methylamide (<b>10</b>)</h4><div class="NLM_p last">Potassium hydroxide (895 mg, 13.6 mmol) was added to a solution of 5-nitro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic acid methyl ester <b>9</b> (1.00 g, 4.5 mmol) in a mixture of 15 mL of methanol and 15 mL of water. The mixture was stirred at reflux until the reaction was complete. The solvents were removed, water was added, and the mixture was acidified by HCl 6 N until pH 3. The precipitate formed was filtered, rinsed by water, and dried under vacuum. The solid (745 mg) was directly used in the next step. Under argon, the crude dissolved with 8 mL of dry DMF and HATU (1.62 g, 4.3 mmol) was added followed by DIEA (3.1 mL, 17.8 mmol), and methylamine hydrochloride (715 mg, 10.7 mmol). The reaction mixture was stirred at room temperature overnight. The mixture was concentrated, and saturated aqueous solution (50 mL) of Na<sub>2</sub>CO<sub>3</sub> was added. The precipitate formed was filtered, rinsed with water and Et<sub>2</sub>O, and dried under vacuum to obtain <b>10</b> (587 mg, 59% over two steps). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 12.96 (s, 1H), 9.17 (d, <i>J</i> = 2.3 Hz, 1H), 9.06 (d, <i>J</i> = 2.3 Hz, 1H), 8.75 (d, <i>J</i> = 4.3 Hz, 1H), 7.32 (s, 1H), 2.83 (d, <i>J</i> = 4.3 Hz, 3H). MS (ESI) <i>m</i>/<i>z</i> 221.1 [M + H]<sup>+</sup> and 219.1 [M – H]<sup>−</sup>.</div></div><div id="sec4_4_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> 5-(5-Amino-2-methyl-benzylamino)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methylamide (<b>11</b>)</h4><div class="NLM_p last">In an autoclave under argon, palladium 10% on charcoal (220 mg, 14% w/w) was added to a solution of 5-nitro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic acid methylamide <b>10</b> (1.56 g, 7.1 mmol) in 800 mL of MeOH. The reaction mixture was stirred overnight at room temperature under hydrogen pressure (30 bar). Then, it was filtered through Celite, rinsed with MeOH, and concentrated. The crude product obtained (880 mg, 65% yield) was directly dissolved in 60 mL of MeOH and 6 mL of AcOH, and 2-methyl-5-nitro-benzaldehyde (764 mg, 4.6 mmol) was added. After 2 h stirring at room temperature, NaBH<sub>3</sub>CN (574 mg, 9.3 mmol) was added, and the reaction mixture was stirred overnight at room temperature. The mixture was concentrated and slowly neutralized by a saturated aqueous solution of NaHCO<sub>3</sub>. The precipitate formed was filtered, rinsed with water and diethyl ether, and dried under vacuum to give the nitro intermediate (1.33g, 84% yield). A total of 500 mg (1.5 mmol) of this crude product was introduced in an autoclave under argon and solubilized with 400 mL of MeOH. Palladium 10% on charcoal (70 mg, 14% w/w) was added, and the reaction mixture was stirred overnight at room temperature under 30 bar of hydrogen pressure. Then, it was filtered through Celite, rinsed with MeOH, and concentrated to obtain <b>11</b> (442 mg, 97% yield for the last step, 53% global yield from <b>10</b>). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 11.55 (s, 1H), 8.31 (d, <i>J</i> = 4.2 Hz, 1H), 7.95 (d, <i>J</i> = 2.3 Hz, 1H), 6.95 (d, <i>J</i> = 2.3 Hz, 1H), 6.82 (d, <i>J</i> = 8.0 Hz, 1H), 6.77 (s, 1H), 6.58 (d, <i>J</i> = 1.9 Hz, 1H), 6.36 (dd, <i>J</i> = 8.0, 1.9 Hz, 1H), 5.77 (t, <i>J</i> = 5.0 Hz, 1H), 4.76 (s, 2H), 4.07 (d, <i>J</i> = 5.0 Hz, 2H), 2.78 (d, <i>J</i> = 4.2 Hz, 3H), 2.16 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 310.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_4_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> 5-{2-Methyl-5-[4-(4-methyl-piperazin-1-ylmethyl)-benzoylamino]-benzylamino}-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methylamide (<b>12x</b>)</h4><div class="NLM_p last">Under argon, 5-(5-amino-2-methyl-benzylamino)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic acid methylamide <b>11</b> (70 mg, 0.23 mmol) was dissolved in 7 mL of dry DMF. 4-[(4-Methyl-1-piperazinyl)methyl]benzoic acid <b>5x</b> (70 mg, 0.30 mmol) was added followed by HATU (95 mg, 0.25 mmol) and DIEA (231 μL, 1.33 mmol). The reaction mixture was stirred at room temperature overnight. Then, the mixture was concentrated and neutralized by a saturated aqueous solution of NaHCO<sub>3</sub>. The precipitate formed was filtered and purified on a reverse chromatography column (H<sub>2</sub>O/ACN with 1% TFA, 100/0 to 0/100) to give after neutralization with NaHCO<sub>3</sub> (aqueous) and filtration <b>12x</b> (4 mg, 3%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 11.51 (s, 1H), 10.09 (s, 1H), 8.26 (d, <i>J</i> = 4.4 Hz, 1H), 7.98 (s, 1H), 7.85 (d, <i>J</i> = 8.1 Hz, 2H), 7.70 (s, 1H), 7.64 (d, <i>J</i> = 7.8 Hz, 1H), 7.39 (d, <i>J</i> = 8.1 Hz, 2H), 7.16 (d, <i>J</i> = 7.8 Hz, 1H), 6.99 (d, <i>J</i> = 2.0 Hz, 1H), 6.77 (d, <i>J</i> = 2.0 Hz, 1H), 5.87 (t, <i>J</i> = 5.2 Hz, 1H), 4.21 (d, <i>J</i> = 5.2 Hz, 2H), 3.50 (s, 3H), 2.78 (d, <i>J</i> = 4.4 Hz, 3H), 2.32 (bs, 10H), 2.15 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 526.3 [M + H]<sup>+</sup>. HPLC purity: 94%.</div></div><div id="sec4_4_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> 5-{5-[4-(3-Dimethylamino-pyrrolidin-1-ylmethyl)-3-trifluoromethyl-benzoylamino]-2-methyl-benzylamino}-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methylamide (<b>12y</b>)</h4><div class="NLM_p last">Under argon, 5-(5-amino-2-methyl-benzylamino)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic acid methylamide <b>11</b> (70 mg, 0.23 mmol) was dissolved in 7 mL of dry DMF. 4-(3-Dimethylamino-pyrrolidin-1-ylmethyl)-3-trifluoromethyl-benzoic acid <b>5y</b> (70 mg, 0.22 mmol) was added followed by HATU (94 mg, 0.25 mmol) and DIEA (231 μL, 1.33 mmol). The reaction mixture was stirred at room temperature overnight. Then, it was concentrated and neutralized by a saturated aqueous solution of NaHCO<sub>3</sub>. The precipitate formed was filtered and purified on a reverse chromatography column (H<sub>2</sub>O/ACN with 1% TFA, 100/0 to 0/100) to give after neutralization with NaHCO<sub>3</sub> (aqueous) and filtration <b>12y</b> (9 mg, 7%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 11.51 (s, 1H), 10.33 (s, 1H), 8.29–8.23 (m, 1H), 8.18 (s, 1H), 8.17 (d, <i>J</i> = 8.3 Hz, 1H), 7.98 (d, <i>J</i> = 2.5 Hz, 1H), 7.85 (d, <i>J</i> = 7.9 Hz, 1H), 7.68 (d, <i>J</i> = 1.8 Hz, 1H), 7.65 (dd, J = 7.9, 2.0 Hz, 1H), 7.19 (d, <i>J</i> = 8.3 Hz, 1H), 6.99 (d, <i>J</i> = 2.5 Hz, 1H), 6.77 (d, <i>J</i> = 2.0 Hz, 1H), 5.90 (t, <i>J</i> = 5.5 Hz, 1H), 4.23 (d, <i>J</i> = 5.5 Hz, 2H), 3.78 (d, <i>J</i> = 15.1 Hz, 1H), 3.74 (d, J = 15.1 Hz, 1H), 2.78 (d, <i>J</i> = 4.6 Hz, 3H), 2.76–2.53 (m, 4H), 2.40–2.30 (m, 1H), 2.40–2.30 (m, 3H), 2.12–2.05 (m, 6H), 1.92–1.82 (m, 1H), 1.68–1.58 (m, 1H). MS (ESI) <i>m</i>/<i>z</i> 608.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_4_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> 5-Formyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methyl Ester (<b>14a</b>)</h4><div class="NLM_p last">5-Cyano-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic acid methyl ester <b>13a</b> (200 mg, 1 mmol) in solution in a mixture of pyridine/H<sub>2</sub>O/AcOH (2/1/1, 150 mL) was stirred with 0.5 mL of Raney nickel in water under 10 bar pressure of hydrogen. The mixture was filtered over Celite and washed with MeOH. The filtrate was concentrated, washed with a saturated aqueous solution of NaHCO<sub>3</sub>, and extracted with AcOEt to give <b>14a</b> as a brown solid (137 mg, 67%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 13.06 (bs, 1H), 10.11 (s, 1H), 8.92 (d, <i>J</i> = 1.7 Hz, 1H), 8.66 (d, <i>J</i> = 1.7 Hz, 1H), 7.39 (s, 1H), 3.90 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 205.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_4_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> 2-Acetyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-5-carbaldehyde (<b>14b</b>)</h4><div class="NLM_p last">2-Acetyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-5-carbonitrile <b>10b</b> (4.02 g, 22 mmol) in dry toluene was cooled down to 0 °C, and DIBAL-H 1 M in cyclohexane (65 mL, 65 mmol) was added dropwise. The mixture was stirred at 0 °C for 1.5 h. Then, 85 mL of MeOH was cautiously added, followed by 25.5 mL of a 2 M solution of H<sub>2</sub>SO<sub>4</sub>. The aluminum salts were filtered on Celite. The filtrate was concentrated and the residue purified by column chromatography on silica gel (petroleum ether/AcOEt from 6/4 to 0/10) to give 2-(1-hydroxy-ethyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-5-carbaldehyde as a yellow solid (1.3 g, 6.8 mmol, 31% yield). This solid was directly dissolved in THF (130 mL). Activated MnO<sub>2</sub> (7.1 g, 82 mmol) was cautiously added, and the mixture was stirred overnight at room temperature. The MnO<sub>2</sub> was eliminated by filtration on Celite and rinsed with hot methanol and DMF (200 mL). The filtrate was concentrated, and the resulting off-white solid was washed with diethyl ether to give <b>14b</b> (844 mg, 65%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 12.83 (s, 1H), 10.11 (s, 1H), 8.93 (d, <i>J</i> = 1.9 Hz, 1H), 8.70 (d, <i>J</i> = 1.9 Hz, 1H), 7.58 (s, 1H), 2.60 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 189.1 [M + H]<sup>+</sup> and 187.1 [M – H]<sup>−</sup>.</div></div><div id="sec4_4_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> 5-Hydroxymethyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methyl Ester (<b>15a</b>)</h4><div class="NLM_p last">Under argon, a solution of 5-formyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic acid methyl ester <b>14a</b> (667 mg, 3.3 mmol) in dry THF (35 mL) was cooled down to 0 °C, and a solution of DIBAL-H in cyclohexane 1 M (9.8 mL, 9.8 mmol) in dry THF (17 mL) was slowly added. The mixture was stirred at 0 °C for 3 h then quenched by addition of water. The mixture was concentrated, and the crude was washed with NaHCO<sub>3</sub> (aqueous) and extracted by AcOEt. Organic layer was dried with Na<sub>2</sub>SO<sub>4</sub>, and AcOEt was evaporated under reduced pressure. The crude was purified by column chromatography on silica gel (petroleum ether/AcOEt/MeOH, 100/0/0 to 0/100/0 to 0/97/3) to give <b>15a</b> (304 mg, 45%) <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 12.45 (s, 1H), 8.38 (d, <i>J</i> = 2.0 Hz, 1H), 8.02 (d, <i>J</i> = 2.0 Hz, 1H), 7.16 (s, 1H), 5.24 (t, <i>J</i> = 5.6 Hz, 1H), 4.59 (d, <i>J</i> = 5.6 Hz, 2H), 3.87 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 207.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_4_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> 5-(5-Amino-2-methyl-phenoxymethyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methyl Ester (<b>16a</b>)</h4><div class="NLM_p last">To a solution of 2-methyl-5-nitrophenol (147 mg, 0.96 mmol) in dry CH<sub>2</sub>Cl<sub>2</sub> (4 mL) under argon was added PPh<sub>3</sub> (252 mg, 0.96 mmol) followed by 5-hydroxymethyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic acid methyl ester <b>12</b> (180 mg, 0.87 mmol). A solution of DEAD (104 μL, 0.66 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2 mL) was slowly added, and the mixture was stirred at room temperature overnight. The crude was filtered, and the precipitate was washed with CH<sub>2</sub>Cl<sub>2</sub>. The crude product (120 mg, yield: 40%) was used directly in the next step without purification. After dissolution in a AcOH/AcOEt mixture (1/2, 5 mL), zinc powder (317 mg, 4.8 mmol) was added. The mixture was stirred at 50 °C for 1.5 h. The reaction mixture was filtered on Celite and washed with NaHCO<sub>3</sub> aqueous solution. After drying, the intermediate <b>16a</b> (137 mg, yield >100%) was directly used without supplementary purification in the next step. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 8.50 (d, <i>J</i> = 1.7 Hz, 1H), 8.17 (d, <i>J</i> = 1.7 Hz, 1H), 7.20 (s, 1H), 6.76 (d, <i>J</i> = 7.9 Hz, 1H), 6.34 (d, <i>J</i> = 0.9 Hz, 1H), 6.07 (dd, <i>J</i> = 7.9, 1.8 Hz, 1H), 5.09 (s, 2H), 4.85 (s, 2H), 3.88 (s, 3H), 1.99 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 312.2 [M + H]<sup>+</sup>. HPLC purity: 81%.</div></div><div id="sec4_4_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> 5-[-2-(2-Methyl-5-nitro-phenyl)-vinyl]-<i>1H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methyl Ester (<b>17a</b>)</h4><div class="NLM_p last">A solution of 5-formyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic acid methyl ester <b>14a</b> (1.0 g, 4.9 mmol), (2-methyl-5-nitro-benzyl)-triphenyl-phosphonium (2.7 g, 5.5 mmol), and LiOH (294 mg, 12.3 mmol) in anhydrous MeOH (100 mL) was stirred under reflux overnight. The precipitate was filtered and washed with MeOH before purification on reverse-phase flash chromatography (H<sub>2</sub>O/ACN) to give <b>17a</b> (769 mg, 69%) as a mixture of two isomers. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, stereoisomer ratio ≈ 7/3, δ) 12.76–12.15 (m, 1H), 8.79 (s, 0.3H), 8.49 (s, 0.7H), 8.15–8.00 (m, 2H), 7.92–7.75 (m, 1H), 7. 60–7.47 (m, 1H), 7.20 (s, 0.3H), 7.07 (s, 0.7H), 6.96 (d, <i>J</i> = 12.1 Hz, 1H), 6.77 (d, <i>J</i> = 12.1 Hz, 1H), 3.89 (s, 0.9H), 3.85 (s, 2.1H), 2.56 (s, 0.9H), 2.36 (s, 2.1H). MS (ESI) <i>m</i>/<i>z</i> 338.1 [M + H]<sup>+</sup> and 336.1 [M – H]<sup>−</sup>. HPLC stereoisomer ratio: 8/2.</div></div><div id="sec4_4_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> 1-{5-[2-(2-Methyl-5-nitro-phenyl)-vinyl]-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-2-yl}-ethanone (<b>17b</b>)</h4><div class="NLM_p last">A solution of 2-acetyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-5-carbaldehyde <b>14b</b> (844 mg, 4.5 mmol), (2-methyl-5-nitro-benzyl)-triphenyl-phosphonium (2.4 g, 4.9 mmol), and LiOH (215 mg, 9.0 mmol) in anhydrous MeOH (150 mL) was stirred at room temperature overnight. The precipitate was filtered and washed with NH<sub>4</sub>Cl aqueous solution, water, and Et<sub>2</sub>O to obtain <b>17b</b> as a yellow solid (1.03 g, 71%) that was directly used in the next step without further purification. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 12.31 (s, 1H), 8.14 (d, <i>J</i> = 1.4 Hz, 1H), 8.05 (dd, <i>J</i> = 8.4, 1.8 Hz, 1H), 7.85 (d, <i>J</i> = 1.8 Hz, 1H), 7.80 (d, <i>J</i> = 1.4 Hz, 1H), 7.55 (d, <i>J</i> = 8.4 Hz, 1H), 7.24 (s, 1H), 6.96 (d, <i>J</i> = 12.1 Hz, 1H), 6.76 (d, <i>J</i> = 12.1 Hz, 1H), 2.50 (s, 3H), 2.34 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 322.1 [M + H]<sup>+</sup> and 320.1 [M – H]<sup>−</sup>. HPLC purity: 88%.</div></div><div id="sec4_4_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> 5-[2-(5-Amino-2-methyl-phenyl)-ethyl]-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methyl Ester (<b>18a</b>)</h4><div class="NLM_p last">5-[-2-(2-Methyl-5-nitro-phenyl)-vinyl]-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic acid methyl ester <b>17a</b> (283 mg, 0.84 mmol) was dissolved in AcOH/AcOEt mixture (1/2, 6 mL). Zinc (819 mg, 12.6 mmol) was added, and the mixture was put in sonic bath at room temperature for 30 min. Then, the mixture was filtered over Celite and washed with AcOEt. The filtrate was concentrated and purified on reverse-phase flash chromatography (H<sub>2</sub>O/ACN with 1% TFA, 100/0 to 0/100) to give after neutralization with NaHCO<sub>3</sub> (aqueous) and filtration <b>18a</b> (144 mg, 56%) as a mixture of two stereoisomers. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, stereoisomer ratio ≈ 8/2, δ) 12.55 (s, 0.2H), 12.47 (s, 0.8H), 8.67 (s, 0.2H), 8.35 (s, 0.2H), 8.16 (s, 0.8H), 7.82 (s, 0.8H), 7.38 (d, <i>J</i> = 16.6 Hz, 0.2H), 7.17 (s, 0.2H), 7.10–7.00 (m, 1.0 H), 6.95–6.83 (m, 1.2 H), 6.73–6.56 (m, 1.6 H), 6.50–6.37 (m, 1.0H), 6.37–6.28 (s, 0.8H) 4.80 (bs, 2H), 3.89 (s, 0.6H), 3.85 (s, 2.4H), 2.26 (s, 0.6H), 2.04 (s, 2.4H). MS (ESI) <i>m</i>/<i>z</i> 189.1 [M + H]<sup>+</sup> and 187.1 [M – H]<sup>−</sup>.</div></div><div id="sec4_4_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> 5-[2-(5-Amino-2-methyl-phenyl)-ethyl]-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methyl Ester (<b>19a</b>)</h4><div class="NLM_p last">5-[-2-(2-Methyl-5-nitro-phenyl)-vinyl]-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic acid methyl ester <b>17a</b> (450 mg, 1.3 mmol) was dissolved in DMF (180 mL) with Pd/C 10% (90 mg, 20% w/w) and stirred for 24 h under hydrogen pressure (10 bar). The reaction mixture was then filtered over Celite bed. The crude product was purified on reverse-phase column chromatography (H<sub>2</sub>O/ACN with 1% TFA, 100/0 to 0/100) to give after neutralization with NaHCO<sub>3</sub> (aqueous) and filtration <b>19a</b> (157 mg, 26%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 12.39 (s, 1H), 8.28 (s, 1H), 7.93 (s, 1H), 7.11 (s, 1H), 6.77 (d, <i>J</i> = 8.0 Hz, 1H), 6.43 (d, <i>J</i> = 2.1 Hz, 1H), 6.32 (dd, <i>J</i> = 8.0, 2.1 Hz, 1H), 4.73 (s, 2H), 3.87 (s, 3H), 2.93–2.80 (m, 2H), 2.79–2.68 (m, 2H), 2.08 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 310.2 [M + H]<sup>+</sup> and 308.1 [M – H]<sup>−</sup>.</div></div><div id="sec4_4_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> 1-{5-[2-(5-Amino-2-methyl-phenyl)-ethyl]-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-2-yl}-ethanone (<b>19b</b>)</h4><div class="NLM_p last">1-{5-[2-(2-Methyl-5-nitro-phenyl)-vinyl]-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-2-yl}-ethanone <b>17b</b> (845 mg, 2.6 mmol) was dissolved in DMF (400 mL) with 10% Pd/C (90 mg, 10% w/w) and stirred overnight under hydrogen pressure (10 bar). The reaction mixture was then filtered on Celite and concentrated to afford a brown powder which was further purified by column chromatography (H<sub>2</sub>O/ACN with 1% TFA, 100/0 to 0/100) to give after neutralization with NaHCO<sub>3</sub> (aqueous) and filtration <b>19b</b> (364 mg, 38%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 12.16 (s, 1H), 8.29 (s, 1H), 7.94 (s, 1H), 7.28 (s, 1H), 6.77 (d, <i>J</i> = 8.0 Hz, 1H), 6.43 (s, 1H), 6.32 (d, <i>J</i> = 8.0 Hz, 1H), 4.72 (s, 2H), 2.92–2.83 (m, 2H), 2.78–2.68 (m, 2H), 2.55 (s, 3H), 2.07 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 294.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_4_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> 5-(2-Methyl-5-nitrobenzamido)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methyl Ester (<b>21a</b>)</h4><div class="NLM_p last">5-Amino-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic acid methyl ester <b>1a</b> (5.74 g, 30 mmol), and 2-methyl-5-nitrobenzoic acid <b>20</b> (5.44 g, 30 mmol) were stirred in DMF (300 mL) at room temperature. HATU (11.42 g, 30 mmol) and DIEA (26 mL, 150 mmol) were added, and the mixture was stirred over the weekend at room temperature. The solvent was evaporated, and saturated NaHCO<sub>3</sub> aqueous solution was added until obtaining a precipitate that was filtered and washed with water followed by a mixture of petroleum ether/diethyl ether (1/1). After drying under vacuum, the nitro intermediate was obtained as powder (9.94 g, yield: 93%) and directly used in the reduction step. The powder was dissolved in methanol with Pd/C 10% (0.95 g, 10% w/w), and the mixture was stirred under hydrogen pressure (35 bar) at room temperature overnight. Then, the mixture was filtered over Celite bed that was washed with hot methanol (∼2 L). The filtrate was concentrated to give the expected product <b>21a</b> (7.35 g, 81%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 10.29 (s, 1H), 8.57–8.52 (m, 2H), 7.15 (s, 1H), 6.94 (d, <i>J</i> = 8.2 Hz, 1H), 6.71 (d, <i>J</i> = 2.3 Hz, 1H), 6.59 (dd, <i>J</i> = 8.2, 2.3 Hz, 1H), 5.08 (s, 2H), 3.86 (s, 3H), 2.21 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 325.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_4_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> <i>N</i>-(3-Amino-4-methyl-phenyl)-4-(4-methyl-piperazin-1-ylmethyl)-benzamide (<b>23x</b>)</h4><div class="NLM_p last">A solution of 4-methyl-3-nitroaniline <b>22</b> (250 mg, 1.6 mmol), 4-(4-methyl-piperazin-1-ylmethyl)-benzoic acid <b>5x</b> (769 mg, 3.2 mmol), and DIEA (860 μL, 4.8 mmol) in dry DMF was stirred at room temperature for 15 min. EDCI (471 mg, 2.4 mmol) was added, and the mixture was stirred overnight at room temperature. Then, the solvent was evaporated, and the crude mixture was washed with saturated NaHCO<sub>3</sub> aqueous solution and extracted with AcOEt. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude product was purified by flash column chromatography on silica gel (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, 100/0 to 75/25) to give a yellow solid (270 mg, yield: 45%). A total of 230 mg of this powder was directly dissolved in a mixture AcOEt/AcOH (2/1). Activated Zn (613 mg) was added, and the mixture was stirred at room temperature for 1 h 20 min. Then, Zn residue was filtered over Celite, and the filtrate was concentrated. The crude mixture was dissolved in water, then basified by addition of NaHCO<sub>3</sub> until pH 7–8 and extracted with AcOEt. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give <b>23x</b> (238 mg, reduction yield: quantitative). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 9.86 (s, 1H), 7.86 (d, <i>J</i> = 8.0 Hz, 2H), 7.40 (d, <i>J</i> = 8.0 Hz, 2H), 7.11 (d, <i>J</i> = 1.4 Hz, 1H), 6.91–6.73 (m, 2H), 4.83 (s, 2H), 3.52 (s, 2H), 2.47–2.25 (m, 8H), 2.19 (s, 3H), 2.01 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 339.3 [M + H]<sup>+</sup> and 337.3 [M – H]<sup>−</sup>.</div></div><div id="sec4_4_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> 5-({2-Methyl-5-[4-(4-methyl-piperazin-1-ylmethyl)-benzoylamino]-phenylamino}-methyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methyl Ester (<b>25x</b>)</h4><div class="NLM_p last">Under argon, 5-formyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic acid methyl ester <b>14a</b> (106 mg, 0.33 mmol) and <i>N</i>-(3-amino-4-methyl-phenyl)-4-(4-methyl-piperazin-1-ylmethyl)-benzamide <b>23x</b> (113 mg, 0.33 mmol) were dissolved in a mixture of MeOH (2 mL) and AcOH (200 μL). The mixture was stirred at room temperature for 2 h. Then, NaBH<sub>3</sub>CN (41 mg, 0.66 mmol) was added, and the mixture was stirred overnight at room temperature. The precipitate was filtered and washed with MeOH and Et<sub>2</sub>O to give <b>25x</b> (30 mg, 17%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 12.44 (s, 1H), 9.85 (s, 1H), 8.48 (d, <i>J</i> = 2.0 Hz, 1H), 8.05 (d, <i>J</i> = 1.6 Hz, 1H), 7.83 (d, <i>J</i> = 8.2 Hz, 2H), 7.40 (d, <i>J</i> = 8.2 Hz, 2H), 7.14 (d, <i>J</i> = 2.0 Hz, 1H), 7.02–6.96 (m, 2H), 6.91 (d, <i>J</i> = 7.8 Hz, 1H), 5.67 (t, <i>J</i> = 5.9 Hz, 1H), 4.44 (d, <i>J</i> = 5.9 Hz, 2H), 3.85 (s, 3H), 3.57 (s, 2H), 3.10–2.55 (m, 8H), 2.13 (s, 3H), 2.08 (s, 2H). MS (ESI) <i>m</i>/<i>z</i> 527 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> General Procedure C for Coupling Reaction to Obtain Compounds <b>24x</b>,<b>y</b> and <b>26x</b>,<b>y</b>–<b>29x</b>,<b>y</b></h3><div class="NLM_p">All the reactants (carboxylic acid reactant, aniline intermediate, HATU, and DIEA) were placed in a dried Schlenck flask under argon and stirred in DMF at room temperature overnight. DMF was evaporated, and saturated NaHCO<sub>3</sub> aqueous solution was added. The resulting precipitate was filtered and purified by washing with MeOH or by flash column chromatography to obtain the expected product.</div><div id="sec4_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> 5-{2-Methyl-5-[4-(4-methyl-piperazin-1-ylmethyl)-benzoylamino]-benzoylamino}-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methyl Ester (<b>24x</b>)</h4><div class="NLM_p last">The reaction was carried out as described in general procedure C using <b>21a</b> (2.0 g, 6.2 mmol), 4-[(4-methyl-1-piperazinyl)methyl]benzoic acid <b>5x</b> (2.8 g, 11.7 mmol), HATU (4.7 g, 12.3 mmol), DIEA (5.5 mL, 31 mmol), and anhydrous DMF (100 mL). Purification by reverse-phase flash chromatography (H<sub>2</sub>O/ACN with 1% TFA, 100/0 to 0/100) yielded after neutralization with NaHCO<sub>3</sub> (aqueous) and filtration <b>24x</b> (500 mg, 15%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 12.48 (s, 1H), 10.52 (s, 1H), 10.36 (s, 1H), 8.60 (s, 2H), 8.00–7.95 (m, 2H), 7.93 (s, 1H), 7.84 (dd, <i>J</i> = 2.1, 8.3 Hz, 1H), 7.44 (d, <i>J</i> = 8.3 Hz, 2H), 7.29 (d, <i>J</i> = 8.3 Hz, 1H), 7.20 (s, 1H), 3.88 (s, 3H), 3.53 (s, 2H), 2.45–2.22 (m, 11H), 2.14 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 541.3 [M + H]<sup>+</sup> and 539.2 [M – H]<sup>−</sup>.</div></div><div id="sec4_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> 5-{5-[4-(3-Dimethylamino-pyrrolidin-1-ylmethyl)-3-trifluoromethyl-benzoylamino]-2-methyl-benzoylamino}-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methyl Ester (<b>24y</b>)</h4><div class="NLM_p last">The reaction was carried out as described in general procedure C using <b>21a</b> (2.0 g, 6.2 mmol), 4-(3-dimethylamino-pyrrolidin-1-ylmethyl)-3-trifluoromethyl-benzoic acid <b>5y</b> (2.3 g, 7.4 mmol), HATU (4.8 g, 12.3 mmol), DIEA (5.5 mL, 31 mmol), and anhydrous DMF (100 mL). Purification by reverse-phase flash chromatography (H<sub>2</sub>O/ACN with 1% TFA, 100/0 to 0/100) yielded after neutralization with NaHCO<sub>3</sub> (aqueous) and filtration <b>24y</b> (1.1 g, 29%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 12.50 (s, 1H), 10.55 (s, 1H), 10.52 (s, 1H), 8.60 (s, 2H), 8.28–8.21 (m, 2H), 7.97–7.80 (m, 3H), 7.33 (d, <i>J</i> = 8.4 Hz, 1H), 7.21 (d, <i>J</i> = 1.9 Hz, 1H), 3.88 (s, 3H), 3.85–3.70 (m, 2H), 2.92–2.77 (m, 1H), 2.76–2.54 (m, 4H), 2.39 (s, 3H), 2.14 (s, 6H), 1.95–1.83 (m, 1H), 1.75–1.60 (m, 1H). MS (ESI) <i>m</i>/<i>z</i> 623.2 [M + H]<sup>+</sup> and 621.2 [M – H]<sup>−</sup>. HPLC purity: 94%.</div></div><div id="sec4_5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> 5-{2-Methyl-5-[4-(4-methyl-piperazin-1-ylmethyl)-benzoylamino]-phenoxymethyl}-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methyl Ester (<b>26x</b>)</h4><div class="NLM_p last">The reaction was carried out as described in general procedure C using <b>16a</b> (72 mg, 0.25 mmol), 4-[(4-methyl-1-piperazinyl)methyl]benzoic acid <b>5x</b> (74 mg, 0.32 mmol), HATU (114 mg, 0.30 mmol), DIEA (216 μL, 1.24 mmol), and anhydrous DMF (2.5 mL). Purification by reverse-phase flash chromatography (H<sub>2</sub>O/ACN with 1% TFA, 100/0 to 0/100) yielded after neutralization with NaHCO<sub>3</sub> (aqueous) and filtration <b>26x</b> (6 mg, 5%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 10.13 (s, 1H), 8.55 (d, <i>J</i> = 1.6 Hz, 1H), 8.22 (d, <i>J</i> = 1.6 Hz, 1H), 7.90 (d, <i>J</i> = 8.2 Hz, 2H), 7.64 (d, <i>J</i> = 1.5 Hz, 1H), 7.43 (d, <i>J</i> = 8.2 Hz, 2H), 7.30 (dd, <i>J</i> = 8.1, 1.5 Hz, 1H), 7.20 (s, 1H), 7.10 (d, <i>J</i> = 8.1 Hz, 1H), 5.19 (s, 2H), 3.88 (s, 3H), 3.55–3.50 (m, 2H), 2.44–2.24 (m, 8H), 2.15 (s, 3H), 2.13 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 528.3[M + H]<sup>+</sup> and 526.3 [M – H]<sup>−</sup>.</div></div><div id="sec4_5_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> 5-{5-[4-(3-Dimethylamino-pyrrolidin-1-ylmethyl)-3-trifluoromethyl-benzoylamino]-2-methyl-phenoxymethyl}-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methyl Ester (<b>26y</b>)</h4><div class="NLM_p last">The reaction was carried out as described in general procedure C using <b>16a</b> (77 mg, 0.25 mmol), 4-(3-dimethylamino-pyrrolidin-1-ylmethyl)-3-trifluoromethyl-benzoic acid <b>5y</b> (95 mg, 0.30 mmol), HATU (114 mg, 0.30 mmol), DIEA (216 μL, 1.24 mmol), and anhydrous DMF (2.5 mL). Purification by reverse-phase flash chromatography (H<sub>2</sub>O/ACN with 1% TFA, 100/0 to 0/100) yielded after neutralization with NaHCO<sub>3</sub> (aqueous) and filtration <b>26y</b> (16 mg, 21%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 10.40 (s, 1H), 8.54 (s, 1H), 8.26–8.18 (m, 3H), 7.90 (d, <i>J</i> = 7.9 Hz, 1H), 7.63 (s, 1H), 7.30 (d, <i>J</i> = 7.8 Hz, 1H), 7.19 (s, 1H), 7.13 (d, <i>J</i> = 7.8 Hz, 1H), 5.20 (s, 2H), 3.87 (s, 3H), 3.88–3.70 (m, 2H), 2.81–2.57 (m, 4H), 2.43–2.33 (m, 1H), 2.14 (s, 3H), 2.09 (s, 6H), 1.96–1.80 (m, 1H), 1.74–1.57 (m, 1H). MS (ESI) <i>m</i>/<i>z</i> 305.7 [M+2H]<sup>2+</sup>.</div></div><div id="sec4_5_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> 5-(2-{2-Methyl-5-[4-(4-methyl-piperazin-1-ylmethyl)-benzoylamino]-phenyl}-vinyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methyl Ester (<b>27x</b>)</h4><div class="NLM_p last">The reaction was carried out as described in general procedure C using <b>18a</b> (72 mg, 0.24 mmol), 4-[(4-methyl-1-piperazinyl)methyl]benzoic acid <b>5x</b> (71 mg, 0.30 mmol), HATU (98 mg, 0.26 mmol), DIEA (204 μL, 1.17 mmol), and anhydrous DMF (3.5 mL). Final compound <b>27x</b> (57 mg, 46%) was isolated from crude after neutralization with NaHCO<sub>3</sub> (aqueous), washing with water, and filtration as a mixture of isomers. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, stereoisomer ratio ≈ 25/75, δ) 12.59 (s, 0.25H), 12.48 (s, 0.75H), 10.17 (s, 0.25H), 10.04 (s, 0.75H), 8.73–8.69 (m, 0.25H), 8.44–8.40 (m, 0.25H), 8.17–8.14 (m, 0.75H), 8.09 (s, 0.25H), 7.94 (d, <i>J</i> = 7.8 Hz, 0.5H), 7.85 (s, 0.75H), 7.80 (d, <i>J</i> = 8.2 Hz, 1.5H), 7.72–7.66 (m, 0.75H), 7.61 (d, <i>J</i> = 7.7 Hz, 0.25H), 7.56–7.52 (m, 0.75H), 7.50–7.42 (m, 0.5H), 7.37 (d, <i>J</i> = 8.2 Hz, 1.5H), 7.28–7.10 (m, 1.75H), 7.05 (s, 0.75H), 6.79 (d, <i>J</i> = 12.3 Hz, 0.75H), 6.72 (d, <i>J</i> = 12.3 Hz, 0.75H), 3.89 (s, 0.75H), 3.84 (s, 2.25H), 3.54 (s, 0.5H), 3.49 (s, 1.5H), 2.44–2.22 (m, 8H), 2.21–2.10 (m, 6H). MS (ESI) <i>m</i>/<i>z</i> 524.3[M + H]<sup>+</sup>.</div></div><div id="sec4_5_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> 5-(2-{5-[4-(3-Dimethylamino-pyrrolidin-1-ylmethyl)-3-trifluoromethyl-benzoylamino]-2-methyl-phenyl}-vinyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methyl Ester (<b>27y</b>)</h4><div class="NLM_p last">The reaction was carried out as described in general procedure C using <b>18a</b> (55 mg, 0.18 mmol), 4-(3-dimethylamino-pyrrolidin-1-ylmethyl)-3-trifluoromethyl-benzoic acid <b>5y</b> (74 mg, 0.23 mmol), HATU (75 mg, 0.20 mmol), DIEA (156 μL, 0.90 mmol), and anhydrous DMF (2.5 mL). Purification by reverse-phase flash chromatography (H<sub>2</sub>O/ACN with 1% TFA, 100/0 to 0/100) yielded after neutralization with NaHCO<sub>3</sub> (aqueous) and filtration <b>26y</b> (10 mg, 9%) as a mixture of isomers (<i>Z</i>/<i>E</i> ≈ 25/75). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 12.59 (s, 0.25H), 12.48 (s, 0.75H), 10.42 (s, 0.25H), 10.27 (s, 0.75H), 8.72 (s, 0.25H), 8.42 (d, <i>J</i> = 1.8 Hz, 0.25H), 8.31–8.22 (m, 0.5H), 8.17–8.03 (m, 2.5H), 7.91 (d, <i>J</i> = 8.1 Hz, 0.25H), 7.88–7.79 (m, 1.5H), 7.69 (dd, <i>J</i> = 8.3, 1.8 Hz, 0.75H), 7.61 (dd, <i>J</i> = 8.1, 1.8 Hz, 0.25H), 7.56–7.48 (m, 1H), 7.29–7.11 (m, 1.5H), 7.05 (s, 0.75H), 6.80 (d, <i>J</i> = 12.3 Hz, 0.75H), 6.73 (d, <i>J</i> = 12.3 Hz, 0.75H), 3.89 (s, 0.75H), 3.84 (s, 2.25H), 3.79 (d, <i>J</i> = 15.4 Hz, 1H), 3.71 (d, <i>J</i> = 15.4 Hz, 1H), 2.82–2.52 (m, 3H), 2.44–2.30 (m, 2H), 2.19 (s, 2.25H), 2.09 (s, 1.5H), 2.07 (s, 4.5H), 1.99 (s, 0.75H), 1.92–1.77 (m, 1H), 1.70–1.55 (m, 1H). MS (ESI) <i>m</i>/<i>z</i> 606.3[M + H]<sup>+</sup> and 604.2 [M – H]<sup>−</sup>.</div></div><div id="sec4_5_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> 5-(2-{2-Methyl-5-[4-(4-methyl-piperazin-1-ylmethyl)-benzoylamino]-phenyl}-ethyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methyl Ester (<b>28x</b>)</h4><div class="NLM_p last">The reaction was carried out as described in general procedure C using <b>19a</b> (100 mg, 0.32 mmol), 4-[(4-methyl-1-piperazinyl)methyl]benzoic acid <b>5x</b> (129 mg, 0.55 mmol), HATU (148 mg, 0.39 mmol), DIEA (168 μL, 0.97 mmol), and anhydrous DMF (2 mL). Purification by reverse-phase flash chromatography (H<sub>2</sub>O/ACN with 1% TFA, 100/0 to 0/100) yielded after neutralization with NaHCO<sub>3</sub> (aqueous) and filtration <b>28x</b> (72 mg, 42%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 12.41 (s, 1H), 10.08 (s, 1H), 8.32 (s, 1H), 7.97 (s, 1H), 7.90 (d, <i>J</i> = 7.8 Hz, 2H), 7.64 (s, 1H), 7.53 (d, <i>J</i> = 8.4 Hz, 1H), 7.43 (d, <i>J</i> = 7.8 Hz, 2H), 7.20–7.02 (m, 2H), 3.87 (s, 3H), 3.52 (s, 2H), 3.04–2.80 (m, 4H), 2.50–2.20 (m, 8H), 2.22 (s, 3H), 2.15 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 526.3[M + H]<sup>+</sup> and 524.2 [M – H]<sup>−</sup>.</div></div><div id="sec4_5_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> 5-(2-{5-[4-(3-Dimethylamino-pyrrolidin-1-ylmethyl)-3-trifluoromethyl-benzoylamino]-2-methyl-phenyl}-ethyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic Acid Methyl Ester (<b>28y</b>)</h4><div class="NLM_p last">The reaction was carried out as described in general procedure C using <b>19a</b> (40 mg, 0.13 mmol), 4-(3-dimethylamino-pyrrolidin-1-ylmethyl)-3-trifluoromethyl-benzoic acid <b>5y</b> (42 mg, 0.13 mmol), HATU (50 mg, 0.13 mmol), DIEA (106 μL, 0.61 mmol), and anhydrous DMF (1.5 mL). Purification by reverse-phase flash chromatography (H<sub>2</sub>O/ACN with 1% TFA, 100/0 to 0/100) yielded after neutralization with NaHCO<sub>3</sub> (aqueous) and filtration <b>28y</b> (30 mg, 38%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 12.40 (s, 1H), 10.32 (s, 1H), 8.32 (s, 1H), 8.25–8.18 (m, 2H), 7.97 (s, 1H), 7.89 (d, <i>J</i> = 8.0 Hz, 1H), 7.61 (s, 1H), 7.55 (d, <i>J</i> = 8.0 Hz, 1H), 7.17–7.08 (m, 2H), 3.87 (s, 3H), 3.86–3.69 (m, 2H), 3.00–2.85 (m, 4H), 2.81–2.52 (m, 4H), 2.43–2.33 (m, 1H), 2.23 (s, 3H), 2.09 (s, 6H), 1.96–1.80 (m, 1H), 1.77–1.57 (m, 1H). MS (ESI) <i>m</i>/<i>z</i> 608.3 [M + H]<sup>+</sup> and 606.3 [M – H]<sup>−</sup>. HPLC purity: 89%.</div></div><div id="sec4_5_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> <i>N</i>-{3-[2-(2-Acetyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)-ethyl]-4-methyl-phenyl}-4-(4-methyl-piperazin-1-ylmethyl)-benzamide (<b>29x</b>)</h4><div class="NLM_p last">The reaction was carried out as described in general procedure C using <b>19b</b> (70 mg, 0.24 mmol), 4-[(4-methyl-1-piperazinyl)methyl]benzoic acid <b>5x</b> (112 mg, 0.48 mmol), HATU (100 mg, 0.26 mmol), DIEA (125 μL, 0.72 mmol), and anhydrous DMF (1.5 mL). Final compound <b>29x</b> (67 mg, 55%) was isolated from crude after neutralization with NaHCO<sub>3</sub> (aqueous), washing with water, and filtration. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 12.16 (s, 1H), 10.07 (s, 1H), 8.32 (d, <i>J</i> = 1.9 Hz, 1H), 7.98 (d, <i>J</i> = 1.8 Hz, 1H), 7.90 (d, <i>J</i> = 8.2 Hz, 2H), 7.63 (d, <i>J</i> = 1.8 Hz, 1H), 7.53 (dd, <i>J</i> = 2.0, 8.2 Hz, 1H), 7.43 (d, <i>J</i> = 8.2 Hz, 2H), 7.29 (d, <i>J</i> = 2.0 Hz, 1H), 7.10 (d, <i>J</i> = 8.2 Hz, 1H), 3.53 (s, 2H), 3.02–2.83 (m, 4H), 2.55 (s, 3H), 2.48–2.25 (m, 8H), 2.21 (s, 3H), 2.17 (s, 3H). MS (ESI) <i>m</i>/<i>z</i> 510.3[M + H]<sup>+</sup> and 508.3 [M – H]<sup>−</sup>.</div></div><div id="sec4_5_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> <i>N</i>-{3-[2-(2-Acetyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)-ethyl]-4-methyl-phenyl}-4-(3-dimethylamino-pyrrolidin-1-ylmethyl)-3-trifluoromethyl-benzamide (<b>29y</b>)</h4><div class="NLM_p last">The reaction was carried out as described in general procedure C using <b>19b</b> (100 mg, 0.34 mmol), 4-(3-dimethylamino-pyrrolidin-1-ylmethyl)-3-trifluoromethyl-benzoic acid <b>5y</b> (119 mg, 0.38 mmol), HATU (143 mg, 0.38 mmol), DIEA (178 μL, 1.02 mmol), and anhydrous DMF (2 mL). Purification by reverse-phase flash chromatography (H<sub>2</sub>O/ACN with 1% TFA, 100/0 to 0/100) yielded after neutralization with NaHCO<sub>3</sub> (aqueous) and filtration <b>29y</b> (29 mg, 14%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>, δ) 12.16 (s, 1H), 10.32 (s, 1H), 8.32 (s, 1H), 8.27–8.18 (m, 2H), 7.98 (s, 1H), 7.89 (d, <i>J</i> = 7.9 Hz, 1H), 7.61 (s, 1H), 7.54 (d, <i>J</i> = 8.1 Hz, 1H), 7.29 (s, 1H), 7.13 (d, <i>J</i> = 8.1 Hz, 1H), 3.88–3.70 (m, 2H), 2.99–2.84 (m, 5H), 2.72–2.52 (m, 3H), 2.45–2.38 (m, 1H), 2.22 (s, 3H), 2.16 (s, 6H), 2.00–1.84 (m, 1H), 1.76–1.62 (m, 1H). MS (ESI) <i>m</i>/<i>z</i> 592.3[M + H]<sup>+</sup> and 590.2 [M – H]<sup>−</sup>.</div></div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i92" class="anchor-spacer"></div><h3 class="article-section__title" id="_i92"> Modeling Studies</h3><div class="NLM_p">The docking files (ligand + protein active site) were prepared for Autodock Vina software<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> by using AutoDock Tools (v1.5.6).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> The following parameters were adjusted in this preparation step: (1) The Gastieger charges and polar hydrogens were added. (2) The grid-box dimensions were set at 16 Å (<i>X</i>), 16 Å (<i>Y</i>), and 28 Å (<i>Z</i>) in the 3D space. (3) The center of the box was positioned at the midpoint of the active site, and the box volume covered the entire active site area plus a significant portion of the solvent-exposed surface of the protein.</div><div class="NLM_p last">The following docking parameters were used in Autodock Vina: (1) All bonds in the inhibitor structures were allowed to rotate freely, except for the multiple bonds, amide bonds, and the bonds in aromatic entities. (2) The kinase 3D structures were considered to be rigid. (3) A Lamarckian genetic algorithm was used for searching the conformational space in the active site. (4) The default grid spacing was set at 0.375 Å. (5) A total of 100 different conformations were assessed, and the 20 highest scored binding modes were maintained for visual inspection. (6) The maximum energy difference between the best and the worst binding modes was set at 3 kcal/mol. (7) The scoring function was a stochastic global optimization method inspired chiefly by X-Score.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Visual inspection of the docking results and image building was done using PyMOL software.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93"> In Vitro Kinase Assays</h3><div class="NLM_p last">In vitro kinase assays were carried out by Life Technologies’ SelectScreen Biochemical Kinase Profiling Service. The inhibitory activity of compounds at a 100 nM concentration was evaluated against each kinase using their ATP <i>K</i><sub>m</sub> concentration except for the B-RAF kinase that was incubated in the presence of a 100 μM ATP concentration. Results reported as a percent of inhibition in the tables are the mean of duplicate points. For IC<sub>50</sub> evaluation, the results were evaluated with 10 duplicate concentration points.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i94" class="anchor-spacer"></div><h3 class="article-section__title" id="_i94"> Proliferation Assays</h3><div class="NLM_p last">HUVEC (human umbilical endothelial vein cells, obtained from Lonza) and HRMEC (human retinal microvascular endothelial cells, obtained from Angio-Proteomie) primary cells were used at a passage less than 8 and cultured in EndoGRO-VEGF Complete Medium (Merck-Millipore). A549, HT29, HepG2, PC-3, MDA-MB-231, Caki-2, and BxPC3 cell lines were obtained from the European Collection of Cell Culture, the NCI-H1975 cell line was obtained from the American Type Culture Collection, and BaF3 cells were kindly provided by Dr. J. M. Pasquet. Cell lines were maintained in DMEM or RPMI media, each complemented with 10% fetal bovine serum and incubated at 37 °C in 5% CO<sub>2</sub>. Human PBMC were freshly isolated by Ficoll from two healthy donors and cultured with RPMI medium complemented with 10% fetal bovine serum. PBMC were activated by adding phytohemagglutinin (PHA, 5 μg/mL) and IL-2 (40U/mL) in cell culture medium from 48 h before the assay. In 96-well plates, cells were distributed at 5 × 10<sup>3</sup> or 1 × 10<sup>4</sup> cells/well depending on the doubling time of the cell type except for human PBMC that were plated at 7.5 × 10<sup>4</sup> cells/well. The day after plating, cells were incubated with escalating concentrations of compounds in duplicate for 72 h. Cell proliferation was measured using MTT (3[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide). The EC<sub>50</sub> values were calculated with six duplicate concentration points from sigmoidal dose–response curves utilizing Prism 5.0 from Graph-Pad Software, with values normalized to the values of DMSO-treated control wells (0%) and 1% SDS control wells (100%).</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i95" class="anchor-spacer"></div><h3 class="article-section__title" id="_i95"> Pharmacokinetics</h3><div class="NLM_p last">The pharmacokinetic profile of <b>6z</b> was assessed in Swiss male mice, 5 weeks old, after single intravenous injection at 2 mg/kg (IV) or oral dosing at 20 mg/kg (PO) using DMSO as vehicle. Blood samples were collected at various time points, and the compound concentrations in plasma were determined by an internal standard LC/MS/MS method using protein precipitation and calibration standards prepared in blank mouse plasma. Reported concentrations are average values from 2 mice/time point/dose group.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i96" class="anchor-spacer"></div><h3 class="article-section__title" id="_i96"> hERG Patch Clamp Assay</h3><div class="NLM_p last">The effects of <b>6z</b> on the hERG ion channel were measured by Cytocentrics Bioscience Gmbh (Germany) according to the conventional (manual) patch clamp technique. Quality-assured HEK 293 cells stably expressing the hERG channel were used. Compound <b>6z</b> was applied at three concentrations (3, 10, and 30 μM, 0.1% DMSO) using a slow perfusion system with a tube pump. Each compound concentration was tested on two individual cells. Cisapride was used as reference compound at a concentration of 200 nM to induce a hERG tail-current inhibition and to validate the experiment.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i97"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00087">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72868" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72868" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b00087" class="ext-link">10.1021/acs.jmedchem.6b00087</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Homology modeling and docking studies. Details of HPLC methods used for purity determination. HPLC purities. NMR spectra. (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00087/suppl_file/jm6b00087_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Structure information for compounds <b>6a</b>–<b>z</b>, <b>7x</b>–<b>z</b>, <b>8x</b>–<b>z</b>, <b>12x</b>,<b>y</b>, <b>24x</b>,<b>y</b>, <b>25x</b>, <b>26x,y</b>, <b>27x</b>,<b>y</b>, <b>28x</b>,<b>y</b>, and <b>29x</b>,<b>y</b>. (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00087/suppl_file/jm6b00087_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00087/suppl_file/jm6b00087_si_001.pdf">jm6b00087_si_001.pdf (7.02 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00087/suppl_file/jm6b00087_si_002.csv">jm6b00087_si_002.csv (6.4 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Protein Data Bank IDs <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3G5D">3G5D</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1UWH">1UWH</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2OIQ">2OIQ</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ASD">4ASD</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1IEP">1IEP</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3VNT">3VNT</a>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RT7">4RT7</a>.</p><div class="testing" data-doi="10.1021/acs.jmedchem.6b00087" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10355" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10355" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Abdelaziz Yasri</span> - <span class="hlFld-Affiliation affiliation">OriBase
Pharma, Cap Gamma, Parc Euromédecine, 1682 rue de la Valsière, CS 17383, Montpellier 34189 CEDEX 4, France</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#1f7e667e6c6d765f706d767d7e6c7a326f777e6d727e317c7072"><span class="__cf_email__" data-cfemail="12736b7361607b527d607b707361773f627a73607f733c717d7f">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bénédicte Daydé-Cazals</span> - <span class="hlFld-Affiliation affiliation">OriBase
Pharma, Cap Gamma, Parc Euromédecine, 1682 rue de la Valsière, CS 17383, Montpellier 34189 CEDEX 4, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bénédicte Fauvel</span> - <span class="hlFld-Affiliation affiliation">OriBase
Pharma, Cap Gamma, Parc Euromédecine, 1682 rue de la Valsière, CS 17383, Montpellier 34189 CEDEX 4, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mathilde Singer</span> - <span class="hlFld-Affiliation affiliation">OriBase
Pharma, Cap Gamma, Parc Euromédecine, 1682 rue de la Valsière, CS 17383, Montpellier 34189 CEDEX 4, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Clémence Feneyrolles</span> - <span class="hlFld-Affiliation affiliation">OriBase
Pharma, Cap Gamma, Parc Euromédecine, 1682 rue de la Valsière, CS 17383, Montpellier 34189 CEDEX 4, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Benoit Bestgen</span> - <span class="hlFld-Affiliation affiliation">OriBase
Pharma, Cap Gamma, Parc Euromédecine, 1682 rue de la Valsière, CS 17383, Montpellier 34189 CEDEX 4, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fanny Gassiot</span> - <span class="hlFld-Affiliation affiliation">OriBase
Pharma, Cap Gamma, Parc Euromédecine, 1682 rue de la Valsière, CS 17383, Montpellier 34189 CEDEX 4, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aurélia Spenlinhauer</span> - <span class="hlFld-Affiliation affiliation">OriBase
Pharma, Cap Gamma, Parc Euromédecine, 1682 rue de la Valsière, CS 17383, Montpellier 34189 CEDEX 4, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pierre Warnault</span> - <span class="hlFld-Affiliation affiliation">OriBase
Pharma, Cap Gamma, Parc Euromédecine, 1682 rue de la Valsière, CS 17383, Montpellier 34189 CEDEX 4, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nathalie Van Hijfte</span> - <span class="hlFld-Affiliation affiliation">OriBase
Pharma, Cap Gamma, Parc Euromédecine, 1682 rue de la Valsière, CS 17383, Montpellier 34189 CEDEX 4, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nozha Borjini</span> - <span class="hlFld-Affiliation affiliation">OriBase
Pharma, Cap Gamma, Parc Euromédecine, 1682 rue de la Valsière, CS 17383, Montpellier 34189 CEDEX 4, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gwénaël Chevé</span> - <span class="hlFld-Affiliation affiliation">OriBase
Pharma, Cap Gamma, Parc Euromédecine, 1682 rue de la Valsière, CS 17383, Montpellier 34189 CEDEX 4, France</span></div></li></ul></li><li></li><li><span class="author-information-subsection-header">Funding</span><p>The research was supported by OriBase Pharma.</p></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e7005-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i100">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68057" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68057" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Dr. Jean-Max Pasquet for providing cell lines and Dr. Francisco Veas and Gregor Dubois for laboratory assistance and discussions.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i101" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i101"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i102" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i102"> Abbreviations Used</h2><tr><td class="NLM_term">MTKI</td><td class="NLM_def"><p class="first last">multitargeted kinase inhibitor</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphinositide 3-kinase</p></td></tr><tr><td class="NLM_term">PDB</td><td class="NLM_def"><p class="first last">Protein Data Bank</p></td></tr><tr><td class="NLM_term">PBP</td><td class="NLM_def"><p class="first last">purine binding pocket</p></td></tr><tr><td class="NLM_term">SP</td><td class="NLM_def"><p class="first last">selectivity pocket I</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">VEGFR2</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor receptor 2</p></td></tr><tr><td class="NLM_term">FGFR2</td><td class="NLM_def"><p class="first last">fibroblast growth factor receptor 2</p></td></tr><tr><td class="NLM_term">PDGFRA</td><td class="NLM_def"><p class="first last">platelet-derived growth factor receptor alpha</p></td></tr><tr><td class="NLM_term">rt</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">nd</td><td class="NLM_def"><p class="first last">not determined</p></td></tr><tr><td class="NLM_term">ACN</td><td class="NLM_def"><p class="first last">acetonitrile</p></td></tr><tr><td class="NLM_term">FA</td><td class="NLM_def"><p class="first last">formic acid</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i103">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06821" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06821" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 23 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Targeting Cancer with Small Molecule Kinase Inhibitors</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">28</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span><span class="refDoi"> DOI: 10.1038/nrc2559</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=10.1038%2Fnrc2559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=19104514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1yg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=28-39&issue=1&author=J.+Zhangauthor=P.+L.+Yangauthor=N.+S.+Gray&title=Targeting+Cancer+with+Small+Molecule+Kinase+Inhibitors&doi=10.1038%2Fnrc2559"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer with small molecule kinase inhibitors</span></div><div class="casAuthors">Zhang, Jianming; Yang, Priscilla L.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-39</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Deregulation of kinase activity has emerged as a major mechanism by which cancer cells evade normal physiol. constraints on growth and survival.  To date, 11 kinase inhibitors have received US Food and Drug Administration approval as cancer treatments, and there are considerable efforts to develop selective small mol. inhibitors for a host of other kinases that are implicated in cancer and other diseases.  Herein we discuss the current challenges in the field, such as designing selective inhibitors and developing strategies to overcome resistance mutations.  This Review provides a broad overview of some of the approaches currently used to discover and characterize new kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriSM3BN_uEz7Vg90H21EOLACvtfcHk0ljC6Xd1MxnuwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1yg&md5=35bc38f414cd21eef5e61ce181b580fb</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc2559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2559%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DP.%2BL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DTargeting%2520Cancer%2520with%2520Small%2520Molecule%2520Kinase%2520Inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26issue%3D1%26spage%3D28%26epage%3D39%26doi%3D10.1038%2Fnrc2559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundström, M.</span><span> </span><span class="NLM_article-title">Recently Targeted Kinases and Their Inhibitors — the Path to Clinical Trials</span> <span class="citation_source-journal">Curr. Opin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">58</span><span class="NLM_x">–</span> <span class="NLM_lpage">63</span><span class="refDoi"> DOI: 10.1016/j.coph.2014.07.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=10.1016%2Fj.coph.2014.07.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=25113945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Ojtb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2014&pages=58-63&author=S.+Knappauthor=M.+Sundstr%C3%B6m&title=Recently+Targeted+Kinases+and+Their+Inhibitors+%E2%80%94+the+Path+to+Clinical+Trials&doi=10.1016%2Fj.coph.2014.07.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Recently targeted kinases and their inhibitors - the path to clinical trials</span></div><div class="casAuthors">Knapp, Stefan; Sundstrom, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">58-63</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein kinases have emerged as one of the most important drug target families for the treatment of cancer.  To date, 28 inhibitors with reported activity vs. one or multiple kinases have been approved for clin. use.  However, the majority of new clin. trials are focused on new subindications using already approved kinase inhibitors or target well validated kinase targets with novel inhibitors.  In contrast, relatively few clin. trials have been initiated using specific inhibitors that inhibit novel kinase targets, despite significant validation efforts in the public domain.  Anal. of the target validation history of first in class kinase inhibitors revealed a long delay between initial disease assocn. and development of inhibitors.  As part of this anal., we have investigated which first in class inhibitor that entered phase I clin. trials over the last five years and also considered which research approaches that were used to validate them.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMyUJTPj_d77Vg90H21EOLACvtfcHk0ljC6Xd1MxnuwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Ojtb7M&md5=805f1abf5dd5ef75f130e3257cdab39a</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2014.07.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2014.07.015%26sid%3Dliteratum%253Aachs%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DSundstr%25C3%25B6m%26aufirst%3DM.%26atitle%3DRecently%2520Targeted%2520Kinases%2520and%2520Their%2520Inhibitors%2520%25E2%2580%2594%2520the%2520Path%2520to%2520Clinical%2520Trials%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2014%26volume%3D17%26spage%3D58%26epage%3D63%26doi%3D10.1016%2Fj.coph.2014.07.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Gerlinger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowan, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horswell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larkin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endesfelder, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gronroos, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarpey, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varela, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillimore, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Begum, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, N. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raine, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Latimer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santos, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nohadani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eklund, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer-Dene, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickering, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stamp, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szallasi, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downward, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Futreal, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swanton, C.</span><span> </span><span class="NLM_article-title">Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">366</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">883</span><span class="NLM_x">–</span> <span class="NLM_lpage">892</span><span class="refDoi"> DOI: 10.1056/NEJMoa1113205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=10.1056%2FNEJMoa1113205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=22397650" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=1%3ACAS%3A528%3ADC%252BC38XktFOgtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=883-892&issue=10&author=M.+Gerlingerauthor=A.+J.+Rowanauthor=S.+Horswellauthor=J.+Larkinauthor=D.+Endesfelderauthor=E.+Gronroosauthor=P.+Martinezauthor=N.+Matthewsauthor=A.+Stewartauthor=P.+Tarpeyauthor=I.+Varelaauthor=B.+Phillimoreauthor=S.+Begumauthor=N.+Q.+McDonaldauthor=A.+Butlerauthor=D.+Jonesauthor=K.+Raineauthor=C.+Latimerauthor=C.+R.+Santosauthor=M.+Nohadaniauthor=A.+C.+Eklundauthor=B.+Spencer-Deneauthor=G.+Clarkauthor=L.+Pickeringauthor=G.+Stampauthor=M.+Goreauthor=Z.+Szallasiauthor=J.+Downwardauthor=P.+A.+Futrealauthor=C.+Swanton&title=Intratumor+Heterogeneity+and+Branched+Evolution+Revealed+by+Multiregion+Sequencing&doi=10.1056%2FNEJMoa1113205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Intratumor heterogeneity and branched evolution revealed by multiregion sequencing</span></div><div class="casAuthors">Gerlinger, Marco; Rowan, Andrew J.; Horswell, Stuart; Larkin, James; Endesfelder, David; Gronroos, Eva; Martinez, Pierre; Matthews, Nicholas; Stewart, Aengus; Tarpey, Patrick; Varela, Ignacio; Phillimore, Benjamin; Begum, Sharmin; McDonald, Neil Q.; Butler, Adam; Jones, David; Raine, Keiran; Latimer, Calli; Santos, Claudio R.; Nohadani, Mahrokh; Eklund, Aron C.; Spencer-Dene, Bradley; Clark, Graham; Pickering, Lisa; Stamp, Gordon; Gore, Martin; Szallasi, Zoltan; Donward, Julian; Futreal, P. Andrew; Swanton, Charles</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">883-892</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Intratumor heterogeneity may foster tumor evolution and adaptation and hinder personalized-medicine strategies that depend on results from single tumor-biopsy samples.  Methods: To examine intratumor heterogeneity, we performed exome sequencing, chromosome aberration anal., and ploidy profiling on multiple spatially sepd. samples obtained from primary renal carcinomas and assocd. metastatic sites.  We characterized the consequences of intratumor heterogeneity using immunohistochem. anal., mutation functional anal., and profiling of mRNA expression.  Results: Phylogenetic reconstruction revealed branched evolutionary tumor growth, with 63 to 69% of all somatic mutations not detectable across every tumor region.  Intratumor heterogeneity was obsd. for a mutation within an autoinhibitory domain of the mammalian target of rapamycin (mTOR) kinase, correlating with S6 and 4EBP phosphorylation in vivo and constitutive activation of mTOR kinase activity in vitro.  Mutational intratumor heterogeneity was seen for multiple tumor-suppressor genes converging on loss of function; SETD2, PTEN, and KDM5C underwent multiple distinct and spatially sepd. inactivating mutations within a single tumor, suggesting convergent phenotypic evolution.  Gene-expression signatures of good and poor prognosis were detected in different regions of the same tumor.  Allelic compn. and ploidy profiling anal. revealed extensive intratumor heterogeneity, with 26 of 30 tumor samples from four tumors harboring divergent allelic-imbalance profiles and with ploidy heterogeneity in two of four tumors.  Conclusions: Intratumor heterogeneity can lead to underestimation of the tumor genomics landscape portrayed from single tumor-biopsy samples and may present major challenges to personalized-medicine and biomarker development.  Intratumor heterogeneity, assocd. with heterogeneous protein function, may foster tumor adaptation and therapeutic failure through Darwinian selection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5FKqZ_4ThTLVg90H21EOLACvtfcHk0ljZ0-P_QBRBQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktFOgtbw%253D&md5=2ab2e658d1218935e12cc934b09e1b95</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1113205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1113205%26sid%3Dliteratum%253Aachs%26aulast%3DGerlinger%26aufirst%3DM.%26aulast%3DRowan%26aufirst%3DA.%2BJ.%26aulast%3DHorswell%26aufirst%3DS.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DEndesfelder%26aufirst%3DD.%26aulast%3DGronroos%26aufirst%3DE.%26aulast%3DMartinez%26aufirst%3DP.%26aulast%3DMatthews%26aufirst%3DN.%26aulast%3DStewart%26aufirst%3DA.%26aulast%3DTarpey%26aufirst%3DP.%26aulast%3DVarela%26aufirst%3DI.%26aulast%3DPhillimore%26aufirst%3DB.%26aulast%3DBegum%26aufirst%3DS.%26aulast%3DMcDonald%26aufirst%3DN.%2BQ.%26aulast%3DButler%26aufirst%3DA.%26aulast%3DJones%26aufirst%3DD.%26aulast%3DRaine%26aufirst%3DK.%26aulast%3DLatimer%26aufirst%3DC.%26aulast%3DSantos%26aufirst%3DC.%2BR.%26aulast%3DNohadani%26aufirst%3DM.%26aulast%3DEklund%26aufirst%3DA.%2BC.%26aulast%3DSpencer-Dene%26aufirst%3DB.%26aulast%3DClark%26aufirst%3DG.%26aulast%3DPickering%26aufirst%3DL.%26aulast%3DStamp%26aufirst%3DG.%26aulast%3DGore%26aufirst%3DM.%26aulast%3DSzallasi%26aufirst%3DZ.%26aulast%3DDownward%26aufirst%3DJ.%26aulast%3DFutreal%26aufirst%3DP.%2BA.%26aulast%3DSwanton%26aufirst%3DC.%26atitle%3DIntratumor%2520Heterogeneity%2520and%2520Branched%2520Evolution%2520Revealed%2520by%2520Multiregion%2520Sequencing%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26issue%3D10%26spage%3D883%26epage%3D892%26doi%3D10.1056%2FNEJMoa1113205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Klein, C. A.</span><span> </span><span class="NLM_article-title">Selection and Adaptation during Metastatic Cancer Progression</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">501</span><span class="NLM_x"> (</span><span class="NLM_issue">7467</span><span class="NLM_x">) </span> <span class="NLM_fpage">365</span><span class="NLM_x">–</span> <span class="NLM_lpage">372</span><span class="refDoi"> DOI: 10.1038/nature12628</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=10.1038%2Fnature12628" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=501&publication_year=2013&pages=365-372&issue=7467&author=C.+A.+Klein&title=Selection+and+Adaptation+during+Metastatic+Cancer+Progression&doi=10.1038%2Fnature12628"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnature12628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature12628%26sid%3Dliteratum%253Aachs%26aulast%3DKlein%26aufirst%3DC.%2BA.%26atitle%3DSelection%2520and%2520Adaptation%2520during%2520Metastatic%2520Cancer%2520Progression%26jtitle%3DNature%26date%3D2013%26volume%3D501%26issue%3D7467%26spage%3D365%26epage%3D372%26doi%3D10.1038%2Fnature12628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Gossage, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisen, T.</span><span> </span><span class="NLM_article-title">Targeting Multiple Kinase Pathways: A Change in Paradigm</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">1973</span><span class="NLM_x">–</span> <span class="NLM_lpage">1978</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-09-3182</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=10.1158%2F1078-0432.CCR-09-3182" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=20215532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktFygu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=1973-1978&issue=7&author=L.+Gossageauthor=T.+Eisen&title=Targeting+Multiple+Kinase+Pathways%3A+A+Change+in+Paradigm&doi=10.1158%2F1078-0432.CCR-09-3182"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Multiple Kinase Pathways: A Change In Paradigm</span></div><div class="casAuthors">Gossage, Lucy; Eisen, Tim</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1973-1978</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Anticancer drugs that target protein kinases include small mol. inhibitors and monoclonal antibodies.  Feedback loops and cross talk between signaling pathways impact significantly on the efficacy of cancer therapeutics, and resistance to targeted agents is a major barrier to effective treatments.  Increasingly, therapies are being designed to target multiple kinase pathways.  This can be achieved using a single agent that inhibits multiple signaling pathways or a combination of highly selective agents.  In this review we discuss the principles of specifically targeting multiple kinase pathways with particular ref. to angiogenic signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwTqIFjKKuX7Vg90H21EOLACvtfcHk0ljZ0-P_QBRBQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktFygu7w%253D&md5=fc074fb853129324db0b36ec148f2401</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-3182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-3182%26sid%3Dliteratum%253Aachs%26aulast%3DGossage%26aufirst%3DL.%26aulast%3DEisen%26aufirst%3DT.%26atitle%3DTargeting%2520Multiple%2520Kinase%2520Pathways%253A%2520A%2520Change%2520in%2520Paradigm%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26issue%3D7%26spage%3D1973%26epage%3D1978%26doi%3D10.1158%2F1078-0432.CCR-09-3182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Dar, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cagan, R. L.</span><span> </span><span class="NLM_article-title">Chemical Genetic Discovery of Targets and Anti-Targets for Cancer Polypharmacology</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">486</span><span class="NLM_x"> (</span><span class="NLM_issue">7401</span><span class="NLM_x">) </span> <span class="NLM_fpage">80</span><span class="NLM_x">–</span> <span class="NLM_lpage">84</span><span class="refDoi"> DOI: 10.1038/nature11127</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=10.1038%2Fnature11127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=22678283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=1%3ACAS%3A528%3ADC%252BC38Xot1Cnu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=486&publication_year=2012&pages=80-84&issue=7401&author=A.+C.+Darauthor=T.+K.+Dasauthor=K.+M.+Shokatauthor=R.+L.+Cagan&title=Chemical+Genetic+Discovery+of+Targets+and+Anti-Targets+for+Cancer+Polypharmacology&doi=10.1038%2Fnature11127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical genetic discovery of targets and anti-targets for cancer polypharmacology</span></div><div class="casAuthors">Dar, Arvin C.; Das, Tirtha K.; Shokat, Kevan M.; Cagan, Ross L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">486</span>
        (<span class="NLM_cas:issue">7401</span>),
    <span class="NLM_cas:pages">80-84</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The complexity of cancer has led to recent interest in polypharmacol. approaches for developing kinase-inhibitor drugs; however, optimal kinase-inhibition profiles remain difficult to predict.  Using a Ret-kinase-driven Drosophila model of multiple endocrine neoplasia type 2 and kinome-wide drug profiling, here the authors identify that AD57 rescues oncogenic Ret-induced lethality, whereas related Ret inhibitors imparted reduced efficacy and enhanced toxicity.  Drosophila genetics and compd. profiling defined three pathways accounting for the mechanistic basis of efficacy and dose-limiting toxicity.  Inhibition of Ret plus Raf, Src and S6K was required for optimal animal survival, whereas inhibition of the anti-target' Tor led to toxicity owing to release of neg. feedback.  Rational synthetic tailoring to eliminate Tor binding afforded AD80 and AD81, compds. featuring balanced pathway inhibition, improved efficacy and low toxicity in Drosophila and mammalian multiple endocrine neoplasia type 2 models.  Combining kinase-focused chem., kinome-wide profiling and Drosophila genetics provides a powerful systems pharmacol. approach towards developing compds. with a maximal therapeutic index.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3OjBELXO9TbVg90H21EOLACvtfcHk0liJBzWlIFiW4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xot1Cnu7w%253D&md5=4ed2f85f51453c1b38ee390a0a5f14db</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnature11127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11127%26sid%3Dliteratum%253Aachs%26aulast%3DDar%26aufirst%3DA.%2BC.%26aulast%3DDas%26aufirst%3DT.%2BK.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DCagan%26aufirst%3DR.%2BL.%26atitle%3DChemical%2520Genetic%2520Discovery%2520of%2520Targets%2520and%2520Anti-Targets%2520for%2520Cancer%2520Polypharmacology%26jtitle%3DNature%26date%3D2012%26volume%3D486%26issue%3D7401%26spage%3D80%26epage%3D84%26doi%3D10.1038%2Fnature11127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Knight, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">Targeting the Cancer Kinome through Polypharmacology</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">130</span><span class="NLM_x">–</span> <span class="NLM_lpage">137</span><span class="refDoi"> DOI: 10.1038/nrc2787</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=10.1038%2Fnrc2787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=20094047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=1%3ACAS%3A528%3ADC%252BC3cXps1Clug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=130-137&issue=2&author=Z.+A.+Knightauthor=H.+Linauthor=K.+M.+Shokat&title=Targeting+the+Cancer+Kinome+through+Polypharmacology&doi=10.1038%2Fnrc2787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the cancer kinome through polypharmacology</span></div><div class="casAuthors">Knight, Zachary A.; Lin, Henry; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">130-137</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Kinase inhibitors are the largest class of new cancer drugs.  However, it is already apparent that most tumors can escape from the inhibition of any single kinase.  If it is necessary to inhibit multiple kinases, how do we choose which ones.  In this Opinion article, we discuss some of the strategies that are currently being used to identify new therapeutic combinations of kinase targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkDv2FeeH58rVg90H21EOLACvtfcHk0liJBzWlIFiW4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXps1Clug%253D%253D&md5=9aaa314e54b43889e147a9f11ac77072</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrc2787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2787%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DTargeting%2520the%2520Cancer%2520Kinome%2520through%2520Polypharmacology%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26issue%3D2%26spage%3D130%26epage%3D137%26doi%3D10.1038%2Fnrc2787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Chevé, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bories, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fauvel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picot, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tible, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daydé-Cazals, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loget, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasri, A.</span><span> </span><span class="NLM_article-title">De Novo Design, Synthesis and Pharmacological Evaluation of New Azaindole Derivatives as Dual Inhibitors of Abl and Src Kinases</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">788</span><span class="NLM_x">–</span> <span class="NLM_lpage">800</span><span class="refDoi"> DOI: 10.1039/c2md20104f</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=10.1039%2Fc2md20104f" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=788-800&issue=7&author=G.+Chev%C3%A9author=C.+Boriesauthor=B.+Fauvelauthor=F.+Picotauthor=A.+Tibleauthor=B.+Dayd%C3%A9-Cazalsauthor=O.+Logetauthor=A.+Yasri&title=De+Novo+Design%2C+Synthesis+and+Pharmacological+Evaluation+of+New+Azaindole+Derivatives+as+Dual+Inhibitors+of+Abl+and+Src+Kinases&doi=10.1039%2Fc2md20104f"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1039%2Fc2md20104f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2md20104f%26sid%3Dliteratum%253Aachs%26aulast%3DChev%25C3%25A9%26aufirst%3DG.%26aulast%3DBories%26aufirst%3DC.%26aulast%3DFauvel%26aufirst%3DB.%26aulast%3DPicot%26aufirst%3DF.%26aulast%3DTible%26aufirst%3DA.%26aulast%3DDayd%25C3%25A9-Cazals%26aufirst%3DB.%26aulast%3DLoget%26aufirst%3DO.%26aulast%3DYasri%26aufirst%3DA.%26atitle%3DDe%2520Novo%2520Design%252C%2520Synthesis%2520and%2520Pharmacological%2520Evaluation%2520of%2520New%2520Azaindole%2520Derivatives%2520as%2520Dual%2520Inhibitors%2520of%2520Abl%2520and%2520Src%2520Kinases%26jtitle%3DMedChemComm%26date%3D2012%26volume%3D3%26issue%3D7%26spage%3D788%26epage%3D800%26doi%3D10.1039%2Fc2md20104f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Fauvel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coisy-Quivy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vivier, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chevé, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boriès, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daydé-Cazals, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feneyrolles, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bestgen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delon, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dufies, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auberger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loget, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasri, A.</span><span> </span><span class="NLM_article-title">Anti-Tumor Activity of Novel Compounds Targeting BCR-ABL, c-SRC and BCR-ABLT315I in Chronic Myelogenous Leukemia</span> <span class="citation_source-journal">Am. J. Cancer Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">28</span><span class="NLM_x">–</span> <span class="NLM_lpage">36</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=28-36&issue=1&author=B.+Fauvelauthor=M.+Coisy-Quivyauthor=S.+Vivierauthor=G.+Chev%C3%A9author=C.+Bori%C3%A8sauthor=B.+Dayd%C3%A9-Cazalsauthor=C.+Feneyrollesauthor=B.+Bestgenauthor=L.+Delonauthor=M.+Dufiesauthor=P.+Aubergerauthor=O.+Logetauthor=A.+Yasri&title=Anti-Tumor+Activity+of+Novel+Compounds+Targeting+BCR-ABL%2C+c-SRC+and+BCR-ABLT315I+in+Chronic+Myelogenous+Leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFauvel%26aufirst%3DB.%26aulast%3DCoisy-Quivy%26aufirst%3DM.%26aulast%3DVivier%26aufirst%3DS.%26aulast%3DChev%25C3%25A9%26aufirst%3DG.%26aulast%3DBori%25C3%25A8s%26aufirst%3DC.%26aulast%3DDayd%25C3%25A9-Cazals%26aufirst%3DB.%26aulast%3DFeneyrolles%26aufirst%3DC.%26aulast%3DBestgen%26aufirst%3DB.%26aulast%3DDelon%26aufirst%3DL.%26aulast%3DDufies%26aufirst%3DM.%26aulast%3DAuberger%26aufirst%3DP.%26aulast%3DLoget%26aufirst%3DO.%26aulast%3DYasri%26aufirst%3DA.%26atitle%3DAnti-Tumor%2520Activity%2520of%2520Novel%2520Compounds%2520Targeting%2520BCR-ABL%252C%2520c-SRC%2520and%2520BCR-ABLT315I%2520in%2520Chronic%2520Myelogenous%2520Leukemia%26jtitle%3DAm.%2520J.%2520Cancer%2520Sci.%26date%3D2013%26volume%3D2%26issue%3D1%26spage%3D28%26epage%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grütter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klüter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rode, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robubi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Hybrid Compound Design to Overcome the Gatekeeper T338M Mutation in cSrc</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x"> (</span><span class="NLM_issue">13</span><span class="NLM_x">) </span> <span class="NLM_fpage">3915</span><span class="NLM_x">–</span> <span class="NLM_lpage">3926</span><span class="refDoi"> DOI: 10.1021/jm9002928</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9002928" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtlWgtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=3915-3926&issue=13&author=M.+Getlikauthor=C.+Gr%C3%BCtterauthor=J.+R.+Simardauthor=S.+Kl%C3%BCterauthor=M.+Rabillerauthor=H.+B.+Rodeauthor=A.+Robubiauthor=D.+Rauh&title=Hybrid+Compound+Design+to+Overcome+the+Gatekeeper+T338M+Mutation+in+cSrc&doi=10.1021%2Fjm9002928"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Hybrid Compound Design To Overcome the Gatekeeper T338M Mutation in cSrc</span></div><div class="casAuthors">Getlik, Matthaeus; Gruetter, Christian; Simard, Jeffrey R.; Kluter, Sabine; Rabiller, Matthias; Rode, Haridas B.; Robubi, Armin; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3915-3926</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The emergence of drug resistance remains a fundamental challenge in the development of kinase inhibitors that are effective over long-term treatments.  Allosteric inhibitors that bind to sites lying outside the highly conserved ATP pocket are thought to be more selective than ATP-competitive inhibitors and may circumvent some mechanisms of drug resistance.  Crystal structures of type I and allosteric type III inhibitors in complex with the tyrosine kinase cSrc allowed to develop these scaffolds into potent type II kinase inhibitors.  One of these compds., I (RL46), disrupts FAK-mediated focal adhesions in cancer cells via direct inhibition of cSrc.  Details gleaned from crystal structures revealed a key feature of a subset of these compds., a surprising flexibility in the vicinity of the gatekeeper residue that allows these compds. to overcome a dasatinib-resistant gatekeeper mutation emerging in cSrc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-72ZDo25pC7Vg90H21EOLACvtfcHk0lhDbdu9MsTXuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtlWgtbY%253D&md5=3ff187e49298ec4690c76a2bc2100274</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm9002928&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9002928%26sid%3Dliteratum%253Aachs%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DGr%25C3%25BCtter%26aufirst%3DC.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DKl%25C3%25BCter%26aufirst%3DS.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DRode%26aufirst%3DH.%2BB.%26aulast%3DRobubi%26aufirst%3DA.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DHybrid%2520Compound%2520Design%2520to%2520Overcome%2520the%2520Gatekeeper%2520T338M%2520Mutation%2520in%2520cSrc%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26issue%3D13%26spage%3D3915%26epage%3D3926%26doi%3D10.1021%2Fjm9002928" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Seeliger, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frank, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henderson, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">C-Src Binds to the Cancer Drug Imatinib with an Inactive Abl/c-Kit Conformation and a Distributed Thermodynamic Penalty</span> <span class="citation_source-journal">Structure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">299</span><span class="NLM_x">–</span> <span class="NLM_lpage">311</span><span class="refDoi"> DOI: 10.1016/j.str.2007.01.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=10.1016%2Fj.str.2007.01.015" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=299-311&issue=3&author=M.+A.+Seeligerauthor=B.+Nagarauthor=F.+Frankauthor=X.+Caoauthor=M.+N.+Hendersonauthor=J.+Kuriyan&title=C-Src+Binds+to+the+Cancer+Drug+Imatinib+with+an+Inactive+Abl%2Fc-Kit+Conformation+and+a+Distributed+Thermodynamic+Penalty&doi=10.1016%2Fj.str.2007.01.015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2007.01.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2007.01.015%26sid%3Dliteratum%253Aachs%26aulast%3DSeeliger%26aufirst%3DM.%2BA.%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DFrank%26aufirst%3DF.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DHenderson%26aufirst%3DM.%2BN.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DC-Src%2520Binds%2520to%2520the%2520Cancer%2520Drug%2520Imatinib%2520with%2520an%2520Inactive%2520Abl%252Fc-Kit%2520Conformation%2520and%2520a%2520Distributed%2520Thermodynamic%2520Penalty%26jtitle%3DStructure%26date%3D2007%26volume%3D15%26issue%3D3%26spage%3D299%26epage%3D311%26doi%3D10.1016%2Fj.str.2007.01.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornmann, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicena, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veach, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Crystal Structures of the Kinase Domain of c-Abl in Complex with the Small Molecule Inhibitors PD173955 and Imatinib (STI-571)</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x"> (</span><span class="NLM_issue">15</span><span class="NLM_x">) </span> <span class="NLM_fpage">4236</span><span class="NLM_x">–</span> <span class="NLM_lpage">4243</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=12154025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=4236-4243&issue=15&author=B.+Nagarauthor=W.+G.+Bornmannauthor=P.+Pellicenaauthor=T.+Schindlerauthor=D.+R.+Veachauthor=W.+T.+Millerauthor=B.+Clarksonauthor=J.+Kuriyan&title=Crystal+Structures+of+the+Kinase+Domain+of+c-Abl+in+Complex+with+the+Small+Molecule+Inhibitors+PD173955+and+Imatinib+%28STI-571%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</span></div><div class="casAuthors">Nagar, Bhushan; Bornmann, William G.; Pellicena, Patricia; Schindler, Thomas; Veach, Darren R.; Miller, W. Todd; Clarkson, Bayard; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4236-4243</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The inadvertent fusion of the bcr gene with the abl gene results in a constitutively active tyrosine kinase (Bcr-Abl) that transforms cells and causes chronic myelogenous leukemia.  Small mol. inhibitors of Bcr-Abl that bind to the kinase domain can be used to treat chronic myelogenous leukemia.  We report crystal structures of the kinase domain of Abl in complex with two such inhibitors, imatinib (also known as STI-571 and Gleevec) and PD173955 (Parke-Davis).  Both compds. bind to the canonical ATP-binding site of the kinase domain, but they do so in different ways.  As shown previously in a crystal structure of Abl bound to a smaller variant of STI-571, STI-571 captures a specific inactive conformation of the activation loop of Abl in which the loop mimics bound peptide substrate.  In contrast, PD173955 binds to a conformation of Abl in which the activation loop resembles that of an active kinase.  The structure suggests that PD173955 would be insensitive to whether the conformation of the activation loop corresponds to active kinases or to that seen in the STI-571 complex.  In vitro kinase assays confirm that this is the case and indicate that PD173955 is at least 10-fold more inhibitory than STI-571.  The structures suggest that PD173955 achieves its greater potency over STI-571 by being able to target multiple forms of Abl (active or inactive), whereas STI-571 requires a specific inactive conformation of Abl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-5qYZHMOZCrVg90H21EOLACvtfcHk0lhSOkcU_14XPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D&md5=843213cd6038ed82a0e43dce56e81a91</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DBornmann%26aufirst%3DW.%2BG.%26aulast%3DPellicena%26aufirst%3DP.%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DVeach%26aufirst%3DD.%2BR.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DCrystal%2520Structures%2520of%2520the%2520Kinase%2520Domain%2520of%2520c-Abl%2520in%2520Complex%2520with%2520the%2520Small%2520Molecule%2520Inhibitors%2520PD173955%2520and%2520Imatinib%2520%2528STI-571%2529%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26issue%3D15%26spage%3D4236%26epage%3D4243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Choi, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adrian, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuntland, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sim, T.</span><span> </span><span class="NLM_article-title">A Type-II Kinase Inhibitor Capable of Inhibiting the T315I “Gatekeeper” Mutant of Bcr-Abl</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x"> (</span><span class="NLM_issue">15</span><span class="NLM_x">) </span> <span class="NLM_fpage">5439</span><span class="NLM_x">–</span> <span class="NLM_lpage">5448</span><span class="refDoi"> DOI: 10.1021/jm901808w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901808w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5439-5448&issue=15&author=H.+G.+Choiauthor=P.+Renauthor=F.+Adrianauthor=F.+Sunauthor=H.+S.+Leeauthor=X.+Wangauthor=Q.+Dingauthor=G.+Zhangauthor=Y.+Xieauthor=J.+Zhangauthor=Y.+Liuauthor=T.+Tuntlandauthor=M.+Warmuthauthor=P.+W.+Manleyauthor=J.+Mestanauthor=N.+S.+Grayauthor=T.+Sim&title=A+Type-II+Kinase+Inhibitor+Capable+of+Inhibiting+the+T315I+%E2%80%9CGatekeeper%E2%80%9D+Mutant+of+Bcr-Abl&doi=10.1021%2Fjm901808w"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm901808w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901808w%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DRen%26aufirst%3DP.%26aulast%3DAdrian%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DLee%26aufirst%3DH.%2BS.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DSim%26aufirst%3DT.%26atitle%3DA%2520Type-II%2520Kinase%2520Inhibitor%2520Capable%2520of%2520Inhibiting%2520the%2520T315I%2520%25E2%2580%259CGatekeeper%25E2%2580%259D%2520Mutant%2520of%2520Bcr-Abl%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D15%26spage%3D5439%26epage%3D5448%26doi%3D10.1021%2Fjm901808w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Koroleva, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadutskii, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farina, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ignatovich, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ermolinskaya, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gusak, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalinichenko, E. N.</span><span> </span><span class="NLM_article-title">A Practical Synthesis of 4-[(4-Methylpiperazin-1-Yl)methyl]benzoic Acid—the Key Precursor toward Imatinib</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x"> (</span><span class="NLM_issue">38</span><span class="NLM_x">) </span> <span class="NLM_fpage">5056</span><span class="NLM_x">–</span> <span class="NLM_lpage">5058</span><span class="refDoi"> DOI: 10.1016/j.tetlet.2012.06.107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=10.1016%2Fj.tetlet.2012.06.107" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2012&pages=5056-5058&issue=38&author=E.+V.+Korolevaauthor=A.+P.+Kadutskiiauthor=A.+V.+Farinaauthor=J.+V.+Ignatovichauthor=A.+L.+Ermolinskayaauthor=K.+N.+Gusakauthor=E.+N.+Kalinichenko&title=A+Practical+Synthesis+of+4-%5B%284-Methylpiperazin-1-Yl%29methyl%5Dbenzoic+Acid%E2%80%94the+Key+Precursor+toward+Imatinib&doi=10.1016%2Fj.tetlet.2012.06.107"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2012.06.107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2012.06.107%26sid%3Dliteratum%253Aachs%26aulast%3DKoroleva%26aufirst%3DE.%2BV.%26aulast%3DKadutskii%26aufirst%3DA.%2BP.%26aulast%3DFarina%26aufirst%3DA.%2BV.%26aulast%3DIgnatovich%26aufirst%3DJ.%2BV.%26aulast%3DErmolinskaya%26aufirst%3DA.%2BL.%26aulast%3DGusak%26aufirst%3DK.%2BN.%26aulast%3DKalinichenko%26aufirst%3DE.%2BN.%26atitle%3DA%2520Practical%2520Synthesis%2520of%25204-%255B%25284-Methylpiperazin-1-Yl%2529methyl%255Dbenzoic%2520Acid%25E2%2580%2594the%2520Key%2520Precursor%2520toward%2520Imatinib%26jtitle%3DTetrahedron%2520Lett.%26date%3D2012%26volume%3D53%26issue%3D38%26spage%3D5056%26epage%3D5058%26doi%3D10.1016%2Fj.tetlet.2012.06.107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Chevé, G.; Daydé-Cazals, B.; Fauvel, B.; Boriès, C.; Yasri, A.</span><span> </span><span class="NLM_article-title">New Azaindole Derivatives As Inhibitors of Protein Kinases</span>. WO2014102378 A1, July 3,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=G.+Chev%C3%A9&author=B.+Dayd%C3%A9-Cazals&author=B.+Fauvel&author=C.+Bori%C3%A8s&author=A.+Yasri&title=New+Azaindole+Derivatives+As+Inhibitors+of+Protein+Kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChev%25C3%25A9%26aufirst%3DG.%26atitle%3DNew%2520Azaindole%2520Derivatives%2520As%2520Inhibitors%2520of%2520Protein%2520Kinases%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Pessina, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malerba, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gribaldo, L.</span><span> </span><span class="NLM_article-title">Hematotoxicity Testing by Cell Clonogenic Assay in Drug Development and Preclinical Trials</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">1055</span><span class="NLM_x">–</span> <span class="NLM_lpage">1065</span><span class="refDoi"> DOI: 10.2174/1381612053381648</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=10.2174%2F1381612053381648" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=15777255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhvVChu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=1055-1065&issue=8&author=A.+Pessinaauthor=I.+Malerbaauthor=L.+Gribaldo&title=Hematotoxicity+Testing+by+Cell+Clonogenic+Assay+in+Drug+Development+and+Preclinical+Trials&doi=10.2174%2F1381612053381648"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Hematotoxicity testing by cell clonogenic assay in drug development and preclinical trials</span></div><div class="casAuthors">Pessina, Augusto; Malerba, Ilaria; Gribaldo, Laura</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1055-1065</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  In vitro clonogenic assays were developed and widely used since many years to investigate the proliferation and the differentiation both of pluripotent hemopoietic stem cells (PHSC) and of the different progenitors of blood cell lineages: megakaryocytes (Colony Forming Unit-Mk) granulocyte -macrophage (CFU-GM), erythrocytes (BFU-E/CFU-E).  As these techniques were introduced, they appeared to be very useful to investigate the pathogenic mechanisms of drug induced blood disorders and also for screening compd. during preclin. safety study.  Because the integrity of the hematopoiesis is also essential to guarantee the immunol. function, the application to the toxicol. of these clonogenic assays, provides an essential tool for better understanding the in vivo observation (exptl. and clin.) by also helping in predicting the degree of a possible in vivo hematotoxic in drug treated patients.  The review introduces to basic concepts on hematopoiesis and on classical evaluation of a drug hematotoxic phenomenon.  It describes the application of each clonogenic test to assess the specific hematotoxicity action.  Moreover it report the most recent studies on standardization, prevalidation and validation of such assays and critically reviews a model for predicting myelotoxicity by discussing the main aspects referred to the evaluation of the in vivo acute neutropenia by the in vitro CFU-GM assay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpexbsOIJbAk7Vg90H21EOLACvtfcHk0lgMR0OIHo9vnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhvVChu7Y%253D&md5=c5aa2ac515dfc1ad2fa92d9dabfa18e6</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.2174%2F1381612053381648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612053381648%26sid%3Dliteratum%253Aachs%26aulast%3DPessina%26aufirst%3DA.%26aulast%3DMalerba%26aufirst%3DI.%26aulast%3DGribaldo%26aufirst%3DL.%26atitle%3DHematotoxicity%2520Testing%2520by%2520Cell%2520Clonogenic%2520Assay%2520in%2520Drug%2520Development%2520and%2520Preclinical%2520Trials%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2005%26volume%3D11%26issue%3D8%26spage%3D1055%26epage%3D1065%26doi%3D10.2174%2F1381612053381648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Hassan, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haglund, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aleskog, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindhagen, E.</span><span> </span><span class="NLM_article-title">Primary Lymphocytes as Predictors for Species Differences in Cytotoxic Drug Sensitivity</span> <span class="citation_source-journal">Toxicol. In Vitro</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">1174</span><span class="NLM_x">–</span> <span class="NLM_lpage">1181</span><span class="refDoi"> DOI: 10.1016/j.tiv.2007.03.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=10.1016%2Fj.tiv.2007.03.009" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=1174-1181&issue=6&author=S.+B.+Hassanauthor=C.+Haglundauthor=A.+Aleskogauthor=R.+Larssonauthor=E.+Lindhagen&title=Primary+Lymphocytes+as+Predictors+for+Species+Differences+in+Cytotoxic+Drug+Sensitivity&doi=10.1016%2Fj.tiv.2007.03.009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.tiv.2007.03.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tiv.2007.03.009%26sid%3Dliteratum%253Aachs%26aulast%3DHassan%26aufirst%3DS.%2BB.%26aulast%3DHaglund%26aufirst%3DC.%26aulast%3DAleskog%26aufirst%3DA.%26aulast%3DLarsson%26aufirst%3DR.%26aulast%3DLindhagen%26aufirst%3DE.%26atitle%3DPrimary%2520Lymphocytes%2520as%2520Predictors%2520for%2520Species%2520Differences%2520in%2520Cytotoxic%2520Drug%2520Sensitivity%26jtitle%3DToxicol.%2520In%2520Vitro%26date%3D2007%26volume%3D21%26issue%3D6%26spage%3D1174%26epage%3D1181%26doi%3D10.1016%2Fj.tiv.2007.03.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Schade, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schieven, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Townsend, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jankowska, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Susulic, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szpurka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maciejewski, J. P.</span><span> </span><span class="NLM_article-title">Dasatinib, a Small-Molecule Protein Tyrosine Kinase Inhibitor, Inhibits T-Cell Activation and Proliferation</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">1366</span><span class="NLM_x">–</span> <span class="NLM_lpage">1377</span><span class="refDoi"> DOI: 10.1182/blood-2007-04-084814</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=10.1182%2Fblood-2007-04-084814" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2007&pages=1366-1377&issue=3&author=A.+E.+Schadeauthor=G.+L.+Schievenauthor=R.+Townsendauthor=A.+M.+Jankowskaauthor=V.+Susulicauthor=R.+Zhangauthor=H.+Szpurkaauthor=J.+P.+Maciejewski&title=Dasatinib%2C+a+Small-Molecule+Protein+Tyrosine+Kinase+Inhibitor%2C+Inhibits+T-Cell+Activation+and+Proliferation&doi=10.1182%2Fblood-2007-04-084814"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1182%2Fblood-2007-04-084814&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2007-04-084814%26sid%3Dliteratum%253Aachs%26aulast%3DSchade%26aufirst%3DA.%2BE.%26aulast%3DSchieven%26aufirst%3DG.%2BL.%26aulast%3DTownsend%26aufirst%3DR.%26aulast%3DJankowska%26aufirst%3DA.%2BM.%26aulast%3DSusulic%26aufirst%3DV.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DSzpurka%26aufirst%3DH.%26aulast%3DMaciejewski%26aufirst%3DJ.%2BP.%26atitle%3DDasatinib%252C%2520a%2520Small-Molecule%2520Protein%2520Tyrosine%2520Kinase%2520Inhibitor%252C%2520Inhibits%2520T-Cell%2520Activation%2520and%2520Proliferation%26jtitle%3DBlood%26date%3D2007%26volume%3D111%26issue%3D3%26spage%3D1366%26epage%3D1377%26doi%3D10.1182%2Fblood-2007-04-084814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Lee, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouwehand, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giannini, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dibb, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bijlmakers, M. J.</span><span> </span><span class="NLM_article-title">Lck Is a Key Target of Imatinib and Dasatinib in T-Cell Activation</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">896</span><span class="NLM_x">–</span> <span class="NLM_lpage">900</span><span class="refDoi"> DOI: 10.1038/leu.2010.11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=10.1038%2Fleu.2010.11" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2010&pages=896-900&issue=4&author=K.+C.+Leeauthor=I.+Ouwehandauthor=A.+L.+Gianniniauthor=N.+S.+Thomasauthor=N.+J.+Dibbauthor=M.+J.+Bijlmakers&title=Lck+Is+a+Key+Target+of+Imatinib+and+Dasatinib+in+T-Cell+Activation&doi=10.1038%2Fleu.2010.11"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fleu.2010.11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2010.11%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%2BC.%26aulast%3DOuwehand%26aufirst%3DI.%26aulast%3DGiannini%26aufirst%3DA.%2BL.%26aulast%3DThomas%26aufirst%3DN.%2BS.%26aulast%3DDibb%26aufirst%3DN.%2BJ.%26aulast%3DBijlmakers%26aufirst%3DM.%2BJ.%26atitle%3DLck%2520Is%2520a%2520Key%2520Target%2520of%2520Imatinib%2520and%2520Dasatinib%2520in%2520T-Cell%2520Activation%26jtitle%3DLeukemia%26date%3D2010%26volume%3D24%26issue%3D4%26spage%3D896%26epage%3D900%26doi%3D10.1038%2Fleu.2010.11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Trott, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. J.</span><span> </span><span class="NLM_article-title">AutoDock Vina: Improving the Speed and Accuracy of Docking with a New Scoring Function, Efficient Optimization, and Multithreading</span> <span class="citation_source-journal">J. Comput. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">455</span><span class="NLM_x">–</span> <span class="NLM_lpage">461</span><span class="refDoi"> DOI: 10.1002/jcc.21334</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=10.1002%2Fjcc.21334" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=19499576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGnur3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2010&pages=455-461&issue=2&author=O.+Trottauthor=A.+J.+Olson&title=AutoDock+Vina%3A+Improving+the+Speed+and+Accuracy+of+Docking+with+a+New+Scoring+Function%2C+Efficient+Optimization%2C+and+Multithreading&doi=10.1002%2Fjcc.21334"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</span></div><div class="casAuthors">Trott, Oleg; Olson, Arthur J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">455-461</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">AutoDock Vina, a new program for mol. docking and virtual screening, is presented.  AutoDock Vina achieves an approx. 2 orders of magnitude speed-up compared with the mol. docking software previously developed in the authors' lab (AutoDock 4), while also significantly improving the accuracy of the binding mode predictions, judging by the authors' tests on the training set used in AutoDock 4 development.  Further speed-up is achieved from parallelism, by using multithreading on multicore machines.  AutoDock Vina automatically calcs. the grid maps and clusters the results in a way transparent to the user.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLecOIkUxIlrVg90H21EOLACvtfcHk0ljToDRpxomYhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGnur3O&md5=c6974af8a1235f7aa09918d3e6f70dc4</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2Fjcc.21334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.21334%26sid%3Dliteratum%253Aachs%26aulast%3DTrott%26aufirst%3DO.%26aulast%3DOlson%26aufirst%3DA.%2BJ.%26atitle%3DAutoDock%2520Vina%253A%2520Improving%2520the%2520Speed%2520and%2520Accuracy%2520of%2520Docking%2520with%2520a%2520New%2520Scoring%2520Function%252C%2520Efficient%2520Optimization%252C%2520and%2520Multithreading%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2010%26volume%3D31%26issue%3D2%26spage%3D455%26epage%3D461%26doi%3D10.1002%2Fjcc.21334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Goodsell, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. J.</span><span> </span><span class="NLM_article-title">Automated Docking of Substrates to Proteins by Simulated Annealing</span> <span class="citation_source-journal">Proteins: Struct., Funct., Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">195</span><span class="NLM_x">–</span> <span class="NLM_lpage">202</span><span class="refDoi"> DOI: 10.1002/prot.340080302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=10.1002%2Fprot.340080302" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1990&pages=195-202&issue=3&author=D.+S.+Goodsellauthor=A.+J.+Olson&title=Automated+Docking+of+Substrates+to+Proteins+by+Simulated+Annealing&doi=10.1002%2Fprot.340080302"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1002%2Fprot.340080302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprot.340080302%26sid%3Dliteratum%253Aachs%26aulast%3DGoodsell%26aufirst%3DD.%2BS.%26aulast%3DOlson%26aufirst%3DA.%2BJ.%26atitle%3DAutomated%2520Docking%2520of%2520Substrates%2520to%2520Proteins%2520by%2520Simulated%2520Annealing%26jtitle%3DProteins%253A%2520Struct.%252C%2520Funct.%252C%2520Genet.%26date%3D1990%26volume%3D8%26issue%3D3%26spage%3D195%26epage%3D202%26doi%3D10.1002%2Fprot.340080302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Wang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span> </span><span class="NLM_article-title">Further Development and Validation of Empirical Scoring Functions for Structure-Based Binding Affinity Prediction</span> <span class="citation_source-journal">J. Comput.-Aided Mol. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">11</span><span class="NLM_x">–</span> <span class="NLM_lpage">26</span><span class="refDoi"> DOI: 10.1023/A:1016357811882</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=10.1023%2FA%3A1016357811882" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2002&pages=11-26&issue=1&author=R.+Wangauthor=L.+Laiauthor=S.+Wang&title=Further+Development+and+Validation+of+Empirical+Scoring+Functions+for+Structure-Based+Binding+Affinity+Prediction&doi=10.1023%2FA%3A1016357811882"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1023%2FA%3A1016357811882&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1016357811882%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DR.%26aulast%3DLai%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DFurther%2520Development%2520and%2520Validation%2520of%2520Empirical%2520Scoring%2520Functions%2520for%2520Structure-Based%2520Binding%2520Affinity%2520Prediction%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2002%26volume%3D16%26issue%3D1%26spage%3D11%26epage%3D26%26doi%3D10.1023%2FA%3A1016357811882" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span>The PyMol Molecular Graphics System, version <span class="NLM_edition">0.99rc6</span>; <span class="NLM_publisher-name">Schrodinger, LLC</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+PyMol+Molecular+Graphics+System%2C+version+0.99rc6%3B+Schrodinger%2C+LLC%3A+New+York%2C+2015."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520PyMol%2520Molecular%2520Graphics%2520System%26pub%3DSchrodinger%252C%2520LLC%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 26 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Bedadyuti Vedvyas Pati, Prateep Singh Sagara, Asit Ghosh, Smruti Ranjan Mohanty, <span class="NLM_string-name hlFld-ContribAuthor">Ponneri Chandrababu Ravikumar</span>. </span><span class="cited-content_cbyCitation_article-title">Ruthenium-Catalyzed Cross Dehydrogenative Annulation of N-(7-Azaindole)benzamides with Maleimides: One-Step Access to Highly Functionalized Pyrroloisoquinoline. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>86 </em>
                                    (9)
                                     , 6551-6565. <a href="https://doi.org/10.1021/acs.joc.1c00367" title="DOI URL">https://doi.org/10.1021/acs.joc.1c00367</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.1c00367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.1c00367%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DRuthenium-Catalyzed%252BCross%252BDehydrogenative%252BAnnulation%252Bof%252BN-%2525287-Azaindole%252529benzamides%252Bwith%252BMaleimides%25253A%252BOne-Step%252BAccess%252Bto%252BHighly%252BFunctionalized%252BPyrroloisoquinoline%26aulast%3DPati%26aufirst%3DBedadyuti%2BVedvyas%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D14022021%26date%3D26042021%26volume%3D86%26issue%3D9%26spage%3D6551%26epage%3D6565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xin Liu, Paul Carr, Michael G. Gardiner, Martin G. Banwell, Ahmed H. Elbanna, Zeinab G. Khalil, <span class="NLM_string-name hlFld-ContribAuthor">Robert J. Capon</span>. </span><span class="cited-content_cbyCitation_article-title">Levoglucosenone and Its Pseudoenantiomer iso-Levoglucosenone as Scaffolds for Drug Discovery and Development. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2020,</strong> <em>5 </em>
                                    (23)
                                     , 13926-13939. <a href="https://doi.org/10.1021/acsomega.0c01331" title="DOI URL">https://doi.org/10.1021/acsomega.0c01331</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.0c01331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.0c01331%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DLevoglucosenone%252Band%252BIts%252BPseudoenantiomer%252Biso-Levoglucosenone%252Bas%252BScaffolds%252Bfor%252BDrug%252BDiscovery%252Band%252BDevelopment%26aulast%3DLiu%26aufirst%3DXin%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D25032020%26date%3D25052020%26date%3D08062020%26volume%3D5%26issue%3D23%26spage%3D13926%26epage%3D13939" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Taejoo Jeong, Suk Hun Lee, Rina Chun, Sangil Han, Sang Hoon Han, Yeong Uk Jeon, Jihye Park, Takehiko Yoshimitsu, Neeraj Kumar Mishra, <span class="NLM_string-name hlFld-ContribAuthor">In Su Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Ru(II)-Catalyzed C–H Aminocarbonylation of N-(Hetero)aryl-7-azaindoles with Isocyanates. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>83 </em>
                                    (8)
                                     , 4641-4649. <a href="https://doi.org/10.1021/acs.joc.8b00388" title="DOI URL">https://doi.org/10.1021/acs.joc.8b00388</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.8b00388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.8b00388%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DRu%252528II%252529-Catalyzed%252BC%2525E2%252580%252593H%252BAminocarbonylation%252Bof%252BN-%252528Hetero%252529aryl-7-azaindoles%252Bwith%252BIsocyanates%26aulast%3DJeong%26aufirst%3DTaejoo%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D09022018%26date%3D06042018%26date%3D04042018%26volume%3D83%26issue%3D8%26spage%3D4641%26epage%3D4649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrea  Sartori</span>, <span class="hlFld-ContribAuthor ">Elisabetta  Portioli</span>, <span class="hlFld-ContribAuthor ">Lucia  Battistini</span>, <span class="hlFld-ContribAuthor ">Lido  Calorini</span>, <span class="hlFld-ContribAuthor ">Alberto  Pupi</span>, <span class="hlFld-ContribAuthor ">Federica  Vacondio</span>, <span class="hlFld-ContribAuthor ">Daniela  Arosio</span>, <span class="hlFld-ContribAuthor ">Francesca  Bianchini</span>, and <span class="hlFld-ContribAuthor ">Franca  Zanardi</span>  . </span><span class="cited-content_cbyCitation_article-title">Synthesis of Novel c(AmpRGD)–Sunitinib Dual Conjugates as Molecular Tools Targeting the αvβ3 Integrin/VEGFR2 Couple and Impairing Tumor-Associated Angiogenesis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (1)
                                     , 248-262. <a href="https://doi.org/10.1021/acs.jmedchem.6b01266" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01266</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01266%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Bof%252BNovel%252Bc%252528AmpRGD%252529%2525E2%252580%252593Sunitinib%252BDual%252BConjugates%252Bas%252BMolecular%252BTools%252BTargeting%252Bthe%252B%2525CE%2525B1v%2525CE%2525B23%252BIntegrin%25252FVEGFR2%252BCouple%252Band%252BImpairing%252BTumor-Associated%252BAngiogenesis%26aulast%3DSartori%26aufirst%3DAndrea%26date%3D2017%26date%3D2016%26date%3D2016%26date%3D25082016%26date%3D20122016%26date%3D12012017%26date%3D06122016%26volume%3D60%26issue%3D1%26spage%3D248%26epage%3D262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yan‐Ying  Zhu</span>, <span class="hlFld-ContribAuthor ">Hui‐Bei  Xu</span>, <span class="hlFld-ContribAuthor ">Jing  Zhang</span>, <span class="hlFld-ContribAuthor ">Yi  Luo</span>, <span class="hlFld-ContribAuthor ">Lin  Dong</span>. </span><span class="cited-content_cbyCitation_article-title">Ru(II)‐Catalyzed Difluoromethylations of 7‐Azaindoles: Access to Novel Fluoro‐7‐Azaindole Derivatives. </span><span class="cited-content_cbyCitation_journal-name">Asian Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>10 </em>
                                    (6)
                                     , 1410-1413. <a href="https://doi.org/10.1002/ajoc.202100159" title="DOI URL">https://doi.org/10.1002/ajoc.202100159</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ajoc.202100159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fajoc.202100159%26sid%3Dliteratum%253Aachs%26jtitle%3DAsian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DRu%252528II%252529%2525E2%252580%252590Catalyzed%252BDifluoromethylations%252Bof%252B7%2525E2%252580%252590Azaindoles%25253A%252BAccess%252Bto%252BNovel%252BFluoro%2525E2%252580%2525907%2525E2%252580%252590Azaindole%252BDerivatives%26aulast%3DZhu%26aufirst%3DYan%25E2%2580%2590Ying%26date%3D2021%26date%3D2021%26volume%3D10%26issue%3D6%26spage%3D1410%26epage%3D1413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu  Ru-Jian</span>, <span class="hlFld-ContribAuthor ">Zhang  Chun-Yan</span>, <span class="hlFld-ContribAuthor ">Zhou  Xiang</span>, <span class="hlFld-ContribAuthor ">Yan-Shi  Xiong</span>, <span class="hlFld-ContribAuthor ">Xue-Min  Duan</span>. </span><span class="cited-content_cbyCitation_article-title">Copper-catalyzed
              ortho
              -selective direct sulfenylation of
              N
              -aryl-7-azaindoles with disulfides. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2021,</strong> <em>19 </em>
                                    (13)
                                     , 2901-2906. <a href="https://doi.org/10.1039/D1OB00106J" title="DOI URL">https://doi.org/10.1039/D1OB00106J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1OB00106J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1OB00106J%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DCopper-catalyzed%252Bortho%252B-selective%252Bdirect%252Bsulfenylation%252Bof%252BN%252B-aryl-7-azaindoles%252Bwith%252Bdisulfides%26aulast%3DRu-Jian%26aufirst%3DYu%26date%3D2021%26date%3D2021%26volume%3D19%26issue%3D13%26spage%3D2901%26epage%3D2906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ting  Guo</span>, <span class="hlFld-ContribAuthor ">Shutao  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances in the Discovery of Multitargeted Tyrosine Kinase Inhibitors as Anticancer Agents. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>16 </em>
                                    (4)
                                     , 600-620. <a href="https://doi.org/10.1002/cmdc.202000658" title="DOI URL">https://doi.org/10.1002/cmdc.202000658</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202000658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202000658%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DRecent%252BAdvances%252Bin%252Bthe%252BDiscovery%252Bof%252BMultitargeted%252BTyrosine%252BKinase%252BInhibitors%252Bas%252BAnticancer%252BAgents%26aulast%3DGuo%26aufirst%3DTing%26date%3D2021%26date%3D2020%26volume%3D16%26issue%3D4%26spage%3D600%26epage%3D620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Md. Muzahid Ahmed  Ezaj</span>, <span class="hlFld-ContribAuthor ">Md.  Junaid</span>, <span class="hlFld-ContribAuthor ">Yeasmin  Akter</span>, <span class="hlFld-ContribAuthor ">Afsana  Nahrin</span>, <span class="hlFld-ContribAuthor ">Aysha  Siddika</span>, <span class="hlFld-ContribAuthor ">Syeda Samira  Afrose</span>, <span class="hlFld-ContribAuthor ">S. M. Abdul  Nayeem</span>, <span class="hlFld-ContribAuthor ">Md. Sajedul  Haque</span>, <span class="hlFld-ContribAuthor ">Mohammad Ali  Moni</span>, <span class="hlFld-ContribAuthor ">S. M. Zahid  Hosen</span>. </span><span class="cited-content_cbyCitation_article-title">Whole proteome screening and identification of potential epitopes of SARS-CoV-2 for vaccine design-an immunoinformatic, molecular docking and molecular dynamics simulation accelerated robust strategy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2021,</strong> <em>4 </em>, 1-26. <a href="https://doi.org/10.1080/07391102.2021.1886171" title="DOI URL">https://doi.org/10.1080/07391102.2021.1886171</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2021.1886171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2021.1886171%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DWhole%252Bproteome%252Bscreening%252Band%252Bidentification%252Bof%252Bpotential%252Bepitopes%252Bof%252BSARS-CoV-2%252Bfor%252Bvaccine%252Bdesign-an%252Bimmunoinformatic%25252C%252Bmolecular%252Bdocking%252Band%252Bmolecular%252Bdynamics%252Bsimulation%252Baccelerated%252Brobust%252Bstrategy%26aulast%3DEzaj%26aufirst%3DMd.%2BMuzahid%2BAhmed%26date%3D2021%26date%3D2021%26volume%3D4%26spage%3D1%26epage%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jidan  Liu</span>, <span class="hlFld-ContribAuthor ">Jinyuan  Jiang</span>, <span class="hlFld-ContribAuthor ">Zhenke  Yang</span>, <span class="hlFld-ContribAuthor ">Qiaohai  Zeng</span>, <span class="hlFld-ContribAuthor ">Jieying  Zheng</span>, <span class="hlFld-ContribAuthor ">Siying  Zhang</span>, <span class="hlFld-ContribAuthor ">Liyao  Zheng</span>, <span class="hlFld-ContribAuthor ">Shang-Shi  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhao-Qing  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Rhodium(
              iii
              )-catalyzed oxidative alkylation of
              N
              -aryl-7-azaindoles with cyclopropanols. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2021,</strong> <em>19 </em>
                                    (5)
                                     , 993-997. <a href="https://doi.org/10.1039/D0OB02323J" title="DOI URL">https://doi.org/10.1039/D0OB02323J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0OB02323J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0OB02323J%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DRhodium%252528%252Biii%252B%252529-catalyzed%252Boxidative%252Balkylation%252Bof%252BN%252B-aryl-7-azaindoles%252Bwith%252Bcyclopropanols%26aulast%3DLiu%26aufirst%3DJidan%26date%3D2021%26date%3D2021%26volume%3D19%26issue%3D5%26spage%3D993%26epage%3D997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alaa A.-M.  Abdel-Aziz</span>, <span class="hlFld-ContribAuthor ">Adel S.  El-Azab</span>, <span class="hlFld-ContribAuthor ">Nawaf A.  AlSaif</span>, <span class="hlFld-ContribAuthor ">Ahmad J.  Obaidullah</span>, <span class="hlFld-ContribAuthor ">Abdulrahman M.  Al-Obaid</span>, <span class="hlFld-ContribAuthor ">Ibrahim A.  Al-Suwaidan</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, potential antitumor activity, cell cycle analysis, and multitarget mechanisms of novel hydrazones incorporating a 4-methylsulfonylbenzene scaffold: a molecular docking study. </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2021,</strong> <em>36 </em>
                                    (1)
                                     , 1521-1539. <a href="https://doi.org/10.1080/14756366.2021.1924698" title="DOI URL">https://doi.org/10.1080/14756366.2021.1924698</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14756366.2021.1924698&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14756366.2021.1924698%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%25252C%252Bpotential%252Bantitumor%252Bactivity%25252C%252Bcell%252Bcycle%252Banalysis%25252C%252Band%252Bmultitarget%252Bmechanisms%252Bof%252Bnovel%252Bhydrazones%252Bincorporating%252Ba%252B4-methylsulfonylbenzene%252Bscaffold%25253A%252Ba%252Bmolecular%252Bdocking%252Bstudy%26aulast%3DAbdel-Aziz%26aufirst%3DAlaa%2BA.-M.%26date%3D2021%26date%3D2021%26volume%3D36%26issue%3D1%26spage%3D1521%26epage%3D1539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Damoder Reddy  Motati</span>, <span class="hlFld-ContribAuthor ">Radhika  Amaradhi</span>, <span class="hlFld-ContribAuthor ">Thota  Ganesh</span>. </span><span class="cited-content_cbyCitation_article-title">Azaindole therapeutic agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2020,</strong> <em>28 </em>
                                    (24)
                                     , 115830. <a href="https://doi.org/10.1016/j.bmc.2020.115830" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115830</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115830&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115830%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DAzaindole%252Btherapeutic%252Bagents%26aulast%3DMotati%26aufirst%3DDamoder%2BReddy%26date%3D2020%26volume%3D28%26issue%3D24%26spage%3D115830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ksenia  Szmigiel-Bakalarz</span>, <span class="hlFld-ContribAuthor ">Markus  Nentwig</span>, <span class="hlFld-ContribAuthor ">Oliver  Oeckler</span>, <span class="hlFld-ContribAuthor ">Magdalena  Malik-Gajewska</span>, <span class="hlFld-ContribAuthor ">Beata  Filip-Psurska</span>, <span class="hlFld-ContribAuthor ">Barbara  Morzyk-Ociepa</span>. </span><span class="cited-content_cbyCitation_article-title">7-Azaindole-3-carboxylic acid and its Pt(II) and Pd(II) complexes: Crystal structure of the ligand, vibrational spectra, DFT calculations and in vitro antiproliferative activity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Structure</span><span> <strong>2020,</strong> <em>1203 </em>, 127441. <a href="https://doi.org/10.1016/j.molstruc.2019.127441" title="DOI URL">https://doi.org/10.1016/j.molstruc.2019.127441</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molstruc.2019.127441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molstruc.2019.127441%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Structure%26atitle%3D7-Azaindole-3-carboxylic%252Bacid%252Band%252Bits%252BPt%252528II%252529%252Band%252BPd%252528II%252529%252Bcomplexes%25253A%252BCrystal%252Bstructure%252Bof%252Bthe%252Bligand%25252C%252Bvibrational%252Bspectra%25252C%252BDFT%252Bcalculations%252Band%252Bin%2525C2%2525A0vitro%252Bantiproliferative%252Bactivity%26aulast%3DSzmigiel-Bakalarz%26aufirst%3DKsenia%26date%3D2020%26volume%3D1203%26spage%3D127441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ling  Li</span>, <span class="hlFld-ContribAuthor ">Dangyun  Liu</span>, <span class="hlFld-ContribAuthor ">Ake  Liu</span>, <span class="hlFld-ContribAuthor ">Jingquan  Li</span>, <span class="hlFld-ContribAuthor ">Hui  Wang</span>, <span class="hlFld-ContribAuthor ">Jingqi  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Genomic Survey of Tyrosine Kinases Repertoire in
              Electrophorus electricus
              With an Emphasis on Evolutionary Conservation and Diversification. </span><span class="cited-content_cbyCitation_journal-name">Evolutionary Bioinformatics</span><span> <strong>2020,</strong> <em>16 </em>, 117693432092251. <a href="https://doi.org/10.1177/1176934320922519" title="DOI URL">https://doi.org/10.1177/1176934320922519</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/1176934320922519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F1176934320922519%26sid%3Dliteratum%253Aachs%26jtitle%3DEvolutionary%2520Bioinformatics%26atitle%3DGenomic%252BSurvey%252Bof%252BTyrosine%252BKinases%252BRepertoire%252Bin%252BElectrophorus%252Belectricus%252BWith%252Ban%252BEmphasis%252Bon%252BEvolutionary%252BConservation%252Band%252BDiversification%26aulast%3DLi%26aufirst%3DLing%26date%3D2020%26date%3D2020%26volume%3D16%26spage%3D117693432092251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhi-Gang  Sun</span>, <span class="hlFld-ContribAuthor ">Jian-Hua  Liu</span>, <span class="hlFld-ContribAuthor ">Jin-Mai  Zhang</span>, <span class="hlFld-ContribAuthor ">Yong  Qian</span>. </span><span class="cited-content_cbyCitation_article-title">Research Progress of Axl Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Current Topics in Medicinal Chemistry</span><span> <strong>2019,</strong> <em>19 </em>
                                    (15)
                                     , 1338-1349. <a href="https://doi.org/10.2174/1568026619666190620155613" title="DOI URL">https://doi.org/10.2174/1568026619666190620155613</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1568026619666190620155613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1568026619666190620155613%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Topics%2520in%2520Medicinal%2520Chemistry%26atitle%3DResearch%252BProgress%252Bof%252BAxl%252BInhibitors%26aulast%3DSun%26aufirst%3DZhi-Gang%26date%3D2019%26volume%3D19%26issue%3D15%26spage%3D1338%26epage%3D1349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Suk Hun  Lee</span>, <span class="hlFld-ContribAuthor ">Kunyoung  Kim</span>, <span class="hlFld-ContribAuthor ">Yeong Uk  Jeon</span>, <span class="hlFld-ContribAuthor ">Amit  Kundu</span>, <span class="hlFld-ContribAuthor ">Prasanta  Dey</span>, <span class="hlFld-ContribAuthor ">Jong Yeon  Hwang</span>, <span class="hlFld-ContribAuthor ">Neeraj Kumar  Mishra</span>, <span class="hlFld-ContribAuthor ">Hyung Sik  Kim</span>, <span class="hlFld-ContribAuthor ">In Su  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Lewis acid-mediated cross-coupling reaction of 7-azaindoles and aldehydes: Cytotoxic evaluation of C3-linked bis-7-azaindoles. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2019,</strong> <em>60 </em>
                                    (34)
                                     , 150974. <a href="https://doi.org/10.1016/j.tetlet.2019.150974" title="DOI URL">https://doi.org/10.1016/j.tetlet.2019.150974</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2019.150974&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2019.150974%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DLewis%252Bacid-mediated%252Bcross-coupling%252Breaction%252Bof%252B7-azaindoles%252Band%252Baldehydes%25253A%252BCytotoxic%252Bevaluation%252Bof%252BC3-linked%252Bbis-7-azaindoles%26aulast%3DLee%26aufirst%3DSuk%2BHun%26date%3D2019%26volume%3D60%26issue%3D34%26spage%3D150974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Neha  Sharma</span>, <span class="hlFld-ContribAuthor ">Anurag</span>. </span><span class="cited-content_cbyCitation_article-title">7-Azaindole Analogues as Bioactive Agents and Recent Results. </span><span class="cited-content_cbyCitation_journal-name">Mini-Reviews in Medicinal Chemistry</span><span> <strong>2019,</strong> <em>19 </em>
                                    (9)
                                     , 727-736. <a href="https://doi.org/10.2174/1389557518666180928154004" title="DOI URL">https://doi.org/10.2174/1389557518666180928154004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1389557518666180928154004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1389557518666180928154004%26sid%3Dliteratum%253Aachs%26jtitle%3DMini-Reviews%2520in%2520Medicinal%2520Chemistry%26atitle%3D7-Azaindole%252BAnalogues%252Bas%252BBioactive%252BAgents%252Band%252BRecent%252BResults%26aulast%3DSharma%26aufirst%3DNeha%26date%3D2019%26volume%3D19%26issue%3D9%26spage%3D727%26epage%3D736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">S.M. Zahid  Hosen</span>, <span class="hlFld-ContribAuthor ">Raju  Dash</span>, <span class="hlFld-ContribAuthor ">Md.  Junaid</span>, <span class="hlFld-ContribAuthor ">Sarmistha  Mitra</span>, <span class="hlFld-ContribAuthor ">Nurul  Absar</span>. </span><span class="cited-content_cbyCitation_article-title">Identification and structural characterization of deleterious non-synonymous single nucleotide polymorphisms in the human SKP2 gene. </span><span class="cited-content_cbyCitation_journal-name">Computational Biology and Chemistry</span><span> <strong>2019,</strong> <em>79 </em>, 127-136. <a href="https://doi.org/10.1016/j.compbiolchem.2019.02.003" title="DOI URL">https://doi.org/10.1016/j.compbiolchem.2019.02.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.compbiolchem.2019.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.compbiolchem.2019.02.003%26sid%3Dliteratum%253Aachs%26jtitle%3DComputational%2520Biology%2520and%2520Chemistry%26atitle%3DIdentification%252Band%252Bstructural%252Bcharacterization%252Bof%252Bdeleterious%252Bnon-synonymous%252Bsingle%252Bnucleotide%252Bpolymorphisms%252Bin%252Bthe%252Bhuman%252BSKP2%252Bgene%26aulast%3DHosen%26aufirst%3DS.M.%2BZahid%26date%3D2019%26volume%3D79%26spage%3D127%26epage%3D136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rina  Chun</span>, <span class="hlFld-ContribAuthor ">Saegun  Kim</span>, <span class="hlFld-ContribAuthor ">Sang Hoon  Han</span>, <span class="hlFld-ContribAuthor ">Ashok Kumar  Pandey</span>, <span class="hlFld-ContribAuthor ">Neeraj Kumar  Mishra</span>, <span class="hlFld-ContribAuthor ">In Su  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Site-selective C–H nitration of N-aryl-7-azaindoles under palladium(II) catalysis. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2018,</strong> <em>59 </em>
                                    (43)
                                     , 3848-3852. <a href="https://doi.org/10.1016/j.tetlet.2018.09.025" title="DOI URL">https://doi.org/10.1016/j.tetlet.2018.09.025</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2018.09.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2018.09.025%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DSite-selective%252BC%2525E2%252580%252593H%252Bnitration%252Bof%252BN-aryl-7-azaindoles%252Bunder%252Bpalladium%252528II%252529%252Bcatalysis%26aulast%3DChun%26aufirst%3DRina%26date%3D2018%26volume%3D59%26issue%3D43%26spage%3D3848%26epage%3D3852" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jing  Guo</span>, <span class="hlFld-ContribAuthor ">Fan  Zhao</span>, <span class="hlFld-ContribAuthor ">Wenbo  Yin</span>, <span class="hlFld-ContribAuthor ">Mingyue  Zhu</span>, <span class="hlFld-ContribAuthor ">Chenzhou  Hao</span>, <span class="hlFld-ContribAuthor ">Yu  Pang</span>, <span class="hlFld-ContribAuthor ">Tianxiao  Wu</span>, <span class="hlFld-ContribAuthor ">Jian  Wang</span>, <span class="hlFld-ContribAuthor ">Dongmei  Zhao</span>, <span class="hlFld-ContribAuthor ">Haitao  Li</span>, <span class="hlFld-ContribAuthor ">Maosheng  Cheng</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, structure-activity relationships study and X-ray crystallography of 3-substituted-indolin-2-one-5-carboxamide derivatives as PAK4 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>155 </em>, 197-209. <a href="https://doi.org/10.1016/j.ejmech.2018.05.051" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.05.051</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.05.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.05.051%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Bstructure-activity%252Brelationships%252Bstudy%252Band%252BX-ray%252Bcrystallography%252Bof%252B3-substituted-indolin-2-one-5-carboxamide%252Bderivatives%252Bas%252BPAK4%252Binhibitors%26aulast%3DGuo%26aufirst%3DJing%26date%3D2018%26volume%3D155%26spage%3D197%26epage%3D209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nulgumnalli Manjunathaiah  Raghavendra</span>, <span class="hlFld-ContribAuthor ">Divya  Pingili</span>, <span class="hlFld-ContribAuthor ">Sundeep  Kadasi</span>, <span class="hlFld-ContribAuthor ">Akhila  Mettu</span>, <span class="hlFld-ContribAuthor ">S.V.U.M.  Prasad</span>. </span><span class="cited-content_cbyCitation_article-title">Dual or multi-targeting inhibitors: The next generation anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>143 </em>, 1277-1300. <a href="https://doi.org/10.1016/j.ejmech.2017.10.021" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.10.021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.10.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.10.021%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDual%252Bor%252Bmulti-targeting%252Binhibitors%25253A%252BThe%252Bnext%252Bgeneration%252Banticancer%252Bagents%26aulast%3DRaghavendra%26aufirst%3DNulgumnalli%2BManjunathaiah%26date%3D2018%26volume%3D143%26spage%3D1277%26epage%3D1300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ying  Sun</span>, <span class="hlFld-ContribAuthor ">Yuanyuan  Shan</span>, <span class="hlFld-ContribAuthor ">Chuansheng  Li</span>, <span class="hlFld-ContribAuthor ">Ru  Si</span>, <span class="hlFld-ContribAuthor ">Xiaoyan  Pan</span>, <span class="hlFld-ContribAuthor ">Binghe  Wang</span>, <span class="hlFld-ContribAuthor ">Jie  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel anti-angiogenesis agents. Part 8: Diaryl thiourea bearing 1 H -indazole-3-amine as multi-target RTKs inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>141 </em>, 373-385. <a href="https://doi.org/10.1016/j.ejmech.2017.10.008" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.10.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.10.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.10.008%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252Banti-angiogenesis%252Bagents.%252BPart%252B8%25253A%252BDiaryl%252Bthiourea%252Bbearing%252B1%252BH%252B-indazole-3-amine%252Bas%252Bmulti-target%252BRTKs%252Binhibitors%26aulast%3DSun%26aufirst%3DYing%26date%3D2017%26volume%3D141%26spage%3D373%26epage%3D385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lin  Zhang</span>, <span class="hlFld-ContribAuthor ">Yuanyuan  Shan</span>, <span class="hlFld-ContribAuthor ">Xingyue  Ji</span>, <span class="hlFld-ContribAuthor ">Mengyuan  Zhu</span>, <span class="hlFld-ContribAuthor ">Chuansheng  Li</span>, <span class="hlFld-ContribAuthor ">Ying  Sun</span>, <span class="hlFld-ContribAuthor ">Ru  Si</span>, <span class="hlFld-ContribAuthor ">Xiaoyan  Pan</span>, <span class="hlFld-ContribAuthor ">Jinfeng  Wang</span>, <span class="hlFld-ContribAuthor ">Weina  Ma</span>, <span class="hlFld-ContribAuthor ">Bingling  Dai</span>, <span class="hlFld-ContribAuthor ">Binghe  Wang</span>, <span class="hlFld-ContribAuthor ">Jie  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and evaluation of triple inhibitors of VEGFR-2, TIE-2 and EphB4 as anti-angiogenic and anti-cancer agents. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2017,</strong> <em>8 </em>
                                    (62)
                                     , 104745-104760. <a href="https://doi.org/10.18632/oncotarget.20065" title="DOI URL">https://doi.org/10.18632/oncotarget.20065</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.20065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.20065%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DDiscovery%252Band%252Bevaluation%252Bof%252Btriple%252Binhibitors%252Bof%252BVEGFR-2%25252C%252BTIE-2%252Band%252BEphB4%252Bas%252Banti-angiogenic%252Band%252Banti-cancer%252Bagents%26aulast%3DZhang%26aufirst%3DLin%26date%3D2017%26date%3D2017%26volume%3D8%26issue%3D62%26spage%3D104745%26epage%3D104760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mijin  Jeon</span>, <span class="hlFld-ContribAuthor ">Jihye  Park</span>, <span class="hlFld-ContribAuthor ">Prasanta  Dey</span>, <span class="hlFld-ContribAuthor ">Yongguk  Oh</span>, <span class="hlFld-ContribAuthor ">Hyunjung  Oh</span>, <span class="hlFld-ContribAuthor ">Sangil  Han</span>, <span class="hlFld-ContribAuthor ">Sung Hee  Um</span>, <span class="hlFld-ContribAuthor ">Hyung Sik  Kim</span>, <span class="hlFld-ContribAuthor ">Neeraj Kumar  Mishra</span>, <span class="hlFld-ContribAuthor ">In Su  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Site-Selective Rhodium(III)-Catalyzed C−H Amination of 7-Azaindoles with Anthranils: Synthesis and Anticancer Evaluation. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2017,</strong> <em>359 </em>
                                    (20)
                                     , 3471-3478. <a href="https://doi.org/10.1002/adsc.201700800" title="DOI URL">https://doi.org/10.1002/adsc.201700800</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.201700800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.201700800%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DSite-Selective%252BRhodium%252528III%252529-Catalyzed%252BC%2525E2%252588%252592H%252BAmination%252Bof%252B7-Azaindoles%252Bwith%252BAnthranils%25253A%252BSynthesis%252Band%252BAnticancer%252BEvaluation%26aulast%3DJeon%26aufirst%3DMijin%26date%3D2017%26date%3D2017%26volume%3D359%26issue%3D20%26spage%3D3471%26epage%3D3478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Barbara  Morzyk-Ociepa</span>, <span class="hlFld-ContribAuthor ">Ksenia  Szmigiel</span>, <span class="hlFld-ContribAuthor ">Rafał  Petrus</span>, <span class="hlFld-ContribAuthor ">Ilona  Turowska-Tyrk</span>, <span class="hlFld-ContribAuthor ">Danuta Michalska</span>. </span><span class="cited-content_cbyCitation_article-title">A novel coordination polymer of 7-azaindole-3-carboxylic acid with sodium ions: crystal and molecular structures, vibrational spectra and DFT calculations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Structure</span><span> <strong>2017,</strong> <em>1144 </em>, 338-346. <a href="https://doi.org/10.1016/j.molstruc.2017.05.059" title="DOI URL">https://doi.org/10.1016/j.molstruc.2017.05.059</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molstruc.2017.05.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molstruc.2017.05.059%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Structure%26atitle%3DA%252Bnovel%252Bcoordination%252Bpolymer%252Bof%252B7-azaindole-3-carboxylic%252Bacid%252Bwith%252Bsodium%252Bions%25253A%252Bcrystal%252Band%252Bmolecular%252Bstructures%25252C%252Bvibrational%252Bspectra%252Band%252BDFT%252Bcalculations%26aulast%3DMorzyk-Ociepa%26aufirst%3DBarbara%26date%3D2017%26volume%3D1144%26spage%3D338%26epage%3D346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kai-Kai  Wang</span>, <span class="hlFld-ContribAuthor ">Wei  Du</span>, <span class="hlFld-ContribAuthor ">Jin  Zhu</span>, <span class="hlFld-ContribAuthor ">Ying-Chun  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Construction of polycyclic spirooxindoles through [3+2] annulations of Morita–Baylis–Hillman carbonates and 3-nitro-7-azaindoles. </span><span class="cited-content_cbyCitation_journal-name">Chinese Chemical Letters</span><span> <strong>2017,</strong> <em>28 </em>
                                    (3)
                                     , 512-516. <a href="https://doi.org/10.1016/j.cclet.2016.11.003" title="DOI URL">https://doi.org/10.1016/j.cclet.2016.11.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cclet.2016.11.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cclet.2016.11.003%26sid%3Dliteratum%253Aachs%26jtitle%3DChinese%2520Chemical%2520Letters%26atitle%3DConstruction%252Bof%252Bpolycyclic%252Bspirooxindoles%252Bthrough%252B%25255B3%25252B2%25255D%252Bannulations%252Bof%252BMorita%2525E2%252580%252593Baylis%2525E2%252580%252593Hillman%252Bcarbonates%252Band%252B3-nitro-7-azaindoles%26aulast%3DWang%26aufirst%3DKai-Kai%26date%3D2017%26volume%3D28%26issue%3D3%26spage%3D512%26epage%3D516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nikolay T.  Tzvetkov</span>, <span class="hlFld-ContribAuthor ">Beate  Neumann</span>, <span class="hlFld-ContribAuthor ">Hans-Georg  Stammler</span>, <span class="hlFld-ContribAuthor ">Liudmil  Antonov</span>. </span><span class="cited-content_cbyCitation_article-title">A simple approach to multifunctionalized N1-alkylated 7-amino-6-azaoxindole derivatives using their in situ stabilized tautomer form. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2016,</strong> <em>72 </em>
                                    (41)
                                     , 6455-6466. <a href="https://doi.org/10.1016/j.tet.2016.08.055" title="DOI URL">https://doi.org/10.1016/j.tet.2016.08.055</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2016.08.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2016.08.055%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DA%252Bsimple%252Bapproach%252Bto%252Bmultifunctionalized%252BN1-alkylated%252B7-amino-6-azaoxindole%252Bderivatives%252Busing%252Btheir%252Bin%252Bsitu%252Bstabilized%252Btautomer%252Bform%26aulast%3DTzvetkov%26aufirst%3DNikolay%2BT.%26date%3D2016%26volume%3D72%26issue%3D41%26spage%3D6455%26epage%3D6466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/medium/jm-2016-00087m_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/large/jm-2016-00087m_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00087&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/medium/jm-2016-00087m_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/large/jm-2016-00087m_0002.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Classical structural scheme of type-I kinase inhibitor docked into the DFG-in conformation. Example of Dasatinib cocrystallized within the SRC kinase (Protein Data Bank: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3G5D">3G5D</a>).<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> (A) Representation of the principal amino acids surrounding the ligand. (B) View of the active site surface. PBP: purine binding pocket, SP I: selectivity pocket I.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/large/jm-2016-00087m_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00087&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/medium/jm-2016-00087m_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/large/jm-2016-00087m_0003.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Classical structural scheme of a type-II kinase inhibitor docked into DFG-out conformation. Example of Imatinib cocrystallized within the SRC kinase (Protein Data Bank: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2OIQ">2OIQ</a>).<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> (A) Representation of the principal amino acids surrounding the ligand. (B) View of the active site surface. PBP: purine binding pocket, SP I: selectivity pocket I, SP II: selectivity pocket II, and SP III: selectivity pocket III.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/large/jm-2016-00087m_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00087&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/medium/jm-2016-00087m_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/large/jm-2016-00087m_0004.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Superposition of the predicted binding mode of <b>6x</b> (in cyan) and Imatinib (in green) within the active site of ABL (in gray). Potential hydrogen bonds are depicted in black dashed lines. Docking studies were carried out with ABL X-ray structure cocrystallized with Imatinib (Protein Data Bank: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1IEP">1IEP</a>).<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/large/jm-2016-00087m_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00087&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/medium/jm-2016-00087m_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/large/jm-2016-00087m_0006.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Route of Synthesis to Explore the Specificity Pocket in the Design of DFG-Out Type-II Inhibitors<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/large/jm-2016-00087m_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00087&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) AcOH/MeOH (1/10), rt, 2 h, then NaBH<sub>3</sub>CN, rt, 16 h-48 h, 82–86%; (b) H<sub>2</sub> (30 bar), Pd/C 10%, DMF or MeOH/HCl aq, rt, 16 h-48 h, 96–97%; (c) carboxylic acid, HATU, DIEA, rt, 12 h or acyl chloride, NEt<sub>3</sub>, DMF, rt, 16 h, 4–55%.</p></p></figure><figure data-id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/medium/jm-2016-00087m_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/large/jm-2016-00087m_0007.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis Pathway to Modify the Substituents on Position 2 of the 7-Azaindole Core<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/large/jm-2016-00087m_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00087&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) KOH or LiOH, MeOH/H<sub>2</sub>O (1/1), reflux, 42–76%; (b) MeNH<sub>2</sub>, HATU, DIEA, DMF, 59%; (c) H<sub>2</sub> (30 bar), Pd/C 10%, MeOH, overnight; (d) 2-methyl-5-nitrobenzaldehyde <b>2</b>, AcOH/MeOH (1/10), rt, 2 h; then, NaBH<sub>3</sub>CN, rt, 16 h. Overall yield for the three steps (c,d,c): 53%. (e) Carboxylic acid, HATU, DIEA, DMF, rt, 16 h, 3–7%.</p></p></figure><figure data-id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/medium/jm-2016-00087m_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/large/jm-2016-00087m_0008.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis Pathway to Modify the Linker in Position 5 of the 7-Azaindole Core<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/large/jm-2016-00087m_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00087&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <b>14a</b>: H<sub>2</sub> (10 bar), Raney Ni, Pyridine/H<sub>2</sub>O/AcOH (2/1/1), overnight, 67%.<b>14b</b>: (1) DIBAL-H, toluene, 0 °C, 1.5 h, 31%; (2) MnO<sub>2</sub>, THF, rt, overnight, 65%. (b) DIBAL-H, THF, 0 °C, 3 h, 45%; (c) 2-methyl-5-nitrophenol, PPh<sub>3</sub>, DEAD, CH<sub>2</sub>Cl<sub>2</sub>, rt, overnight, 40%; (d) Zn, AcOEt/AcOH (2/1), 50 °C, rt, 1 h 30; (e) 2-methyl-5-nitrobenzyl-triphenylphosphonium, LiOH, MeOH, rt or reflux, overnight, 69–71%; (f) Zn, AcOH/AcOEt (1/2), sonic bath, rt, 30 min, 56%; (g) H<sub>2</sub> (10 bar), Pd/C 10%, DMF, rt, 24 h, 26%–38%; (h) HATU, DIEA, DMF, rt, w-end, 93%; (i) H<sub>2</sub> (35 bar), Pd/C 10%, MeOH, rt, overnight, 81%; (j) <b>5x</b> or <b>5y</b>, DIEA, HATU, DMF, rt, overnight, 5–55%; (k) <b>5x</b>, DIEA, EDCI, rt, overnight, 45%; (l) Zn, AcOEt/AcOH (2/1), rt, 1 h 20, quant. yield; (m) (1) <b>14a</b>, AcOH/MeOH (10/1), rt, 2 h; (2) NaBH<sub>3</sub>CN, rt, overnight, 17%.</p></p></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/medium/jm-2016-00087m_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/large/jm-2016-00087m_0005.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. In vitro evaluation of cytotoxic effect of <b>6z</b> on activated (PHA/IL-2) or resting human PBMC from two healthy donors (error bars represent SD).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00087/20160422/images/large/jm-2016-00087m_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00087&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i103">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88244" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88244" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 23 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Targeting Cancer with Small Molecule Kinase Inhibitors</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">28</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span><span class="refDoi"> DOI: 10.1038/nrc2559</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=10.1038%2Fnrc2559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=19104514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1yg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=28-39&issue=1&author=J.+Zhangauthor=P.+L.+Yangauthor=N.+S.+Gray&title=Targeting+Cancer+with+Small+Molecule+Kinase+Inhibitors&doi=10.1038%2Fnrc2559"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer with small molecule kinase inhibitors</span></div><div class="casAuthors">Zhang, Jianming; Yang, Priscilla L.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-39</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Deregulation of kinase activity has emerged as a major mechanism by which cancer cells evade normal physiol. constraints on growth and survival.  To date, 11 kinase inhibitors have received US Food and Drug Administration approval as cancer treatments, and there are considerable efforts to develop selective small mol. inhibitors for a host of other kinases that are implicated in cancer and other diseases.  Herein we discuss the current challenges in the field, such as designing selective inhibitors and developing strategies to overcome resistance mutations.  This Review provides a broad overview of some of the approaches currently used to discover and characterize new kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriSM3BN_uEz7Vg90H21EOLACvtfcHk0lgJslmvsAnhKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1yg&md5=35bc38f414cd21eef5e61ce181b580fb</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc2559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2559%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DP.%2BL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DTargeting%2520Cancer%2520with%2520Small%2520Molecule%2520Kinase%2520Inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26issue%3D1%26spage%3D28%26epage%3D39%26doi%3D10.1038%2Fnrc2559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundström, M.</span><span> </span><span class="NLM_article-title">Recently Targeted Kinases and Their Inhibitors — the Path to Clinical Trials</span> <span class="citation_source-journal">Curr. Opin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">58</span><span class="NLM_x">–</span> <span class="NLM_lpage">63</span><span class="refDoi"> DOI: 10.1016/j.coph.2014.07.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=10.1016%2Fj.coph.2014.07.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=25113945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Ojtb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2014&pages=58-63&author=S.+Knappauthor=M.+Sundstr%C3%B6m&title=Recently+Targeted+Kinases+and+Their+Inhibitors+%E2%80%94+the+Path+to+Clinical+Trials&doi=10.1016%2Fj.coph.2014.07.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Recently targeted kinases and their inhibitors - the path to clinical trials</span></div><div class="casAuthors">Knapp, Stefan; Sundstrom, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">58-63</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein kinases have emerged as one of the most important drug target families for the treatment of cancer.  To date, 28 inhibitors with reported activity vs. one or multiple kinases have been approved for clin. use.  However, the majority of new clin. trials are focused on new subindications using already approved kinase inhibitors or target well validated kinase targets with novel inhibitors.  In contrast, relatively few clin. trials have been initiated using specific inhibitors that inhibit novel kinase targets, despite significant validation efforts in the public domain.  Anal. of the target validation history of first in class kinase inhibitors revealed a long delay between initial disease assocn. and development of inhibitors.  As part of this anal., we have investigated which first in class inhibitor that entered phase I clin. trials over the last five years and also considered which research approaches that were used to validate them.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMyUJTPj_d77Vg90H21EOLACvtfcHk0lgJslmvsAnhKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Ojtb7M&md5=805f1abf5dd5ef75f130e3257cdab39a</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2014.07.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2014.07.015%26sid%3Dliteratum%253Aachs%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DSundstr%25C3%25B6m%26aufirst%3DM.%26atitle%3DRecently%2520Targeted%2520Kinases%2520and%2520Their%2520Inhibitors%2520%25E2%2580%2594%2520the%2520Path%2520to%2520Clinical%2520Trials%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2014%26volume%3D17%26spage%3D58%26epage%3D63%26doi%3D10.1016%2Fj.coph.2014.07.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Gerlinger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowan, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horswell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larkin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endesfelder, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gronroos, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarpey, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varela, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillimore, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Begum, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, N. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raine, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Latimer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santos, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nohadani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eklund, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer-Dene, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickering, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stamp, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szallasi, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downward, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Futreal, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swanton, C.</span><span> </span><span class="NLM_article-title">Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">366</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">883</span><span class="NLM_x">–</span> <span class="NLM_lpage">892</span><span class="refDoi"> DOI: 10.1056/NEJMoa1113205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=10.1056%2FNEJMoa1113205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=22397650" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=1%3ACAS%3A528%3ADC%252BC38XktFOgtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=883-892&issue=10&author=M.+Gerlingerauthor=A.+J.+Rowanauthor=S.+Horswellauthor=J.+Larkinauthor=D.+Endesfelderauthor=E.+Gronroosauthor=P.+Martinezauthor=N.+Matthewsauthor=A.+Stewartauthor=P.+Tarpeyauthor=I.+Varelaauthor=B.+Phillimoreauthor=S.+Begumauthor=N.+Q.+McDonaldauthor=A.+Butlerauthor=D.+Jonesauthor=K.+Raineauthor=C.+Latimerauthor=C.+R.+Santosauthor=M.+Nohadaniauthor=A.+C.+Eklundauthor=B.+Spencer-Deneauthor=G.+Clarkauthor=L.+Pickeringauthor=G.+Stampauthor=M.+Goreauthor=Z.+Szallasiauthor=J.+Downwardauthor=P.+A.+Futrealauthor=C.+Swanton&title=Intratumor+Heterogeneity+and+Branched+Evolution+Revealed+by+Multiregion+Sequencing&doi=10.1056%2FNEJMoa1113205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Intratumor heterogeneity and branched evolution revealed by multiregion sequencing</span></div><div class="casAuthors">Gerlinger, Marco; Rowan, Andrew J.; Horswell, Stuart; Larkin, James; Endesfelder, David; Gronroos, Eva; Martinez, Pierre; Matthews, Nicholas; Stewart, Aengus; Tarpey, Patrick; Varela, Ignacio; Phillimore, Benjamin; Begum, Sharmin; McDonald, Neil Q.; Butler, Adam; Jones, David; Raine, Keiran; Latimer, Calli; Santos, Claudio R.; Nohadani, Mahrokh; Eklund, Aron C.; Spencer-Dene, Bradley; Clark, Graham; Pickering, Lisa; Stamp, Gordon; Gore, Martin; Szallasi, Zoltan; Donward, Julian; Futreal, P. Andrew; Swanton, Charles</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">883-892</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Intratumor heterogeneity may foster tumor evolution and adaptation and hinder personalized-medicine strategies that depend on results from single tumor-biopsy samples.  Methods: To examine intratumor heterogeneity, we performed exome sequencing, chromosome aberration anal., and ploidy profiling on multiple spatially sepd. samples obtained from primary renal carcinomas and assocd. metastatic sites.  We characterized the consequences of intratumor heterogeneity using immunohistochem. anal., mutation functional anal., and profiling of mRNA expression.  Results: Phylogenetic reconstruction revealed branched evolutionary tumor growth, with 63 to 69% of all somatic mutations not detectable across every tumor region.  Intratumor heterogeneity was obsd. for a mutation within an autoinhibitory domain of the mammalian target of rapamycin (mTOR) kinase, correlating with S6 and 4EBP phosphorylation in vivo and constitutive activation of mTOR kinase activity in vitro.  Mutational intratumor heterogeneity was seen for multiple tumor-suppressor genes converging on loss of function; SETD2, PTEN, and KDM5C underwent multiple distinct and spatially sepd. inactivating mutations within a single tumor, suggesting convergent phenotypic evolution.  Gene-expression signatures of good and poor prognosis were detected in different regions of the same tumor.  Allelic compn. and ploidy profiling anal. revealed extensive intratumor heterogeneity, with 26 of 30 tumor samples from four tumors harboring divergent allelic-imbalance profiles and with ploidy heterogeneity in two of four tumors.  Conclusions: Intratumor heterogeneity can lead to underestimation of the tumor genomics landscape portrayed from single tumor-biopsy samples and may present major challenges to personalized-medicine and biomarker development.  Intratumor heterogeneity, assocd. with heterogeneous protein function, may foster tumor adaptation and therapeutic failure through Darwinian selection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5FKqZ_4ThTLVg90H21EOLACvtfcHk0lgJslmvsAnhKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktFOgtbw%253D&md5=2ab2e658d1218935e12cc934b09e1b95</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1113205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1113205%26sid%3Dliteratum%253Aachs%26aulast%3DGerlinger%26aufirst%3DM.%26aulast%3DRowan%26aufirst%3DA.%2BJ.%26aulast%3DHorswell%26aufirst%3DS.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DEndesfelder%26aufirst%3DD.%26aulast%3DGronroos%26aufirst%3DE.%26aulast%3DMartinez%26aufirst%3DP.%26aulast%3DMatthews%26aufirst%3DN.%26aulast%3DStewart%26aufirst%3DA.%26aulast%3DTarpey%26aufirst%3DP.%26aulast%3DVarela%26aufirst%3DI.%26aulast%3DPhillimore%26aufirst%3DB.%26aulast%3DBegum%26aufirst%3DS.%26aulast%3DMcDonald%26aufirst%3DN.%2BQ.%26aulast%3DButler%26aufirst%3DA.%26aulast%3DJones%26aufirst%3DD.%26aulast%3DRaine%26aufirst%3DK.%26aulast%3DLatimer%26aufirst%3DC.%26aulast%3DSantos%26aufirst%3DC.%2BR.%26aulast%3DNohadani%26aufirst%3DM.%26aulast%3DEklund%26aufirst%3DA.%2BC.%26aulast%3DSpencer-Dene%26aufirst%3DB.%26aulast%3DClark%26aufirst%3DG.%26aulast%3DPickering%26aufirst%3DL.%26aulast%3DStamp%26aufirst%3DG.%26aulast%3DGore%26aufirst%3DM.%26aulast%3DSzallasi%26aufirst%3DZ.%26aulast%3DDownward%26aufirst%3DJ.%26aulast%3DFutreal%26aufirst%3DP.%2BA.%26aulast%3DSwanton%26aufirst%3DC.%26atitle%3DIntratumor%2520Heterogeneity%2520and%2520Branched%2520Evolution%2520Revealed%2520by%2520Multiregion%2520Sequencing%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26issue%3D10%26spage%3D883%26epage%3D892%26doi%3D10.1056%2FNEJMoa1113205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Klein, C. A.</span><span> </span><span class="NLM_article-title">Selection and Adaptation during Metastatic Cancer Progression</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">501</span><span class="NLM_x"> (</span><span class="NLM_issue">7467</span><span class="NLM_x">) </span> <span class="NLM_fpage">365</span><span class="NLM_x">–</span> <span class="NLM_lpage">372</span><span class="refDoi"> DOI: 10.1038/nature12628</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=10.1038%2Fnature12628" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=501&publication_year=2013&pages=365-372&issue=7467&author=C.+A.+Klein&title=Selection+and+Adaptation+during+Metastatic+Cancer+Progression&doi=10.1038%2Fnature12628"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnature12628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature12628%26sid%3Dliteratum%253Aachs%26aulast%3DKlein%26aufirst%3DC.%2BA.%26atitle%3DSelection%2520and%2520Adaptation%2520during%2520Metastatic%2520Cancer%2520Progression%26jtitle%3DNature%26date%3D2013%26volume%3D501%26issue%3D7467%26spage%3D365%26epage%3D372%26doi%3D10.1038%2Fnature12628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Gossage, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisen, T.</span><span> </span><span class="NLM_article-title">Targeting Multiple Kinase Pathways: A Change in Paradigm</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">1973</span><span class="NLM_x">–</span> <span class="NLM_lpage">1978</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-09-3182</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=10.1158%2F1078-0432.CCR-09-3182" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=20215532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktFygu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=1973-1978&issue=7&author=L.+Gossageauthor=T.+Eisen&title=Targeting+Multiple+Kinase+Pathways%3A+A+Change+in+Paradigm&doi=10.1158%2F1078-0432.CCR-09-3182"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Multiple Kinase Pathways: A Change In Paradigm</span></div><div class="casAuthors">Gossage, Lucy; Eisen, Tim</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1973-1978</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Anticancer drugs that target protein kinases include small mol. inhibitors and monoclonal antibodies.  Feedback loops and cross talk between signaling pathways impact significantly on the efficacy of cancer therapeutics, and resistance to targeted agents is a major barrier to effective treatments.  Increasingly, therapies are being designed to target multiple kinase pathways.  This can be achieved using a single agent that inhibits multiple signaling pathways or a combination of highly selective agents.  In this review we discuss the principles of specifically targeting multiple kinase pathways with particular ref. to angiogenic signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwTqIFjKKuX7Vg90H21EOLACvtfcHk0lhIHkfTc-7L5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktFygu7w%253D&md5=fc074fb853129324db0b36ec148f2401</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-3182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-3182%26sid%3Dliteratum%253Aachs%26aulast%3DGossage%26aufirst%3DL.%26aulast%3DEisen%26aufirst%3DT.%26atitle%3DTargeting%2520Multiple%2520Kinase%2520Pathways%253A%2520A%2520Change%2520in%2520Paradigm%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26issue%3D7%26spage%3D1973%26epage%3D1978%26doi%3D10.1158%2F1078-0432.CCR-09-3182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Dar, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cagan, R. L.</span><span> </span><span class="NLM_article-title">Chemical Genetic Discovery of Targets and Anti-Targets for Cancer Polypharmacology</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">486</span><span class="NLM_x"> (</span><span class="NLM_issue">7401</span><span class="NLM_x">) </span> <span class="NLM_fpage">80</span><span class="NLM_x">–</span> <span class="NLM_lpage">84</span><span class="refDoi"> DOI: 10.1038/nature11127</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=10.1038%2Fnature11127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=22678283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=1%3ACAS%3A528%3ADC%252BC38Xot1Cnu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=486&publication_year=2012&pages=80-84&issue=7401&author=A.+C.+Darauthor=T.+K.+Dasauthor=K.+M.+Shokatauthor=R.+L.+Cagan&title=Chemical+Genetic+Discovery+of+Targets+and+Anti-Targets+for+Cancer+Polypharmacology&doi=10.1038%2Fnature11127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical genetic discovery of targets and anti-targets for cancer polypharmacology</span></div><div class="casAuthors">Dar, Arvin C.; Das, Tirtha K.; Shokat, Kevan M.; Cagan, Ross L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">486</span>
        (<span class="NLM_cas:issue">7401</span>),
    <span class="NLM_cas:pages">80-84</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The complexity of cancer has led to recent interest in polypharmacol. approaches for developing kinase-inhibitor drugs; however, optimal kinase-inhibition profiles remain difficult to predict.  Using a Ret-kinase-driven Drosophila model of multiple endocrine neoplasia type 2 and kinome-wide drug profiling, here the authors identify that AD57 rescues oncogenic Ret-induced lethality, whereas related Ret inhibitors imparted reduced efficacy and enhanced toxicity.  Drosophila genetics and compd. profiling defined three pathways accounting for the mechanistic basis of efficacy and dose-limiting toxicity.  Inhibition of Ret plus Raf, Src and S6K was required for optimal animal survival, whereas inhibition of the anti-target' Tor led to toxicity owing to release of neg. feedback.  Rational synthetic tailoring to eliminate Tor binding afforded AD80 and AD81, compds. featuring balanced pathway inhibition, improved efficacy and low toxicity in Drosophila and mammalian multiple endocrine neoplasia type 2 models.  Combining kinase-focused chem., kinome-wide profiling and Drosophila genetics provides a powerful systems pharmacol. approach towards developing compds. with a maximal therapeutic index.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3OjBELXO9TbVg90H21EOLACvtfcHk0lhIHkfTc-7L5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xot1Cnu7w%253D&md5=4ed2f85f51453c1b38ee390a0a5f14db</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnature11127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11127%26sid%3Dliteratum%253Aachs%26aulast%3DDar%26aufirst%3DA.%2BC.%26aulast%3DDas%26aufirst%3DT.%2BK.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DCagan%26aufirst%3DR.%2BL.%26atitle%3DChemical%2520Genetic%2520Discovery%2520of%2520Targets%2520and%2520Anti-Targets%2520for%2520Cancer%2520Polypharmacology%26jtitle%3DNature%26date%3D2012%26volume%3D486%26issue%3D7401%26spage%3D80%26epage%3D84%26doi%3D10.1038%2Fnature11127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Knight, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">Targeting the Cancer Kinome through Polypharmacology</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">130</span><span class="NLM_x">–</span> <span class="NLM_lpage">137</span><span class="refDoi"> DOI: 10.1038/nrc2787</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=10.1038%2Fnrc2787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=20094047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=1%3ACAS%3A528%3ADC%252BC3cXps1Clug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=130-137&issue=2&author=Z.+A.+Knightauthor=H.+Linauthor=K.+M.+Shokat&title=Targeting+the+Cancer+Kinome+through+Polypharmacology&doi=10.1038%2Fnrc2787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the cancer kinome through polypharmacology</span></div><div class="casAuthors">Knight, Zachary A.; Lin, Henry; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">130-137</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Kinase inhibitors are the largest class of new cancer drugs.  However, it is already apparent that most tumors can escape from the inhibition of any single kinase.  If it is necessary to inhibit multiple kinases, how do we choose which ones.  In this Opinion article, we discuss some of the strategies that are currently being used to identify new therapeutic combinations of kinase targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkDv2FeeH58rVg90H21EOLACvtfcHk0lhE1ZpSKu0N_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXps1Clug%253D%253D&md5=9aaa314e54b43889e147a9f11ac77072</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrc2787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2787%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DTargeting%2520the%2520Cancer%2520Kinome%2520through%2520Polypharmacology%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26issue%3D2%26spage%3D130%26epage%3D137%26doi%3D10.1038%2Fnrc2787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Chevé, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bories, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fauvel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picot, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tible, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daydé-Cazals, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loget, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasri, A.</span><span> </span><span class="NLM_article-title">De Novo Design, Synthesis and Pharmacological Evaluation of New Azaindole Derivatives as Dual Inhibitors of Abl and Src Kinases</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">788</span><span class="NLM_x">–</span> <span class="NLM_lpage">800</span><span class="refDoi"> DOI: 10.1039/c2md20104f</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=10.1039%2Fc2md20104f" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=788-800&issue=7&author=G.+Chev%C3%A9author=C.+Boriesauthor=B.+Fauvelauthor=F.+Picotauthor=A.+Tibleauthor=B.+Dayd%C3%A9-Cazalsauthor=O.+Logetauthor=A.+Yasri&title=De+Novo+Design%2C+Synthesis+and+Pharmacological+Evaluation+of+New+Azaindole+Derivatives+as+Dual+Inhibitors+of+Abl+and+Src+Kinases&doi=10.1039%2Fc2md20104f"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1039%2Fc2md20104f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2md20104f%26sid%3Dliteratum%253Aachs%26aulast%3DChev%25C3%25A9%26aufirst%3DG.%26aulast%3DBories%26aufirst%3DC.%26aulast%3DFauvel%26aufirst%3DB.%26aulast%3DPicot%26aufirst%3DF.%26aulast%3DTible%26aufirst%3DA.%26aulast%3DDayd%25C3%25A9-Cazals%26aufirst%3DB.%26aulast%3DLoget%26aufirst%3DO.%26aulast%3DYasri%26aufirst%3DA.%26atitle%3DDe%2520Novo%2520Design%252C%2520Synthesis%2520and%2520Pharmacological%2520Evaluation%2520of%2520New%2520Azaindole%2520Derivatives%2520as%2520Dual%2520Inhibitors%2520of%2520Abl%2520and%2520Src%2520Kinases%26jtitle%3DMedChemComm%26date%3D2012%26volume%3D3%26issue%3D7%26spage%3D788%26epage%3D800%26doi%3D10.1039%2Fc2md20104f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Fauvel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coisy-Quivy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vivier, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chevé, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boriès, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daydé-Cazals, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feneyrolles, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bestgen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delon, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dufies, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auberger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loget, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasri, A.</span><span> </span><span class="NLM_article-title">Anti-Tumor Activity of Novel Compounds Targeting BCR-ABL, c-SRC and BCR-ABLT315I in Chronic Myelogenous Leukemia</span> <span class="citation_source-journal">Am. J. Cancer Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">28</span><span class="NLM_x">–</span> <span class="NLM_lpage">36</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=28-36&issue=1&author=B.+Fauvelauthor=M.+Coisy-Quivyauthor=S.+Vivierauthor=G.+Chev%C3%A9author=C.+Bori%C3%A8sauthor=B.+Dayd%C3%A9-Cazalsauthor=C.+Feneyrollesauthor=B.+Bestgenauthor=L.+Delonauthor=M.+Dufiesauthor=P.+Aubergerauthor=O.+Logetauthor=A.+Yasri&title=Anti-Tumor+Activity+of+Novel+Compounds+Targeting+BCR-ABL%2C+c-SRC+and+BCR-ABLT315I+in+Chronic+Myelogenous+Leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFauvel%26aufirst%3DB.%26aulast%3DCoisy-Quivy%26aufirst%3DM.%26aulast%3DVivier%26aufirst%3DS.%26aulast%3DChev%25C3%25A9%26aufirst%3DG.%26aulast%3DBori%25C3%25A8s%26aufirst%3DC.%26aulast%3DDayd%25C3%25A9-Cazals%26aufirst%3DB.%26aulast%3DFeneyrolles%26aufirst%3DC.%26aulast%3DBestgen%26aufirst%3DB.%26aulast%3DDelon%26aufirst%3DL.%26aulast%3DDufies%26aufirst%3DM.%26aulast%3DAuberger%26aufirst%3DP.%26aulast%3DLoget%26aufirst%3DO.%26aulast%3DYasri%26aufirst%3DA.%26atitle%3DAnti-Tumor%2520Activity%2520of%2520Novel%2520Compounds%2520Targeting%2520BCR-ABL%252C%2520c-SRC%2520and%2520BCR-ABLT315I%2520in%2520Chronic%2520Myelogenous%2520Leukemia%26jtitle%3DAm.%2520J.%2520Cancer%2520Sci.%26date%3D2013%26volume%3D2%26issue%3D1%26spage%3D28%26epage%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grütter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klüter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rode, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robubi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Hybrid Compound Design to Overcome the Gatekeeper T338M Mutation in cSrc</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x"> (</span><span class="NLM_issue">13</span><span class="NLM_x">) </span> <span class="NLM_fpage">3915</span><span class="NLM_x">–</span> <span class="NLM_lpage">3926</span><span class="refDoi"> DOI: 10.1021/jm9002928</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9002928" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtlWgtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=3915-3926&issue=13&author=M.+Getlikauthor=C.+Gr%C3%BCtterauthor=J.+R.+Simardauthor=S.+Kl%C3%BCterauthor=M.+Rabillerauthor=H.+B.+Rodeauthor=A.+Robubiauthor=D.+Rauh&title=Hybrid+Compound+Design+to+Overcome+the+Gatekeeper+T338M+Mutation+in+cSrc&doi=10.1021%2Fjm9002928"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Hybrid Compound Design To Overcome the Gatekeeper T338M Mutation in cSrc</span></div><div class="casAuthors">Getlik, Matthaeus; Gruetter, Christian; Simard, Jeffrey R.; Kluter, Sabine; Rabiller, Matthias; Rode, Haridas B.; Robubi, Armin; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3915-3926</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The emergence of drug resistance remains a fundamental challenge in the development of kinase inhibitors that are effective over long-term treatments.  Allosteric inhibitors that bind to sites lying outside the highly conserved ATP pocket are thought to be more selective than ATP-competitive inhibitors and may circumvent some mechanisms of drug resistance.  Crystal structures of type I and allosteric type III inhibitors in complex with the tyrosine kinase cSrc allowed to develop these scaffolds into potent type II kinase inhibitors.  One of these compds., I (RL46), disrupts FAK-mediated focal adhesions in cancer cells via direct inhibition of cSrc.  Details gleaned from crystal structures revealed a key feature of a subset of these compds., a surprising flexibility in the vicinity of the gatekeeper residue that allows these compds. to overcome a dasatinib-resistant gatekeeper mutation emerging in cSrc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-72ZDo25pC7Vg90H21EOLACvtfcHk0lhE1ZpSKu0N_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtlWgtbY%253D&md5=3ff187e49298ec4690c76a2bc2100274</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm9002928&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9002928%26sid%3Dliteratum%253Aachs%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DGr%25C3%25BCtter%26aufirst%3DC.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DKl%25C3%25BCter%26aufirst%3DS.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DRode%26aufirst%3DH.%2BB.%26aulast%3DRobubi%26aufirst%3DA.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DHybrid%2520Compound%2520Design%2520to%2520Overcome%2520the%2520Gatekeeper%2520T338M%2520Mutation%2520in%2520cSrc%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26issue%3D13%26spage%3D3915%26epage%3D3926%26doi%3D10.1021%2Fjm9002928" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Seeliger, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frank, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henderson, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">C-Src Binds to the Cancer Drug Imatinib with an Inactive Abl/c-Kit Conformation and a Distributed Thermodynamic Penalty</span> <span class="citation_source-journal">Structure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">299</span><span class="NLM_x">–</span> <span class="NLM_lpage">311</span><span class="refDoi"> DOI: 10.1016/j.str.2007.01.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=10.1016%2Fj.str.2007.01.015" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=299-311&issue=3&author=M.+A.+Seeligerauthor=B.+Nagarauthor=F.+Frankauthor=X.+Caoauthor=M.+N.+Hendersonauthor=J.+Kuriyan&title=C-Src+Binds+to+the+Cancer+Drug+Imatinib+with+an+Inactive+Abl%2Fc-Kit+Conformation+and+a+Distributed+Thermodynamic+Penalty&doi=10.1016%2Fj.str.2007.01.015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2007.01.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2007.01.015%26sid%3Dliteratum%253Aachs%26aulast%3DSeeliger%26aufirst%3DM.%2BA.%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DFrank%26aufirst%3DF.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DHenderson%26aufirst%3DM.%2BN.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DC-Src%2520Binds%2520to%2520the%2520Cancer%2520Drug%2520Imatinib%2520with%2520an%2520Inactive%2520Abl%252Fc-Kit%2520Conformation%2520and%2520a%2520Distributed%2520Thermodynamic%2520Penalty%26jtitle%3DStructure%26date%3D2007%26volume%3D15%26issue%3D3%26spage%3D299%26epage%3D311%26doi%3D10.1016%2Fj.str.2007.01.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornmann, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicena, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veach, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Crystal Structures of the Kinase Domain of c-Abl in Complex with the Small Molecule Inhibitors PD173955 and Imatinib (STI-571)</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x"> (</span><span class="NLM_issue">15</span><span class="NLM_x">) </span> <span class="NLM_fpage">4236</span><span class="NLM_x">–</span> <span class="NLM_lpage">4243</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=12154025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=4236-4243&issue=15&author=B.+Nagarauthor=W.+G.+Bornmannauthor=P.+Pellicenaauthor=T.+Schindlerauthor=D.+R.+Veachauthor=W.+T.+Millerauthor=B.+Clarksonauthor=J.+Kuriyan&title=Crystal+Structures+of+the+Kinase+Domain+of+c-Abl+in+Complex+with+the+Small+Molecule+Inhibitors+PD173955+and+Imatinib+%28STI-571%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</span></div><div class="casAuthors">Nagar, Bhushan; Bornmann, William G.; Pellicena, Patricia; Schindler, Thomas; Veach, Darren R.; Miller, W. Todd; Clarkson, Bayard; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4236-4243</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The inadvertent fusion of the bcr gene with the abl gene results in a constitutively active tyrosine kinase (Bcr-Abl) that transforms cells and causes chronic myelogenous leukemia.  Small mol. inhibitors of Bcr-Abl that bind to the kinase domain can be used to treat chronic myelogenous leukemia.  We report crystal structures of the kinase domain of Abl in complex with two such inhibitors, imatinib (also known as STI-571 and Gleevec) and PD173955 (Parke-Davis).  Both compds. bind to the canonical ATP-binding site of the kinase domain, but they do so in different ways.  As shown previously in a crystal structure of Abl bound to a smaller variant of STI-571, STI-571 captures a specific inactive conformation of the activation loop of Abl in which the loop mimics bound peptide substrate.  In contrast, PD173955 binds to a conformation of Abl in which the activation loop resembles that of an active kinase.  The structure suggests that PD173955 would be insensitive to whether the conformation of the activation loop corresponds to active kinases or to that seen in the STI-571 complex.  In vitro kinase assays confirm that this is the case and indicate that PD173955 is at least 10-fold more inhibitory than STI-571.  The structures suggest that PD173955 achieves its greater potency over STI-571 by being able to target multiple forms of Abl (active or inactive), whereas STI-571 requires a specific inactive conformation of Abl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-5qYZHMOZCrVg90H21EOLACvtfcHk0ljyr2yPRoq__w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D&md5=843213cd6038ed82a0e43dce56e81a91</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DBornmann%26aufirst%3DW.%2BG.%26aulast%3DPellicena%26aufirst%3DP.%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DVeach%26aufirst%3DD.%2BR.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DCrystal%2520Structures%2520of%2520the%2520Kinase%2520Domain%2520of%2520c-Abl%2520in%2520Complex%2520with%2520the%2520Small%2520Molecule%2520Inhibitors%2520PD173955%2520and%2520Imatinib%2520%2528STI-571%2529%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26issue%3D15%26spage%3D4236%26epage%3D4243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Choi, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adrian, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuntland, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sim, T.</span><span> </span><span class="NLM_article-title">A Type-II Kinase Inhibitor Capable of Inhibiting the T315I “Gatekeeper” Mutant of Bcr-Abl</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x"> (</span><span class="NLM_issue">15</span><span class="NLM_x">) </span> <span class="NLM_fpage">5439</span><span class="NLM_x">–</span> <span class="NLM_lpage">5448</span><span class="refDoi"> DOI: 10.1021/jm901808w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901808w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5439-5448&issue=15&author=H.+G.+Choiauthor=P.+Renauthor=F.+Adrianauthor=F.+Sunauthor=H.+S.+Leeauthor=X.+Wangauthor=Q.+Dingauthor=G.+Zhangauthor=Y.+Xieauthor=J.+Zhangauthor=Y.+Liuauthor=T.+Tuntlandauthor=M.+Warmuthauthor=P.+W.+Manleyauthor=J.+Mestanauthor=N.+S.+Grayauthor=T.+Sim&title=A+Type-II+Kinase+Inhibitor+Capable+of+Inhibiting+the+T315I+%E2%80%9CGatekeeper%E2%80%9D+Mutant+of+Bcr-Abl&doi=10.1021%2Fjm901808w"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm901808w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901808w%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DRen%26aufirst%3DP.%26aulast%3DAdrian%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DLee%26aufirst%3DH.%2BS.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DSim%26aufirst%3DT.%26atitle%3DA%2520Type-II%2520Kinase%2520Inhibitor%2520Capable%2520of%2520Inhibiting%2520the%2520T315I%2520%25E2%2580%259CGatekeeper%25E2%2580%259D%2520Mutant%2520of%2520Bcr-Abl%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D15%26spage%3D5439%26epage%3D5448%26doi%3D10.1021%2Fjm901808w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Koroleva, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadutskii, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farina, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ignatovich, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ermolinskaya, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gusak, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalinichenko, E. N.</span><span> </span><span class="NLM_article-title">A Practical Synthesis of 4-[(4-Methylpiperazin-1-Yl)methyl]benzoic Acid—the Key Precursor toward Imatinib</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x"> (</span><span class="NLM_issue">38</span><span class="NLM_x">) </span> <span class="NLM_fpage">5056</span><span class="NLM_x">–</span> <span class="NLM_lpage">5058</span><span class="refDoi"> DOI: 10.1016/j.tetlet.2012.06.107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=10.1016%2Fj.tetlet.2012.06.107" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2012&pages=5056-5058&issue=38&author=E.+V.+Korolevaauthor=A.+P.+Kadutskiiauthor=A.+V.+Farinaauthor=J.+V.+Ignatovichauthor=A.+L.+Ermolinskayaauthor=K.+N.+Gusakauthor=E.+N.+Kalinichenko&title=A+Practical+Synthesis+of+4-%5B%284-Methylpiperazin-1-Yl%29methyl%5Dbenzoic+Acid%E2%80%94the+Key+Precursor+toward+Imatinib&doi=10.1016%2Fj.tetlet.2012.06.107"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2012.06.107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2012.06.107%26sid%3Dliteratum%253Aachs%26aulast%3DKoroleva%26aufirst%3DE.%2BV.%26aulast%3DKadutskii%26aufirst%3DA.%2BP.%26aulast%3DFarina%26aufirst%3DA.%2BV.%26aulast%3DIgnatovich%26aufirst%3DJ.%2BV.%26aulast%3DErmolinskaya%26aufirst%3DA.%2BL.%26aulast%3DGusak%26aufirst%3DK.%2BN.%26aulast%3DKalinichenko%26aufirst%3DE.%2BN.%26atitle%3DA%2520Practical%2520Synthesis%2520of%25204-%255B%25284-Methylpiperazin-1-Yl%2529methyl%255Dbenzoic%2520Acid%25E2%2580%2594the%2520Key%2520Precursor%2520toward%2520Imatinib%26jtitle%3DTetrahedron%2520Lett.%26date%3D2012%26volume%3D53%26issue%3D38%26spage%3D5056%26epage%3D5058%26doi%3D10.1016%2Fj.tetlet.2012.06.107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Chevé, G.; Daydé-Cazals, B.; Fauvel, B.; Boriès, C.; Yasri, A.</span><span> </span><span class="NLM_article-title">New Azaindole Derivatives As Inhibitors of Protein Kinases</span>. WO2014102378 A1, July 3,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=G.+Chev%C3%A9&author=B.+Dayd%C3%A9-Cazals&author=B.+Fauvel&author=C.+Bori%C3%A8s&author=A.+Yasri&title=New+Azaindole+Derivatives+As+Inhibitors+of+Protein+Kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChev%25C3%25A9%26aufirst%3DG.%26atitle%3DNew%2520Azaindole%2520Derivatives%2520As%2520Inhibitors%2520of%2520Protein%2520Kinases%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Pessina, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malerba, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gribaldo, L.</span><span> </span><span class="NLM_article-title">Hematotoxicity Testing by Cell Clonogenic Assay in Drug Development and Preclinical Trials</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">1055</span><span class="NLM_x">–</span> <span class="NLM_lpage">1065</span><span class="refDoi"> DOI: 10.2174/1381612053381648</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=10.2174%2F1381612053381648" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=15777255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhvVChu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=1055-1065&issue=8&author=A.+Pessinaauthor=I.+Malerbaauthor=L.+Gribaldo&title=Hematotoxicity+Testing+by+Cell+Clonogenic+Assay+in+Drug+Development+and+Preclinical+Trials&doi=10.2174%2F1381612053381648"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Hematotoxicity testing by cell clonogenic assay in drug development and preclinical trials</span></div><div class="casAuthors">Pessina, Augusto; Malerba, Ilaria; Gribaldo, Laura</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1055-1065</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  In vitro clonogenic assays were developed and widely used since many years to investigate the proliferation and the differentiation both of pluripotent hemopoietic stem cells (PHSC) and of the different progenitors of blood cell lineages: megakaryocytes (Colony Forming Unit-Mk) granulocyte -macrophage (CFU-GM), erythrocytes (BFU-E/CFU-E).  As these techniques were introduced, they appeared to be very useful to investigate the pathogenic mechanisms of drug induced blood disorders and also for screening compd. during preclin. safety study.  Because the integrity of the hematopoiesis is also essential to guarantee the immunol. function, the application to the toxicol. of these clonogenic assays, provides an essential tool for better understanding the in vivo observation (exptl. and clin.) by also helping in predicting the degree of a possible in vivo hematotoxic in drug treated patients.  The review introduces to basic concepts on hematopoiesis and on classical evaluation of a drug hematotoxic phenomenon.  It describes the application of each clonogenic test to assess the specific hematotoxicity action.  Moreover it report the most recent studies on standardization, prevalidation and validation of such assays and critically reviews a model for predicting myelotoxicity by discussing the main aspects referred to the evaluation of the in vivo acute neutropenia by the in vitro CFU-GM assay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpexbsOIJbAk7Vg90H21EOLACvtfcHk0ljyr2yPRoq__w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhvVChu7Y%253D&md5=c5aa2ac515dfc1ad2fa92d9dabfa18e6</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.2174%2F1381612053381648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612053381648%26sid%3Dliteratum%253Aachs%26aulast%3DPessina%26aufirst%3DA.%26aulast%3DMalerba%26aufirst%3DI.%26aulast%3DGribaldo%26aufirst%3DL.%26atitle%3DHematotoxicity%2520Testing%2520by%2520Cell%2520Clonogenic%2520Assay%2520in%2520Drug%2520Development%2520and%2520Preclinical%2520Trials%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2005%26volume%3D11%26issue%3D8%26spage%3D1055%26epage%3D1065%26doi%3D10.2174%2F1381612053381648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Hassan, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haglund, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aleskog, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindhagen, E.</span><span> </span><span class="NLM_article-title">Primary Lymphocytes as Predictors for Species Differences in Cytotoxic Drug Sensitivity</span> <span class="citation_source-journal">Toxicol. In Vitro</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">1174</span><span class="NLM_x">–</span> <span class="NLM_lpage">1181</span><span class="refDoi"> DOI: 10.1016/j.tiv.2007.03.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=10.1016%2Fj.tiv.2007.03.009" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=1174-1181&issue=6&author=S.+B.+Hassanauthor=C.+Haglundauthor=A.+Aleskogauthor=R.+Larssonauthor=E.+Lindhagen&title=Primary+Lymphocytes+as+Predictors+for+Species+Differences+in+Cytotoxic+Drug+Sensitivity&doi=10.1016%2Fj.tiv.2007.03.009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.tiv.2007.03.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tiv.2007.03.009%26sid%3Dliteratum%253Aachs%26aulast%3DHassan%26aufirst%3DS.%2BB.%26aulast%3DHaglund%26aufirst%3DC.%26aulast%3DAleskog%26aufirst%3DA.%26aulast%3DLarsson%26aufirst%3DR.%26aulast%3DLindhagen%26aufirst%3DE.%26atitle%3DPrimary%2520Lymphocytes%2520as%2520Predictors%2520for%2520Species%2520Differences%2520in%2520Cytotoxic%2520Drug%2520Sensitivity%26jtitle%3DToxicol.%2520In%2520Vitro%26date%3D2007%26volume%3D21%26issue%3D6%26spage%3D1174%26epage%3D1181%26doi%3D10.1016%2Fj.tiv.2007.03.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Schade, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schieven, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Townsend, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jankowska, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Susulic, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szpurka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maciejewski, J. P.</span><span> </span><span class="NLM_article-title">Dasatinib, a Small-Molecule Protein Tyrosine Kinase Inhibitor, Inhibits T-Cell Activation and Proliferation</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">1366</span><span class="NLM_x">–</span> <span class="NLM_lpage">1377</span><span class="refDoi"> DOI: 10.1182/blood-2007-04-084814</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=10.1182%2Fblood-2007-04-084814" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2007&pages=1366-1377&issue=3&author=A.+E.+Schadeauthor=G.+L.+Schievenauthor=R.+Townsendauthor=A.+M.+Jankowskaauthor=V.+Susulicauthor=R.+Zhangauthor=H.+Szpurkaauthor=J.+P.+Maciejewski&title=Dasatinib%2C+a+Small-Molecule+Protein+Tyrosine+Kinase+Inhibitor%2C+Inhibits+T-Cell+Activation+and+Proliferation&doi=10.1182%2Fblood-2007-04-084814"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1182%2Fblood-2007-04-084814&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2007-04-084814%26sid%3Dliteratum%253Aachs%26aulast%3DSchade%26aufirst%3DA.%2BE.%26aulast%3DSchieven%26aufirst%3DG.%2BL.%26aulast%3DTownsend%26aufirst%3DR.%26aulast%3DJankowska%26aufirst%3DA.%2BM.%26aulast%3DSusulic%26aufirst%3DV.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DSzpurka%26aufirst%3DH.%26aulast%3DMaciejewski%26aufirst%3DJ.%2BP.%26atitle%3DDasatinib%252C%2520a%2520Small-Molecule%2520Protein%2520Tyrosine%2520Kinase%2520Inhibitor%252C%2520Inhibits%2520T-Cell%2520Activation%2520and%2520Proliferation%26jtitle%3DBlood%26date%3D2007%26volume%3D111%26issue%3D3%26spage%3D1366%26epage%3D1377%26doi%3D10.1182%2Fblood-2007-04-084814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Lee, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouwehand, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giannini, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dibb, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bijlmakers, M. J.</span><span> </span><span class="NLM_article-title">Lck Is a Key Target of Imatinib and Dasatinib in T-Cell Activation</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">896</span><span class="NLM_x">–</span> <span class="NLM_lpage">900</span><span class="refDoi"> DOI: 10.1038/leu.2010.11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=10.1038%2Fleu.2010.11" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2010&pages=896-900&issue=4&author=K.+C.+Leeauthor=I.+Ouwehandauthor=A.+L.+Gianniniauthor=N.+S.+Thomasauthor=N.+J.+Dibbauthor=M.+J.+Bijlmakers&title=Lck+Is+a+Key+Target+of+Imatinib+and+Dasatinib+in+T-Cell+Activation&doi=10.1038%2Fleu.2010.11"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fleu.2010.11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2010.11%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%2BC.%26aulast%3DOuwehand%26aufirst%3DI.%26aulast%3DGiannini%26aufirst%3DA.%2BL.%26aulast%3DThomas%26aufirst%3DN.%2BS.%26aulast%3DDibb%26aufirst%3DN.%2BJ.%26aulast%3DBijlmakers%26aufirst%3DM.%2BJ.%26atitle%3DLck%2520Is%2520a%2520Key%2520Target%2520of%2520Imatinib%2520and%2520Dasatinib%2520in%2520T-Cell%2520Activation%26jtitle%3DLeukemia%26date%3D2010%26volume%3D24%26issue%3D4%26spage%3D896%26epage%3D900%26doi%3D10.1038%2Fleu.2010.11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Trott, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. J.</span><span> </span><span class="NLM_article-title">AutoDock Vina: Improving the Speed and Accuracy of Docking with a New Scoring Function, Efficient Optimization, and Multithreading</span> <span class="citation_source-journal">J. Comput. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">455</span><span class="NLM_x">–</span> <span class="NLM_lpage">461</span><span class="refDoi"> DOI: 10.1002/jcc.21334</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=10.1002%2Fjcc.21334" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=19499576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGnur3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2010&pages=455-461&issue=2&author=O.+Trottauthor=A.+J.+Olson&title=AutoDock+Vina%3A+Improving+the+Speed+and+Accuracy+of+Docking+with+a+New+Scoring+Function%2C+Efficient+Optimization%2C+and+Multithreading&doi=10.1002%2Fjcc.21334"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</span></div><div class="casAuthors">Trott, Oleg; Olson, Arthur J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">455-461</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">AutoDock Vina, a new program for mol. docking and virtual screening, is presented.  AutoDock Vina achieves an approx. 2 orders of magnitude speed-up compared with the mol. docking software previously developed in the authors' lab (AutoDock 4), while also significantly improving the accuracy of the binding mode predictions, judging by the authors' tests on the training set used in AutoDock 4 development.  Further speed-up is achieved from parallelism, by using multithreading on multicore machines.  AutoDock Vina automatically calcs. the grid maps and clusters the results in a way transparent to the user.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLecOIkUxIlrVg90H21EOLACvtfcHk0lg3cR0QAnT2yA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGnur3O&md5=c6974af8a1235f7aa09918d3e6f70dc4</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2Fjcc.21334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.21334%26sid%3Dliteratum%253Aachs%26aulast%3DTrott%26aufirst%3DO.%26aulast%3DOlson%26aufirst%3DA.%2BJ.%26atitle%3DAutoDock%2520Vina%253A%2520Improving%2520the%2520Speed%2520and%2520Accuracy%2520of%2520Docking%2520with%2520a%2520New%2520Scoring%2520Function%252C%2520Efficient%2520Optimization%252C%2520and%2520Multithreading%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2010%26volume%3D31%26issue%3D2%26spage%3D455%26epage%3D461%26doi%3D10.1002%2Fjcc.21334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Goodsell, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. J.</span><span> </span><span class="NLM_article-title">Automated Docking of Substrates to Proteins by Simulated Annealing</span> <span class="citation_source-journal">Proteins: Struct., Funct., Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">195</span><span class="NLM_x">–</span> <span class="NLM_lpage">202</span><span class="refDoi"> DOI: 10.1002/prot.340080302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=10.1002%2Fprot.340080302" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1990&pages=195-202&issue=3&author=D.+S.+Goodsellauthor=A.+J.+Olson&title=Automated+Docking+of+Substrates+to+Proteins+by+Simulated+Annealing&doi=10.1002%2Fprot.340080302"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1002%2Fprot.340080302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprot.340080302%26sid%3Dliteratum%253Aachs%26aulast%3DGoodsell%26aufirst%3DD.%2BS.%26aulast%3DOlson%26aufirst%3DA.%2BJ.%26atitle%3DAutomated%2520Docking%2520of%2520Substrates%2520to%2520Proteins%2520by%2520Simulated%2520Annealing%26jtitle%3DProteins%253A%2520Struct.%252C%2520Funct.%252C%2520Genet.%26date%3D1990%26volume%3D8%26issue%3D3%26spage%3D195%26epage%3D202%26doi%3D10.1002%2Fprot.340080302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Wang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span> </span><span class="NLM_article-title">Further Development and Validation of Empirical Scoring Functions for Structure-Based Binding Affinity Prediction</span> <span class="citation_source-journal">J. Comput.-Aided Mol. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">11</span><span class="NLM_x">–</span> <span class="NLM_lpage">26</span><span class="refDoi"> DOI: 10.1023/A:1016357811882</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;key=10.1023%2FA%3A1016357811882" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2002&pages=11-26&issue=1&author=R.+Wangauthor=L.+Laiauthor=S.+Wang&title=Further+Development+and+Validation+of+Empirical+Scoring+Functions+for+Structure-Based+Binding+Affinity+Prediction&doi=10.1023%2FA%3A1016357811882"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1023%2FA%3A1016357811882&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1016357811882%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DR.%26aulast%3DLai%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DFurther%2520Development%2520and%2520Validation%2520of%2520Empirical%2520Scoring%2520Functions%2520for%2520Structure-Based%2520Binding%2520Affinity%2520Prediction%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2002%26volume%3D16%26issue%3D1%26spage%3D11%26epage%3D26%26doi%3D10.1023%2FA%3A1016357811882" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span>The PyMol Molecular Graphics System, version <span class="NLM_edition">0.99rc6</span>; <span class="NLM_publisher-name">Schrodinger, LLC</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+PyMol+Molecular+Graphics+System%2C+version+0.99rc6%3B+Schrodinger%2C+LLC%3A+New+York%2C+2015."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520PyMol%2520Molecular%2520Graphics%2520System%26pub%3DSchrodinger%252C%2520LLC%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3G5D" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3G5D','PDB','3G5D'); return false;">PDB: 3G5D</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2OIQ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2OIQ','PDB','2OIQ'); return false;">PDB: 2OIQ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1IEP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1IEP','PDB','1IEP'); return false;">PDB: 1IEP</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1UWH" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1UWH','PDB','1UWH'); return false;">PDB: 1UWH</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ASD" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ASD','PDB','4ASD'); return false;">PDB: 4ASD</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3VNT" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3VNT','PDB','3VNT'); return false;">PDB: 3VNT</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RT7" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RT7','PDB','4RT7'); return false;">PDB: 4RT7</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i97"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00087">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_84327"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b00087">10.1021/acs.jmedchem.6b00087</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Homology modeling and docking studies. Details of HPLC methods used for purity determination. HPLC purities. NMR spectra. (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00087/suppl_file/jm6b00087_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Structure information for compounds <b>6a</b>–<b>z</b>, <b>7x</b>–<b>z</b>, <b>8x</b>–<b>z</b>, <b>12x</b>,<b>y</b>, <b>24x</b>,<b>y</b>, <b>25x</b>, <b>26x,y</b>, <b>27x</b>,<b>y</b>, <b>28x</b>,<b>y</b>, and <b>29x</b>,<b>y</b>. (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00087/suppl_file/jm6b00087_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00087/suppl_file/jm6b00087_si_001.pdf">jm6b00087_si_001.pdf (7.02 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00087/suppl_file/jm6b00087_si_002.csv">jm6b00087_si_002.csv (6.4 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Protein Data Bank IDs <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3G5D">3G5D</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1UWH">1UWH</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2OIQ">2OIQ</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ASD">4ASD</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1IEP">1IEP</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3VNT">3VNT</a>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RT7">4RT7</a>.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b00087&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-8%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b00087" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b00087" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677ac8367eb6196f","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
